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Abstract 
 
Membranous Nephropathy (MN) is one of the leading causes of end-stage renal 
disease (ESRD). MN is an autoimmune disease in which autoantibodies target 
antigens at the level of the glomerular basement membrane. The nature of these 
antibodies and the reason why they develop are not fully understood. 
One of the strategies towards a better understanding of the disorder is genetic 
analysis, of which two approaches have been attempted: linkage mapping, based 
on a family suggestive for X-linked transmission of the MN trait; and whole 
genome association mapping, based on three case-control cohorts. The first 
cohort (335 cases and ethnically matched controls from the UK) was genotyped 
using SNP markers and analysed in an exploratory study which led to the 
identification of two highly significant loci of association. Two cohorts (146 
biopsy proven MN cases and ethnically matched controls from the Dutch 
research group in Nijmegen and 75 biopsy proven cases and ethnically matched 
controls from the French research group in Paris) were used to successfully 
replicate the results. 
The two loci which we identified and independently confirmed are located on 
chromosome 2 and on chromosome 6. 
The chromosome 2 locus includes the PLA2R gene, confirming the hypothesis of 
Beck et al. which identified PLA2R as a key antigen in idiopathic MN by using 
an immunological approach [1]. 
The chromosome 6 locus lies within the extended Human Leukocyte Antigene 
(HLA) system locus, with the highest significance for association reached by 
alleles of HLA-DQA1. 
Our results suggest that the susceptibility to membranous nephropathy is 
associated to genetic variants at the level of both PLA2R1 and HLA loci. The 
causative variants could be some of the polymorphisms captured by the 
genotyping array which was analysed or, more likely variants (single nucleotide 
or copy number variant type) situated nearby (and therefore in linkage 
disequilibrium).   5
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1  Membranous nephropathy 
1.1  Historical introduction 
 
 “Superficially, it might be said that the function of the kidneys is to make urine, but in a 
more considered view one can say that the kidneys make the stuff of philosophy itself’ 
 
Homer W Smith 
 
Since early history, urine, being readily accessible to investigation, has offered 
an opportunity for insights in the understanding of states of health and disease 
[2]. Its quantitative (e.g. polyuria – diabetes; Ebers Papyrus [3]) or qualitative 
(e.g. sweet urine – diabetes; Willis [4], possibly Ayurveda [5]), variations have 
always been considered to be important signs of disease. 
Hippocrates was the first to describe the association of ‘foaming urine’ (which 
nowadays is considered a sign of proteinuria [6]) and renal disease in the context 
of the humoral theory of disease: 
 
“When bubbles settle on the surface of the urine, they indicate disease of the kidneys, 
and that the complaint will be protracted.” 
(Aphorisms: VII, 34 [7]) 
 
Renal dropsy (which is a contraction of hydropsy, oedema of renal cause) was 
described by Saliceto (Gulielmus de) in the XIII
th century [8]. The first clear 
description of proteinuria (precipitation of urine with heat or acetic acid) 
happened in the XVII
th century (Dekkers Frederik, 1673) [9]. Around the same 
period (1674) the association of oedema with proteinuria was noted by 
Domenico Cotugno / Cotunnius [10]. 
It was Richard Bright who defined the relation between dropsy, coagulable urine 
and renal disease [11], combination which was called morbus brightii (Bright’s 
disease). The variable pathologic changes of the kidneys which became evident 
at  postmortem investigations suggested many underlying causes for this 
syndrome. 
The division of Bright’s disease in two broad groups, based on pathological 
findings, led to the conclusion that the disorders of the kidney can be of 
inflammatory cause (nephritis) – in which glomerular lesions were predominant; 
as well as of non-inflammatory nature (nephrosis) – in which the tubular lesions   14
were considered to be prevailing. The concept of nephrosis has been introduced 
in 1905 by Friedrich von Muller specifically to convey the distinction between 
inflammatory and noninflammatory (‘degenerative’) pathologic processes of the 
kidney [12]. It survives today only in the name of  the nephrotic syndrome [13]. 
The term nephrotic syndrome started to be used in the 1920-30s and was defined 
by Bradley and Tyson [14] as being: 
 
”…one of the most striking phenomena of renal disease. The combination of gross 
edema, hypoproteinemia, hypercholesterolemia, lipidemia and heavy proteinuria, in the 
absence of congestive heart failure, is unique and easily recognised.” 
 
A proportion of patients with nephrotic syndrome were noticed to have minimal 
glomerular changes, or even normal glomeruli. The cases with non-significant 
glomerular changes (with no cardiovascular causes of the nephrotic syndrome 
apparent i.e. no hypertension or cardiac hypertrophy) were grouped by Munk 
(1913) under the term lipoid nephrosis [15]. Due to the lack of  glomerular 
morphological changes it was initially thought that ‘nephrosis’ was a 
predominantly tubular disorder.  
E. T. Bell (1929) used Mallory’s anilin blue (Heidenhain, azan-carmine) 
connective tissue stain (McGregor’s technique [16]) to delineate changes in the 
glomerular basement membrane in some of the cases of lipoid nephrosis latu 
senso  [17]. He suggested in 1938 a clinical pathological classification of 
glomerulopathies (dividing them in acute versus subacute and chronic) and 
described the membranous type of glomerular lesion under the name diffuse (as 
opposed to focal) membranous glomerulitis / glomerulonephritis (in opposition 
to the proliferative form) [18]. Later he included this entity together with lipoid 
nephrosis  strictu senso (what is now referred to as minimal change disease), 
lobular glomerulonephritis (today’s membranoproliferative  glomerulonephritis) 
and chronic glomerulonephritis (today’s focal and segmental glomerulosclerosis) 
within the Ellis type II ‘nephritis’ clinical category [19] (which is characterized 
by an insidious onset, with marked albuminuria and oedema) [20]. 
Anecdotally: the first mentioning in PubMed of the term membranous 
glomerulonephritis dates from 1955 [21]. 
In 1957 David Jones applied the special staining method that now bears his name 
(periodic acid-silver methenamine) to kidney biopsy specimens, thus delineating 
the specific / defining features of the anatomopathological lesion [22]. The   15
alternative name ‘membranous nephropathy’ was suggested: the term ‘pathy’ as 
opposed to ‘nephritis’ reflects the fact that the morphological changes at the level 
of the glomerulus are not associated with inflammatory changes [23]. 
The techniques of immunofluorescence [24] and electron microscopy [25], 
applied to the kidney in the 1950s-1960s, allowed histopathological observation 
at increased resolution, allowing for further refinement of the classification of 
glomerulopathies according to the identified morphological patterns [26]. 
Electron microscopy also permitted a better understanding of the ultrastructure 
and pathology of the glomerular basal membrane, although the existence of this 
important structure was known from the days of optical microscopy (the first to 
introduce the term basal membrane in 1857 were Todd and Bowman [27]).  
1.2  Definition / Etymology 
Membranous nephropathy (nephros means kidney in Greek and patein suggests 
it being a disorder of non-inflammatory nature) is a glomerular disease, the term 
membranous referring to the morphological aspect of the glomerular basement 
membrane in this disorder [28]. Membranous nephropathy is therefore a 
pathologic diagnosis. 
1.3  Histology 
The conspicuous target structure in membranous nephropathy, i.e. the glomerular 
basement membrane, is a central element of the glomerular filtration barrier. The 
glomerular filtration barrier is a selectively permeable structure consisting of 
three layers (from blood to urine): glomerular (fenestrated) endothelium, 
glomerular basement membrane and the interdigitated foot processes of 
podocytes (glomerular visceral epithelial cells which are interconnected by a 
multiprotein structure called slit diaphragm), see Figure 1. 
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Figure 1 Schematic ultrastructure of the glomerular filtration barrier 
FP – (podocyte) foot processes, SE – subepithelial space, SD – slit diaphragm,   
GBM – glomerular basement membrane, ESL – endothelial surface layer, EF – endothelial 
fenestra. 
 
Alterations of the glomerular filtration barrier lead to the  loss of selectivity of 
the structure, with passage of macromolecules in the urine, leading to the clinical 
manifestation which is the nephrotic syndrome  [29]. 
1.4  Histopathology 
Membranous nephropathy is characterized histopathologically by three 
components [20]: the thickening of the glomerular basement membrane [30], 
finely granular immune deposits in the subepithelial space at the base of the foot 
processes of the podocytes (considered a pathognomonic aspect of membranous 
nephropathy) [31] and the presence of immunoglobulin G (IgG) in the 
aforementioned electrondense deposits [32]. 
The thickening of the glomerular basal membrane is thought to be the result of 
the interplay between deposition of immune deposits and synthesis of additional 
matrix material. 
Through immunofluorescence microscopy one can visualise the immune deposits 
themselves by using stainings for total immunoglobulin G (IgG) or IgG4 whereas 
newly synthesized matrix material can be highlighted by the methenamine silver   17
/ Periodic acid-Schiff (PAS) staining for basement membranes (Jones’ stain) 
[22]. 
 
Morphologically one can distinguish the four stages of membranous nephropathy 
that were defined by Ehrenreich and Churg [33,34]: 
 
1.  The first (early) stage shows only minimal changes: glomeruli appear almost 
normal by light microscopy, the capillary lumens are dilated, the thickening 
of the capillary wall is not detectable (this feature becomes visible by silver 
staining). Mesangial expansion and proliferation are usually absent. 
Immunofluorescence shows finely granular or pseudo-linear IgG deposits 
along the glomerular capillary wall. Electronomicroscopically small layers of 
electrondense sharply demarcated immune deposits with focal and segmental 
distribution can be observed on the epithelial face of the glomerular basement 
membrane. Projections of the basement membrane (‘spikes’) are small or 
absent. Podocyte foot processes show effacement are a constant feature of 
this stage. 
2.  In the second (fully developed) stage the glomerular enlargement and diffuse 
thickening of the capillary wall become visible on light microscopy. 
Mesangial expansion and proliferation are present in some cases. By silver 
staining, the extensions of the glomerular basement membrane appear black, 
being argyrophilic and therefore opaque to light transmission. These ‘spike-
like indentations’ are the ones first described by David Jones in 1957 [22]. 
The interposing immune deposits appear lucent under light microscopy. 
Transmission Electron Microscopy (TEM) shows the image reversed (in a 
photographically negative manner): one can observe large, numerous, sharply 
demarcated electrondense immune deposits separated by the ‘spike’ like 
extrusions which have the same electron density as the basement membrane 
(representing the newly synthesized extracellular matrix material that has 
been added to the glomerular basement membrane). The spikes have the 
tendency to encircle the immune deposits. Foot process effacement is diffuse. 
3.  In the third (advanced) stage the more severe thickening of the glomerular 
basement membrane is visible by light microscopy. The capillary wall has a 
mottled appearance. Some cases present with mesangial proliferation and   18
sclerosis. By silver staining immune deposits appear like holes in the 
glomerular basement membrane (being translucent in contrast to the 
surrounding opaque argyrophilic material). By electron microscopy large and 
diffuse deposits, all along the glomerular basement membrane, appear as 
being engulfed by the extracellular matrix spikes. Their appearance is highly 
variable: coarsely or finely granular, with their electron density being greater, 
equal or less than that of the basement membrane material. The basement 
membrane appears thick and irregular. 
4.  In the fourth (late) stage the deposits are be incorporated in glomerular 
basement membrane, which is thickened by the apposition of newly 
synthesized matrix. Glomerulosclerosis (segmental or global) becomes 
evident by light microscopy. 
 
 
 
Figure 2 Pathological stages of membranous nephropathy 
Electron microscopically aspects of the glomerular basement membrane in the four 
pathological stages of membranous nephropathy; BM = basement membrane ; D = (intra 
BM) deposit ; M = medium electron-dense linear subepithelial deposit ; En = endothelium ; 
Ep = epithelium ; P = podocyte ; Sp = spike [35]. 
 
The pathological aspects observed in the renal interstitium (macrophagic 
infiltration, overproduction of matrix by fibroblasts, eventually leading to 
tubulointerstitial fibrosis) are thought to be secondary – due to the  toxic effect   19
proteinuria has on the tubular and interstitial cells (through plasma iron and 
proteins like the C5b-9 complex, lipid derived chemotactic factors, etc.). 
 
Based on the pathology some variants of membranous nephropathy have been 
described such as: 
 
•  Membranous nephropathy with spherules [36], 
•  Segmental membranous nephropathy [37] (as opposed to the ‘usual’ form 
which is global [38]), 
•  Childhood membranous nephropathy with anti-tubular basement 
membrane nephritis [39]. 
 
In some instances secondary forms of membranous nephropathy (mostly lupus 
nephritis) show features that distinguish them from the idiopathic ones. 
Idiopathic membranous nephropathy is exclusively subepithelial whereas lupus 
nephritis presents with mesangial and subendothelial immune deposits. Lupus 
and malignancy associated membranous nephropathies also present with 
different immunoglobulin classes (predominantly IgG2 and IgG3 as opposed to 
the predominant IgG4 class which predominates in the idiopathic form). At the 
electronomicroscopical resolution level, lupus nephropathies sometimes present 
with tubuloreticular inclusions in the glomerular endothelium. 
1.5  Clinical aspects 
Membranous nephropathy has an insidious onset, usually with (subclinical) 
proteinuria which leads later to peripheral oedema. It can be diagnosed at any age 
but its age distribution shows two peaks at 30 to 40 and 50 to 60 years. Males are 
more often affected than females (with the sex ratio being 2-3:1). 
Of all the individuals affected by membranous nephropathy, 20% stay 
asymptomatic with non-nephrotic levels of proteinuria (< 3.5 g/day) and 80% 
become clinically manifest, presenting a full blown nephrotic syndrome with:   20
 
•  proteinuria (> 3.5 g/day) 
•  hypoalbuminemia 
•  hyperlipidemia 
•  fluid retention (oedema) 
 
Microscopic hematuria is present in about half of the adult patients afflicted with 
membranous nephropathy, being considered a marker of active disease. 
Macroscopic hematuria is very unusual. 
Hypertension is also an uncommon finding in membranous nephropathy (30%). 
It is estimated that about 40% of membranous nephropathy patients are at 
increased risk for thromboembolic phenomena (renal vein thrombosis). 
1.6  Epidemiology 
Membranous nephropathy is a relatively rare disease [40] despite the fact of it 
being the main cause of idiopathic nephrotic syndrome in adults (about one third 
of all cases of nephrotic syndrome, even more so  – up to half in older white 
adults [28]). 
Children are rarely affected by membranous nephropathy: 2 - 15% (average of 
5%) of pediatric patients with nephrotic syndrome show lesions reminiscent of 
membranous nephropathy at renal biopsy. 
A certain degree of geographic variability has also been reported, with a higher 
proportion of membranous nephropathy determining nephrotic syndrome in 
Greece and Macedonia and a lower proportion in the United Kingdom [28]. 
1.7  Etiology 
The deposition of immune complexes on the epithelial side of the glomerular 
basement membrane appears to be triggered by a number of agents in genetically 
susceptible individuals. 
In one third of the cases membranous nephropathy is considered to be secondary 
to (or has at least been associated with) infections (hepatitis B virus, malaria, 
syphilis, schistosomiasis etc.), drugs (non-steroid antiinflammatory drugs, 
penicillamine, gold salts etc.), toxins, chronical immunological disorders (class V 
lupus nephritis, rheumatoid arthritis, autoimmune thyroid disorders, Sjogren’s   21
syndrome etc. [40]), allografts (kidney, bone marrow [41]) and malignancies. 
Even though potential antigens have been identified in secondary membranous 
nephropathy there is no definitive proof of their pathogenicity. 
In about two thirds of the cases of membranous nephropathy the etiology remains 
unknown – this subset of membranous nephropathy cases being referred to as 
idiopathic membranous nephropathy - IMN). 
The current paradigm asserts that idiopathic membranous nephropathy is 
autoimmune in nature. This hypothesis stems from the identification, in 1976,  of 
possible antigens in what was then called ‘immune complex nephritis’ [42,43]. 
Autoantigens have been described for a rare form of congenital membranous 
nephropathy (neutral endopeptidase, NEP, initial case report [44], more cases 
[45]) as well as for the common adult form of IMN (M-type phospholipase A2 
receptor, PLA2R) [1]. 
1.8  Pathogeny 
The first one to suggest that renal diseases can be caused by immune reactions 
was Schick in 1907 [46]. The autoimmune hypothesis in renal pathology 
gathered renewed support when in 1949 Lange et al. were able to demonstrate 
the presence of antibodies against kidney tissue emulsion in a group of patients 
with chronic glomerulonephritis [47]. 
1.8.1  Heymann nephritis 
A pathophysiological model for human membranous nephropathy was 
established on the basis of an experimental rat model which was developed in the 
‘50s by Walter Heyman (and has therefore been called Heymann nephritis) [48]. 
Heymann nephritis is induced by the immunization of rats with a mixture of 
antigens derived from rat proximal tubular brush border. These rats develop 
proteinuria with the histological features of human membranous nephropathy 
[49]. 
The triggering antigen in Heymann nephritis is a complex: HNAC (Heymann 
Nephritis Antigen Complex) [50,51] formed by megalin (gp330, LRP2 – Low 
density lipoprotein-related protein 2) and RAP (Receptor Associated Protein, 
LRPAP1 – Low density lipoprotein receptor-related protein associated protein 1). 
Megalin, the first protein to be described as a pathogenic antigen of Heymann   22
nephritis [52], is an endocytic receptor of the low-density lipoprotein receptor 
family which is located in the coated pits of the soles of rat podocyte foot 
processes and in the proximal tubular brush border [53]. Megalin and RAP form 
multimeric complexes in the endoplasmic reticulum, where RAP acts as a 
chaperone to assist the folding of megalin [54], complexes which are then 
trafficked to the cell surface [55].  At least five pathogenic epitopes, thought to 
lead to the formation of immune deposits, have been identified on the Heyman 
Nephritis Antigen Complex. One of them is located on RAP [56], the other four 
on megalin [57]. 
1.8.2  Experimental membranous nephropathy pathomechanisms 
It is believed that the antigen is capped by autoantibodies in the coated pits on 
the soles of the podocyte. Subsequently the antibody-antigen complexes are shed 
on the glomerular basement membrane where they become stabilized in the 
lamina rara externa by cross-linking, leading to the (in situ) formation of 
subepithelial deposits [58]. 
The next step in the pathogenetic scenario is the lesion of glomerular epithelial 
cells, which is mediated by the complement membrane attack complex (MAC)  
[59]. Kerjaschki et al. showed that in Heymann Nephritis antibodies activated 
complement leading to C5b-9 (MAC) formation, its insertion in the podocyte 
[60] and assembly in the plasma membrane. Once MAC are assembled in the 
plasma membrane they can lead to the disruption of its permeable selectivity 
through formation of transmembrane channels or the rearrangement of 
membrane lipids with loss of membrane integrity [61]. As opposed to 
erythrocytes, nucleated cells (including glomerular epithelial cells) require higher 
doses of C5b-9 in order to be lysed, possibly through their ability to eliminate the 
complement channels / lesions and through a better osmoregulatory capacity 
[62]. Lower doses of MAC induces a sublethal (sublytic) response of nucleated 
cells [63] which appears to be due to the activation of specific signalling 
pathways. These pathogenic signals (calcium influx, transactivation of receptor 
tyrosine kinases, activation of phospholipase A2 with its consequences on 
arachidonic acid / prostanoid metabolism and induction of ER stress response, 
transcription factors, reactive oxygen species, enzymes, growth factors and   23
signals for proliferations, extracellular matrix) may lead to disruptions of the 
structure or functions of the targeted cells [61]. 
 
The autoimmune mechanism in which podocyte-membrane proteins are the 
autoantigenic targets was confirmed in different animal models of experimental 
membranous nephropathy: in mice aminopeptidase A [64] and in rabbits 
dipeptidyl peptidase IV and enkephalinase (neutral endopeptidase) [65] were 
shown to be the respective targets. 
1.8.3  Human pathomechanisms 
1.8.3.1 Immune deposit formation 
One important question is whether  the immune deposits on the epithelial surface 
of the glomerular basement membrane are circulating immune complexes that 
were dissociated on the endothelial side, then passed through the membrane and 
reassociated on the epithelial side (due to their small size and cationic charge) or 
whether the immune deposits were formed locally (in situ complex formation) by 
antibodies binding circulating antigens that have been previously ‘planted’ on the 
endothelial surface or by antibodies binding intrinsic target antigens. In the case 
of the Heymann nephritis the latter hypothesis (antibodies binding in situ to an 
intrinsic target antigen) has been proven through experiments involving isolated 
perfused rat kidneys [66], but human megalin (glycoprotein 330, LRP2 low-
density lipoprotein - related protein 2) has not been detected in subepithelial 
immune deposits in patients with membranous nephropathy, furthermore it 
appears not to be expressed in human podocytes [67]. 
1.8.3.2 Glomerular injury 
As in the case of the experimental nephritis of the rat, the lesion of the podocytes 
is thought to be mediated by the C5b-9 (MAC, membrane attack complex) 
multimer. Even though IgG4, the major component of the immune deposits in 
idiopathic membranous nephropathy, is believed to be anti-inflammatory not pro-
inflammatory (not binding and therefore not activating complement) [68], 
complement somehow gets activated at the site of the lesion. The C5 component 
of complement is cleaved, C5a (a chemotactic factor) is supposedly flushed   24
downstream by the filtration forces at the glomerular barrier, therefore not 
moving back across the glomerular basement membrane to attract inflammatory 
cells from the circulation, thus explaining the paucicellularity of the lesion. The 
C5b fragment together with the C6 complement component form the so-called 
‘lipophilic complex’ which inserts itself in the membrane of the podocyte. Once 
in the membrane, the lipophilic complex recruits the fractions C7, C8 and C9 to 
form the membrane attack complex / pore forming complex. The podocyte 
endocytes the pore forming complexes and transports them intracellularly in 
multivesicular bodies, to be later extruded on the urinary side. In the process, 
even though the podocytes are not lysed they are activated, leading to a cascade 
of signal transduction pathways which further lead to the production of 
potentially nephritogenic molecules: oxidants, proteases, cytokines, growth 
factors, vasoactive molecules and extracellular matrix. The increased expression 
of TGF (Transforming Growth Factors; TGFβ2, TGFβ3) and TGF receptors by 
the podocytes leads to the increased synthesis of matrix molecules which leads to 
the thickening of the glomerular basement membrane between the immune 
deposits (forming the characteristic argyrophilic ‘spikes’, later to become ‘clubs’, 
that are made visible through silver methenamine staining). In time the 
extracellular matrix synthesised de novo grows around and ultimately embeds the 
initial immune deposits. The podocyte number decreases through apoptosis, the 
remaining cells detach due to the expansion of the glomerular volume secondary 
to the increased intraglomerular pressure. Some areas of the glomerular basement 
membrane are denuded because of the limited ability of podocytes to proliferate 
(cyclin kinase inhibitors seem to be overexpressed leading to cell cycle arrest). 
1.8.3.3 Interstitium 
It has been suggested that the interstitium suffers secondary in glomerulopathies, 
the mechanism being common to all unselective proteinuric disorders. 
Unselectivelly filtered through the glomerular barrier, plasma proteins (C5b-9 
complex), lipid derived chemotactic factors and iron may have a toxic effect on 
tubular cells. This toxic effect exerts itself through macrophagic infiltration and 
overproduction of matrix by fibroblasts, leading eventually to tubulointerstitial 
fibrosis.   25
1.8.3.4 Alloimmune antenatal MN mechanism 
Debiec et al. [44] described a family in which the mother, deficient in neutral 
endopeptidase (NEP), was immunized anti NEP during a miscarriage (the father 
being NEP positive). Circulating anti-NEP antibodies crossed the placenta in a 
subsequent pregnancy, leading to alloimmune antenatal membranous 
nephropathy. The clearance of the maternal anti-NEP antibodies led to the 
resolving of the disease in the child. It has been observed that in order for 
proteinuria to occur IgG1 anti-NEP antibodies are necessary: children of mothers 
with only the IgG4 subclass of anti-NEP antibodies are not affected [45]. 
Neutral endopeptidase (NEP) 
The gene encoding NEP is located on chromosome 3q25.2 [69], its approved 
name (HGNC – HUGO Gene Nomenclature Committee [70]) is membrane 
metallo-endopeptidase (MME), alternative names are: CD10, and CALLA 
(Common Acute Lymphoblastic Leukemia Antigen). The product of the gene is 
also called neprilysin (renal endopeptidase, kidney ‘enkephalinase’, enzyme code 
E.C.3.4.24.11). It is a 100-kD type II transmembrane glycoprotein which is 
highly expressed in kidney (in the brush border of proximal tubules and on the 
glomerular epithelium). The enzyme is a neutral endopeptidase that cleaves 
peptides at the amino side of hydrophobic residues, thereby inactivating peptide 
hormones (e.g. glucagon, enkephalins, substance P, neurotensin, oxytocin, and 
bradykinin). It is worth mentioning that NEP has been shown to have an 
inflammation modulating effect [71]. 
1.8.3.5 Postnatal autoimmune mechanisms 
M-type phospholipase A2 receptor (PLA2R) 
Anti-PLA2R (M-type phospholipase A2 receptor) antibodies have been found in 
an initial report by Beck et al. (2009) [1] in the sera of 75% of idiopathic 
membranous nephropathy patients but not in that of secondary membranous 
nephropathy, other glomerular or autoimmune disorders or normal controls [40]. 
Anti-PLA2R antibodies only detect PLA2R in its non-reduced state, suggesting 
the dependence of the epitope(s) conformation on disulfide bonds. This also   26
might explain why the antigen has not been found before, despite the fact that 
similar techniques have been used [40]. 
PLA2R1 is a transmembrane protein member of the mannose receptor family 
[72]. The mammalian mannose receptor family is a member of the C-type Lectin 
superfamily [73], one of the families of membrane bound pattern recognition 
receptors [74]. 
Pattern recognition receptors 
Pattern recognition receptors are important elements in the mechanism of innate 
immunity. The ‘first line’ immunological cells that encounter potentially 
threatening pathogens, professional antigen-presenting cells (APCs: 
macrophages, dendritic cells and B cells) are equipped with receptors which role 
is to recognize foreign antigens. Whilst B cells rely on a set of somatically 
variable receptors (surface immunoglobulins) to discriminate between a large 
variety of possible epitopes, macrophages and dendritic cells are reduced to fixed 
germline-encoded receptors to recognize simpler patterns of antigenic 
determinants. These fixed receptors are complement, Fc receptors and a large 
array of pattern recognition receptors (PRRs) [75]. PRRs recognize pathogen-
associated molecular patterns (PAMPs) – highly conserved structures present in 
large groups of microorganisms (peptidoglycan PGN, lipopolysaccharides LPS, 
lipoteichoic acid LTA). PRRs can be classified in soluble / humoral (mannan-
binding lectin MBL, collectins, ficolins, pentraxins and complement) and cell-
bound receptors. The cell-bound receptors are either intracellular (NOD-like 
receptors NLRs, RIG-I-like receptors RLRs and cytosolic DNA receptors) or 
transmembrane (Toll-like receptors and C-type lectin receptors) [76]. 
Glycans (mono-, oligo- or polysaccharides and their conjugates, present at cell 
surfaces, incorporated in extracellular matrix or secreted - attached to 
glycoproteins) serve structural as well as functional roles (cell-cell and cell-
matrix recognition, signalling etc.). Lectins or lectin receptors are glycan-binding 
proteins (which do not transform the saccharides and which have a nonimmune 
origin [77]) which participate to the non-structural roles of sugars. Their sugar-
binding activity can be ascribed to modules referred to as carbohydrate-
recognition domains (CRDs). Using the arrangement of CRDs  as a   27
differentiating factor one can distinguish many families of lectin receptors, which 
have different cellular localizations [78], see Classification 1. 
 
IC cytoplasmatic  calnexin  (ER) 
   M-type  (ER) 
   F-box  (cytoplasmic)    
Selectins  L-type (ER, ERGIC, Golgi) 
     P-type  (secretory  pathway) 
     E - t y p e   ( ? )  
  ctplsm & mmbr  R-type (Golgi, mmbr) 
  mmbr  I-type lectins / siglecs (mmbr) 
EC & IC  ctplsm S-type lectins / galectins (ctplsm, EC) 
  mmbr  ficolins  (mmbr,  EC) 
      C-type including collectins (mmbr, EC) 
   interlectins  (mmbr,  EC) 
      SUEL-related lectins (mucus, mmbr) [79] 
EC chitinase-like  lectins  (EC) 
 F-type  (EC) 
 collectins  (EC?) 
  lectin-like pentraxins [80] 
 
Classification (1) Lectin (receptor) families 
Cellular localization: IC = intracellular; EC = extracellular; ER = endoplasmic reticulum;   
ERGIC = endoplasmic reticulum golgi intermediate compartment; ctplsm = cytoplasmatic  ; 
mmbr = membrane. 
 
Arguably the most important role of lectins is that of recognition molecules 
within the immune system [81]. 
C-type lectin receptors 
C-type lectin receptors are a superfamily of proteins encountered only in 
pluricellular animals (metazoans). The domain which characterizes the 
superfamily is the C-type lectin-like domain (CTLD). CTLDs are characterized 
by a double loop (‘loop-in-a-loop’) which is stabilized by two disulfide bridges at 
its base. Vertebrate proteins that contain CTDLs (CTLDcps = CTDL containing   28
proteins) are classified based on their overall domain structure in 17 groups 
(families) [73] see Classification 2. 
 
I –lecticans, 
II – the ASGR group,  
III – collectins,  
IV – selectins,  
V – NK receptors,  
VI – the macrophage mannose receptor group,  
VII – Reg proteins,  
VIII – the chondrolectin group,  
IX – the tetranectin group,  
X – polycystin 1,  
XI – attractin,  
XII – EMBP, 
XIII – DGCR2,  
XIV – the thrombomodulin group,  
XV – Bimlec,  
XVI –SEEC,  
XVII – CBCP 
 
Classification (2) of vertebrate proteins containing C-type lectin domains 
ASGR = AsialoGlycoprotein Receptor; Reg = regenerating; EMBP = Eosinophil Major Basic 
Protein; DGCR = DiGeorge syndrom Critical Region; Bimlec = uncharacterized lectin (which 
had a descriptive name assigned); SEEC = group of soluble proteins containig SCP, EGF (twice) 
and CTLD domains; CBCP = Calxβ and CTLD containing Protein; CTLD = C-type lectin-like 
domain. 
 
C-type lectins have been shown to be expressed by antigen presenting cells 
(APCs) and to play a role in the innate immune system [82]. 
The (macrophage) mannose receptor family 
The (macrophage) mannose receptor family, the VI
th structural group of 
CTLDcps, encompasses, besides PLA2R, the mannose receptor (MRC1), the 
endocytic receptor Endo180 (formerly named so, now known as MRC2 – 
mannose receptor C type2), DEC205 (its accepted Human Gene Name   29
Committee name being LY75 -  lymphocyte antigen 75) and the avian (yolk sac) 
Ig Y receptor (which is PLA1R) [72]. 
 
 
 
Figure 3 Mannose receptor  gene family 
Phylogenetic tree obtained with TreeFam [83,84]. BOVIN = Bos taurus; PANTR = Pan 
troglodytes; MACMU = Macaca mulatta; CANFA = Canis familiaris; MONDO = 
Monodelphis domestica; CHICK = Gallus gallus; GASAC = Gasterosteus aculeatus; XENTR 
= Xenopus tropicalis; TETNG = Tetraodon nigroviridis; BRARE = Danio rerio; CIOIN = 
Ciona intestinalis; CIOSA = Ciona savignyi.   30
 
All the members of the family are type I transmembrane proteins with a large 
extracellular segment which is arranged in a similar way: at the N-terminal a 
cystine rich domain (CysR), followed towards the membrane surface by a 
fibronectin type II domain (FNII) and 8 (respectively 10 in the case of DEC205) 
C-type lectin like domains (CTLDs) / carbohydrate recognition domains (CRDs). 
It has been shown for MR and Endo180 that only one of the CTLDs retains lectin 
activity (CTLD2 in the case of Endo180 and CTLD4 in the case of MR). 
Different conditions could alter the availability of the binding sites and thus the 
function of these proteins. Single particle electron microscopy studies have 
suggested a model for the three-dimensional conformation of members of the 
mannose receptor family. In this model the N-terminal end is ‘bent’ towards the 
‘active/functional CTLD of the receptor, thus generating a globular head. The 
compact folded conformation seems to occur under certain conditions (changes 
in pH, association with ligand binding etc.), this appearing to be a general 
property of the family [85]. 
The residues required for calcium-dependent sugar binding in the mannose 
receptor are not conserved in the PLA2R CTLDs, denoting the lack of calcium 
dependent lectin activity of the receptor [72]. 
The intracellular domain contains a motif which has been originally identified in 
the LDL (low density lipoprotein) receptor – to mediate coated-pit mediated 
endocytosis (Asn-Pro-Xxx-Tyr) [86]. 
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Figure 4 Domain structure of Phospholipase A2 Receptor (PLA2R1) 
N – extracellular N terminal end ; CRD - cystine rich domain (thin vertical lines: S-S bounds); 
FNII - fibronectin type II domain; CTLD - C-type lectin like domains; mmbr – transmembrane 
domain; ctplsm – intracellular domain; C – intracellular C terminal end. 
 
Phospholipases A2 
Phospholipases A2 (PLA2) are a very diverse family (superfamily) of lipolytic 
esterases  (mammals having least 19 distinct members [87]). The enzymatic 
function of PLA2 implies hydrolization at the sn-2 position of membrane 
phospholipids, which leads in vivo to the release of lysophospholipids and 
polyunsaturated fatty acids which are further transformed in bioactive 
eicosanoids with various biological functions [88].  
 
 
 
Figure 5 Hydrolysis reaction catalyzed by Phospholipase A2 (PLA2) 
Modified after [89]; 1-P-2-APC = 1-Palmitoyl-2-arachidonyl-phosphatidylcholine;   
AA = Arachidonic acid; 1-PLPC = 1-Palmitoyl-lysophosphatidylcholine.  
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One can distinguish secreted (sPLA2s) and intracellular PLA2s (cytosolic 
cPLA2s, calcium-independent and platelet activating factor (PAF) acetyl 
hydrolase / oxidized lipid lipoprotein associated) [90]. First to be  characterized 
were the toxic secreted PLA2s in the venom of bees [91] and snakes [92]. It is 
worth noting that PLA2 beside having an enzymatic / toxic action, is the major 
allergenic component of bee venom [93]. 
Secreted Phospholipase A2 (sPLA2) 
The human genome contains ten sPLA2 genes. In order to perform its 
biochemical function hydrophilic sPLA2 has to adsorb directly to the 
hydrophobic substrate membrane interface. Pancreatic sPLA2s have a role in 
dietary phospholipid digestion, cPLA2s have a role in eicosanoid generation 
through arachidonic acid release. The functions of many of the sPLA2 proteins 
are unknown, it is not clear if they modulate eicosanoid production, some of their 
functions may even be unrelated to the enzymatic capabilities as suggested by the 
fact that group XIIB sPLA2-like lacks lipolytic activity - due to a polymorphism 
at the catalytic residue. Group IIA sPLA2 accumulate to high levels during 
inflammation. A large body of evidence suggests that sPLA2 and cPLA2 
cooperate in releasing arachidonic acid. The molecular mechanism of this 
cooperation is yet to be described, although it has been suggested that sPLA2 
action on phospholipids takes place – in the secretory compartment, before the 
enzyme leaves the cell. It is still a matter of debate whether the (probably 
eicosanoid mediated) effect of sPLA2 is proinflammatory or antiinflammatory 
[94]. 
A better established role for sPLA2s is the one in host defence through the innate 
immunity component of the immune system. The enzyme seems to be expressed 
at locations where it can strategically contribute to anti-microorganism defence – 
potential ports of entry (tears, seminal plasma, Paneth cells and intestinal lumen, 
inflammatory exudates, bronchoalveolar lavage, serum, prostatic epithelial cells 
and their secretions etc). Potential production of soluble PLA2R in the human 
kidneys has been suggested, based on the existence of an alternatively spliced 
transcript at this level [95]. 
The bactericidal activity of sPLA2 against Gram-negative bacteria necessitates 
the presence of serum permeability increasing protein. sPLA2s are not able by   33
themselves to penetrate the lipopolysaccharide outer layer of the envelope of 
Gram-negative bacteria. In order to be penetrated, the envelope has to be 
previously disrupted by the permeability increasing protein or the MAC of 
complement [96]. The anti Gram-positive bactericidal activity of sPLA2 is 
independent of serum factors. It was demonstrated in the context Paneth cells 
secretion (cryptidins and sPLA2) which contributes to the low content in 
microorganisms of the small intestine, despite their repeated oral entry [97]. As a 
matter of fact it has been proven that sPLA2 is the principal bactericidal 
component against Gram-positive  bacteria in human tears [98]. 
The mechanism of the bactericidal effect of sPLA2 is based on the electrostatic 
attraction between the basic enzyme and the acidic components of the surface of 
Gram-positive bacteria (lipoteichoic acids) and subsequent hydrolization of the 
phospholipid components of the bacterial membrane [99]. 
Given that sPLA2s in the venom of insects and snakes are very similar to 
mammalian sPLAs it is likely that the latter would be toxic if left unchecked. 
One of the mechanisms to control sPLA2 function is its inhibition and 
degradation via binding to specific binding proteins [89]. Two types of receptors 
were identified (using as a ‘bait’ a neurotoxic sPLA2 from the snake venom) 
[100]. N-type (Neuronal) receptors are diverse in nature and bind to neurotoxic 
sPLA2s. Their structure and functions are not known and it has been suggested 
that the nomenclature ‘receptor’ would be inappropriate for the binding proteins 
of neurotoxic sPLA2s [95]. 
The M-type (Muscular) receptor is PLA2R1. PLA2R1 was first cloned from 
rabbit [101]. It is upregulated by inflammatory stimuli [102]. Mammalian 
sPLA2s are divided in two groups with respect to their affinity to PLA2R1: some 
bind to it with low nanomolar affinity, some do not bind at all [103]. The ones 
that bind are inhibited by the binding. The receptor has two isoforms, a soluble 
one and a membrane bound one. The membrane bound receptor internalizes after 
binding the enzyme, leading to its degradation. Therefore a role has been 
suggested for the receptor in controlling the activity of sPLA2 through its 
clearance after it has been secreted  [100]. Other proteins of the C-type lectin 
superfamily have been shown to bind and inhibit sPLA2s, most remarkably 
snakes seem to be inhibiting the potential self toxic effect of their own venom 
through Plasmin alpha Inhibitors (PLI-α; which are homologous to C-type   34
lectins) [104]. The diversity of sPLA2s binding proteins suggests that sPLA2s do 
not only function through their enzymatic but also through mechanisms 
independent of their PLA2 activity [105]. 
Catalytically independent functions of sPLA2 
In the context of renal pathology, two interesting catalytically independent 
functions of sPLA2 are worth mentioning: Mukherjee et al. described how 
uteroglobin, inhibiting sPLA2 activity and thus decreasing the level of 
lysophosphatidic acid (LPA), may prevent the activation of integrins which 
enhance tissue deposition of fibronectin (FN) in the glomeruli of mice (in a 
model of familial FN-deposit glomerulopathy) [106]; Birts et al. [107] described 
cell debris removal facilitation by GIIA human PLA2 (PLA2GIIA). 
Debris removal 
PLA2GIIA was first described in the synovial fluid of patients affected by 
rheumatoid arthritis [108]. It has been shown to rise during sepsis, to be 
associated with inflammatory disease, being recognized as an acute phase protein 
[109]. It exerts an antibacterial function due to its high affinity for bacterial 
membrane anionic phospholipids but has a very low affinity for the plasma 
membrane of normal host cells (due to the zwitterionic nature of their outer 
phospholipid monolayer). Only the cell membranes of cells that have been 
activated during the  immune response and of cells that initiated apoptosis are 
hydrolyzed [110], it has been therefore suggested that the enzyme plays a role in 
the clearance of damaged cells [111]. The mechanism of the biological response 
induced by the binding of sPLA2GIIA to the cell surface is not well understood. 
sPLA2GIIA does not have high affinity cell surface receptors, it has been shown 
to bind to surface heparan sulfate proteoglycan (HSPG). Binding does not require 
enzyme catalysis and is followed by energy dependent uptake and trafficking of 
sPLA2GIIA to the cell nucleus. The result is significant swelling of the target 
cells, characteristic of macropinocytosis, which may play a role in the clearance 
of pathological anionic cell debris. By doing so sPLA2GIIA seems to have a 
resolving, primary antiinflammatory role in the course of the inflammatory 
response [107].   35
 
Secretoglobin  / Uteroglobin (UGB) 
The many synonyms of secretoglobin family 1A member 1 (SCGB1A1) [112] 
(uteroglobin, blastokinin, uteroglobin-like antigen / protein, Clara cell secretory 
protein / CCSP, polychlorinated biphenyl-binding protein etc. [113]), reflect 
either localisation or functional aspects clarified by each of the naming 
authorities.  SCGB1A1 is a secreted protein inducible by steroids [114] which 
has been deemed one of the most powerful endogenous anti-inflammatory and 
immune-modulating (‘natural immunosuppressor’ [115]) agents [116], 
containing a representative peptide of a class called antiinflammins [117]. It is 
produced by the secretory epithelia of organs that communicate with the external 
environment [116]. It is expressed in the uterus (hence its name), thymus, 
pituitary gland, the respiratory tract, the gastrointestinal tract (including the 
pancreas), the mammary gland, the prostate and seminal vesicles [118]. It also 
has been shown to be present in the blood and in urine (urine protein-1 [119]) 
although it seems not to be synthesized in the kidney [106]. The surface 
structures of (rabbit) uteroglobin and that of sPLA2 are virtually superimposable 
[120]. Uteroglobin is a strong inhibitor of sPLA2 activity [121]. Uteroglobin has 
also been shown to be a sex dependent marker or renal (tubular or glomerular) 
dysfunction even though its gene (SCGB1 A1, secretoglobin, family 1A, 
member1) is encoded on an autosome (chromosome 11q12.3) [122]. Mutations 
of uteroglobin in mice leads to severe renal disease due to massive deposition of 
fibronectin (FN1) at the level of the glomeruli [123]. Extracellular matrix 
assembly through fibronectin self-aggregation (fibrillogenesis) relies on the 
binding of fibronectin (and activation of) receptor-like integrin heterodimers 
(particularly α1β5 integrin) [124]. This process has been shown to be promoted 
by lysophosphatidic acid, which is generated by PLA2. It has been shown in 
mice that uteroglobin is able to prevent fibronectin deposition at the level of the 
glomerulus by counteracting fibronectin self-aggregation through its high affinity 
binding of fibronectin, which forms fibronectin-uteroglobin heteromers [106]. In 
humans, familial glomerular nephritis with fibronectin deposits (GFND, [OMIM 
601894]) [125] seems to have a similar underlying pathogenetic mechanism,   36
even though mutations of fibronectin [126] and not of uteroglobin [127] have 
been implied in its etiology. 
 
- Amyloid 
- Non-amyloid - Ig-derived  - cryoglobulinemia (type 2) 
    -   M I D D  
    -  GP  in  monoclonal  γ-pathies 
    -   S L E   ( S y s t e m i c   Lupus Erythematosus) 
    -  Immunotactoid  fibrillary  GP 
      - non-immune complex mediated / [128] - fibronectin GP 
     -   d i a b e t i c   G P  
 
 
Classification (3) of fibrillary glomerulopathies 
MIDD - Monoclonal Immune Deposition Disease; GP - glomerulopathy. 
 
Besides its role in non-immuno complex mediated diseases, uteroglobin seems to 
be implicated as a protective factor in IgA nephropathy (IGAN) at least in mice 
[129], the same role in humans being debated with arguments for [130] and 
against [131]. The mechanism of this protective effect has been suggested to 
imply UGB competing with IgA for the heparin-binding site of FN thus 
preventing the FN-IgA complex formation, a normal process [132] which seems 
to be enhanced in IGAN [133]. 
 
The mechanisms of sPLA2 receptor interaction at the cell membrane are little 
known. One of the better characterized sPLA-2 binding proteins is the M-type 
receptor or PLA2R1. 
M-type PLA2 Receptor 
The M-type PLA2 receptor exists in two isoforms: membrane bound and 
secreted [134]. At least a part of the secreted isoform seems to be produced by 
cleaving of the membrane bound receptor by metalloproteinases (similarly to the 
mannose receptor [135]). PLA2R has been shown to be  expressed in rats in the 
kidney (glomerular mesangial cells[136]), in the lung (on alveolar type II 
epithelial cells), in the vessels (rat vascular smooth muscle cells and vascular   37
endothelial cells), in the cartilage (synovial cells and chondrocytes) on a subset 
of splenic lymphocytes and on neutrophils [136]. The expression of PLA2R in 
humans has been documented for lung, kidney (it has been shown to be abundant 
on the podocytes of normal human kidneys [1]) and pancreas [137]. 
The contact between sPLA2 and its receptor takes place at the opening of the 
catalytic site of sPLA2. It has been shown that blockers of the binding of sPLA2s 
to the M-type receptor inhibits sPLA2 activity [138]. On the receptor part, the 
domains responsible for binding are the CRD-like domains [139], CRD3 to 
CRD5 being sufficient in conferring sPLA2-IB binding activity. As mentioned 
before PLA2R has no calcium dependent lectin activity, therefore sPLA2 binding 
to the receptor is calcium independent. N-linked sugar residues at the 15 potential 
N-glycosylation sites of PLA2R seem to be essential for the optimum recognition 
of sPLA2-IB (in mouse and bovine cells) [139]. 
PLA2s which have been shown in mice to bind to PLA2R are part of groups IB, 
IIA (with lower affinity: 6-10X lower [103]) and X. (apparently conserved 
positions of 16 cysteine residues account for this binding specificity). PLA2R 
ligands (group IB and X. sPLA2) are synthesized as inactive pro-enzymes, with a 
propeptide sequence at the NH2 terminals [140]. The conversion from the pro-
form to the mature form through proteolytic cleavage of the propeptide seems to 
be essential for optimum binding to the receptor [141]. The activation of the 
ligands is catalyzed by proteolytic enzymes (trypsin, plasmin and proprotein 
convertases) [142]. 
There is a high sequence identity of the PLA2 receptors among various mammals 
(rabbit, mouse, bovine and human) [143]. Human ligands of PLA2R are not well 
defined. PLA2R binds sPLA2 group IB (sPLA2-IB and PLA2R being also co-
expressed in human in the pancreas, lung, and kidney), apparently doesn’t bind 
group IIA and it is not known whether it binds group X sPLAs. 
The receptor appears to be involved in the regulation of sPLA2 function, in both 
senses (stimulatory and inhibitory). The inhibitory function seems to be elicited 
through endocytosis internalization of its ligands by the membrane bound 
isoform as well as through inhibitory binding by the circulating soluble form. 
Group X sPLA2 enzymes possess very potent hydrolizing activity towards 
phosphatidylcholine, against which the protective mechanism of clearance via 
PLA2R mediated endocytosis seems to be particularly important.   38
The stimulatory function seems to be a biological consequence of PLA2R 
occupation by ligands, which leads to induction of signal transduction systems. 
As opposed to other enzyme ligands (e.g. proteinase activated receptors), where 
the enzymatic activity is required for ligand recognition and induction of the 
biological function, the enzymatic activity of sPLA2-IB is suppressed by binding 
to PLA2R. 
Some of the effects induced by the PLA2-IB / PLA2R system are: growth 
promotion / proliferation, chemokinetic migration / cell invasion into the 
extracellular matrix, secretagogue effects in endocrine organs (release of 
progesterone in the corpora lutea of the rat, co-secretion of insulin in the rat 
pancreatic islets); effects mediated through production of lipid mediators 
(thromboxane, arachidonic acid, prostaglandins): contractile responses (guinea 
pig lung parenchyma) [95]. 
The source of the soluble isoform of PLA2R is somewhat obscure. It has been 
proposed to be the liver, and its production by the human kidney was also 
suggested by an alternatively processed transcript [137] – but this has not been 
confirmed. 
Other members of the C-type lectin superfamily (e.g. SP-A surfactant protein A 
[144]) seem to be candidates for sPLA2 binding proteins through similar CRDs. 
 
PLA2R has been shown to be activated by C5b-9 [145-149]. Its activation is 
supposed to lead to the expression of stress proteins [150] which are important in 
the glomerular epithelial cell lesion mechanism [151,152]. 
Anti-PLA2R antibodies 
Anti-PLA2R antibodies in membranous nephropathy are of the IgG 
immunoglobulins subclass 4 [153,154]. They have been shown to be highly 
specific (100%) and sensitive (>75%) for idiopathic membranous nephropathy. 
Possible reasons for the sensitivity not reaching 100% are: 
 
•  technical issues of the immunoblot assay 
•  heterogeneity - additional antigens (vide infra)   39
•  misclassification of patients with nephrotic idiopathic membranous 
nephropathy (as opposed to them having an unrecognized secondary 
cause) 
•  absence of immunologic disease activity at the time of the sampling 
 
The last possibility is considered by Beck et al.  to be the leading hypothesis of 
due to the fact that anti-PLA2R antibodies have been shown to be present in 
patients initially nephrotic due to idiopathic membranous nephropathy, absent in 
many of the cases of patients undergoing remission and present again in the cases 
of relapse.  
Other glomerular antigens 
Other targets of the autoantibodies in idiopathic membranous nephropathy, such 
as intracellular glomerular proteins [155] have been hypothesized. It has also 
been suggested that low-levels of anti-NEP antibodies are needed for the 
pathogenesis in adults with IMN [156]. 
Recently two autoantigens (AKR1B1 and SOD2) which are deemed possible 
targets in IMN have been identified through a combined proteomic approach by 
Prunotto et al. [157]. Autoantibodies from sera of patients with membranous 
nephropathy have been blotted on two-dimensional (2D) electrophoresis gels 
which were used to separate human podocyte membrane protein extracts. The 
proteins which were bound by autoantibodies were afterwards characterized by 
MALDI-TOF (matrix-assisted laser desorption/ionization time of flight) mass 
spectrometry. The initial screen yielded a set of proteins that had been targeted 
by autoantibodies in MN sera: SOD2, AR, alpha-enolase, secernin-1, ubiquitin 
hydrolase and Ser/Thr protein phosphatase 2A. AR and SOD2 were later 
confirmed by Western blot, and their renal expression was established by 
immunofluorescence (IF) and immune electron microscopy (IEM). Prunotto et 
al. suggest that neo-expression (neither of them are expressed in glomeruli under 
physiological conditions – but might be induced under oxidative stress 
conditions) of these two autoantigens might be a continuation mechanism of the 
inaugural event which is represented by deposition of anti-NEP, anti-PLA2R etc. 
antibodies.   40
Aldose reductase 
Aldose reductase(AR) / aldo-keto reductase family 1 member B1 (AKR1B1) is a 
member of the aldo-keto reductase family, which includes more than 40 
members. This particular member catalyzes NADPH-dependent reduction of a 
number of aldehydes, including the aldehyde form of glucose into sorbitol (being 
implicated in the development of diabetic complications) and the aldehyde 
phospholipids (generated through the oxidation of unsaturated fatty acids) [158]. 
Manganese superoxide dismutase 
Superoxid dismutase 3 (SOD2) is a member of the iron / manganese superoxid 
dismutase family, important component of the endogenous antioxidant cell 
protective system. Manganese SOD2 catalyses the toxic superoxide by-products 
of oxidative phosphorylation to hydrogen peroxide and diatomic oxygen. 
1.8.4  Similar / related disorders 
1.8.4.1 Association of MN with other autoimmune disorders 
Rare (sometimes just one case report in the medical literature) associations of 
membranous nephropathy with immunological [159] and autoimmune disorders 
have been reported: rheumatoid arthritis [160], celiac disease [161], ankylosing 
spondilitis [162], bullous pemphigoid [163], scleroderma [164], Crohn’s disease 
[165], Sjogren syndrome [166], autoimmune thyroiditis [167]. 
1.8.4.2 Basement Membrane Pathology 
A specific role of basement membrane lesions in human pathology was first 
established in 1990, with the identification of collagen mutations in Alport 
syndrome [168,169]. 
Renal basement membrane pathology 
Pathological entities in which the basement membrane is affected have been 
classified in genetically mediated and acquired basement membrane disorders 
[170]. 
Genetically mediated disorders are considered to be mainly structural defects, a 
proportion of the acquired basement membrane disorders are diseases with an 
(auto)immune component (in which the immune response is oriented against the   41
basement membrane) and there is an overlap category (in which the structural 
defects / variants of components the basement membrane could lead to the loss 
of tolerance and immune response oriented against themselves). 
Structural defects 
The major protein components of all basement membranes are laminin, type IV 
collagen, entactin / nidogen and sulfated proteoglycans [171], the main 
proteoglycan of the glomerular basement membrane is perlecan [172]. Mutations 
of laminin lead to Pierson syndrome (microcoria – congenital nephrotic 
syndrome; [OMIM #609049]). Mutations in type IV collagen lead to: Alport 
syndrome  [173,174] (which is geneticaly heterogeneous, with all forms resulting 
from collagen type IV mutations and three described transmission modes: X 
linked [OMIM #301050] 85%, autosomal recessive [OMIM #203780] 15% and 
autosomal dominant [OMIM #104200] rare), thin basement membrane syndrome 
(TBMD, Benign Familial Hematuria BFH [OMIM #141200], clinically similar to 
Alport syndrome but milder) and Hereditary Angiopathy with Nephropathy, 
Aneurysms and Muscle Cramps syndrome (HANAC, [OMIM #611773]). 
Mutations of entactin / nidogen have not been associated to any phenotype and 
perlecan has not been shown to lead to a kidney phenotype (its mutations are 
associated with Silverman Handmaker [OMIM #224410] and Schwartz Jampel 
syndrome [OMIM #255800] type dwarfisms). 
Mutations of the transcription factor LMX1B (LIM homeodomain 1B) lead to 
nail-patella syndrome [OMIM #161200] through the dysregulation of the 
synthesis of glomerular basement membrane collagen [175]. 
Autoimmune Diseases targeting Basement Membranes 
The targets of autoimmune responses against basement membranes [176] include 
the skin basement membrane – epidermis junction (Bullous Pemphigoid – BP, 
epidermolysis bullosa – EB), the lung basement membrane and the glomerular 
basement membrane (GBM) – both affected in the case of Goodpasture 
Syndrome (GPS, also called Anti GBM disease; an autoimmune disease of lung 
and kidney, [OMIM 233450]) [177].   42
 
Anti GBM disease (Goodpasture Syndrome) 
In the model of Goodpasture Syndrome [178] host factors have been theoretized 
to be immune response genes. This has been suggested by familial instances of 
the disease [179], including a case report of a pair of identical twins that were 
exposed to gasoline and turpentine for two weeks and five days before the onset 
of the disorder [180]. 
MHC class II locus has been deemed to be an important modulator of the 
immune response in GPS. Associations have been published between the 
inflammatory response of GPS in humans and HLA-DR and DQ alleles 
[181,182]. 
Due to limited sample sizes and strong linkage disequilibrium between DR and 
DQ alleles in humans it has been difficult to differentiate the attribution of 
susceptibility between the two regions. In a study in mice the susceptibility to 
anti-GBM disease was linked to the Aβ/Aα region in the H-2
s strain which 
corresponds to the human HLA-DQ region [183]. 
 
Anti GBM disease has been shown in rare cases to overlap with MN (17 cases in 
the literature review by Patel et al.) [184]. This rare immune related glomerular 
condition might suggest the existence of a (partial) common pathogenic pathway 
between the two disorders. One possibility mentioned by Patel et al. is the 
altering of the glomerular basement membrane by the intra- and epimembranous 
immune complexes of membranous nephropathy followed by release of 
glomerular basement material (normal or altered) which may lead to the 
development of an anti-GBM response. 
1.8.4.3 Autoimmune kidney diseases 
The anatomical – clinical classification of kidney disorders (vide infra) is 
unsatisfactory from an etiological pathogenetical point of view. The group of 
primarily autoimmune kidney diseases includes anti-GBM disease 
(Goodpasture’s syndrome), IgA nephritis (IGAN), membranous nephropathy and 
membranoproliferative glomerulonephritis [185]. Two of them where not treated 
in the context of basement membrane pathology and are mentioned for   43
completeness and possible parallels / overlaps of their respective pathogenic 
mechanisms. 
IGAN 
IgA nephropathy, also called Berger’s disease [186], has been shown to be an 
autoimmune disorder in which the autoantigen is the abnormally glycosylated 
IgA class 1 antibody [187]. Genetic studies [188]: a genome wide association 
analysis showed a strong signal of association in the MHC region on 
chromosome 6p, consistent with the autoimmune hypothesis [189]. 
Some evidence from the literature may suggest the existence of  UGB 
(uteroglobin), FN (fibronectin) and IgA connections [130,132,133,190]. A 
review of the medical literature also reveals that membranous nephropathy and 
IgA nephropathy do not tend to overlap, on the contrary membranous 
nephropathy seems to coincide with instances of IgA deficiency [191]. 
Membranoproliferative glomerulonephritis 
Membranoproliferative glomerulonephritis [192] is an class of inflammatory 
glomerulopathies (hence the name glomerulonephritis) which are grouped 
together on the basis of similar pathologic glomerular changes suggesting 
common pathogenetic mechanisms [193]. It is characterised by glomerular 
mesangial expansion (due to both increased matrix and cellularity; hence the 
alternative name mesangioproliferative) and thickening of the capillary walls, 
due to accumulation of (subendothelial and intramembranous) immune deposits, 
cellular interposition and new basement membrane synthesis [194]. It is further 
split in two [195] (possibly three [196]) morphological subclasses: 
 
I. classical (with subendothelial immune complex deposits, in which the 
classical complement pathway is activated), 
II. rare (it is even disputed whether it is a real instance of 
membranoproliferative glomerulonephritis [197]) - dense deposit disease 
(with intra-membranous dense deposits, associated with C3NeF – C3 
nephritic factor: a serum immunoglobulin which stabilizes C3bBb – C3 
convertase leading to the persistent activation of the alternative 
complement pathway),   44
III. considered a subtype of class I (type I + additional subepithelial 
deposits) 
 
The etiology of membranoproliferative glomerulonephritis has not been 
completely elucidated, but a strong link of former ‘idiopathic’ forms to hepatitis 
C virus (HCV) infection cryoglobulinemia was established [198]. The genetic 
component / predisposition can be inferred from familial occurrences [199,200]. 
Mesangioproliferative glomerulonephritis has also been associated with infected 
atrioventricular shunts, complement component deficiencies (C2, C3 and factor 
H) and partial lipodystrophy. 
1.9  Kidney disorder classification 
Anatomically, membranous nephropathy is a glomerular (as opposed to tubular 
or interstitial) kidney disorder. Glomerular disorders are encompassed under the 
XIV
th chapter (Diseases of the genitourinary system, categories N00 - N99) of 
the International Classification of Diseases version 10 (2007) [201], see 
classification 4.   45
 
 
N00 Acute nephritic syndrome 
N01 Rapidly progressive nephritic syndrome 
N02 Recurrent and persistent haematuria 
N03 Chronic nephritic syndrome 
N04 Nephrotic syndrome 
N05 Unspecified nephritic syndrome 
N06 Isolated proteinuria with specified morphological lesion 
N07 Hereditary nephropathy, not elsewhere classified 
N08 Glomerular disorders in diseases classified elsewhere. 
 
.0 Minor glomerular abnormality (minimal change lesion) 
.1 Focal and segmental glomerular lesions 
.2 Diffuse membranous glomerulonephritis 
.3 Diffuse mesangial proliferative glomerulonephritis 
.4 Diffuse endocapillary proliferative glomerulonephritis 
.5 Diffuse mesangiocapillary glomerulonephritis – 
Membranoproliferative glomerulonephritis (types 1 and 3, NOS) 
.6 Dense deposit disease - Membranoproliferative glomerulonephritis 2. 
.7 Diffuse crescentic glomerulonephritis – 
 Extracapillary glomerulonephritis 
.8 Other - Proliferative glomerulonephritis NOS 
.9 Unspecified 
 
Classification (4) of glomerular diseases 
Glomerular diseases (with the exception of hypertensive renal disease) are classified, according 
to the World Health Organisation (WHO) International Classification of Diseases (ICD) criteria, 
in 8 three letter categories (N00 – N08; relating to clinical syndromes) according to mixed   
predominantly clinical (hematuria, proteinuria, nephritic syndrome, nephrotic syndrome) / 
temporal / evolutive (acute, rapidly progressive, recurrent, persistent, chronic) criteria: Each of 
the aforementioned categories have possible (fourth character) morphological subdivisions 
(which should not be used unless specifically identified – e.g. by renal biopsy or autopsy). NOS = 
not otherwise specified.   46
 
1.10  Genetics 
There are several arguments suggesting a strong genetic component in the 
etiology of MN. Familial aggregation has been described in the literature, and it 
is known that the variability of the immune molecules modulating the 
(auto)immune response is genetically encoded – as shown in the aforementioned 
anti-GBM paradigm. 
Suggestive for the genetic control of the susceptibility for membranous 
nephropathy are also the numerous accounts of association of this disease status 
with major histocompatibility complex / human leucocyte antigen (immunologic 
and genetic) markers. 
More or less successful small scale association studies have also been attempted 
based on a candidate gene approach. 
1.10.1  Familial clustering 
Taking in account the caveat that familial aggregation can be often considered a 
result of shared environment [202], there is still an argument for it suggesting a 
possible genetic susceptibility. Proof for familial aggregation [202-205], familial 
aggregation in the context of a geographical isolate [206], occurrence of 
membranous nephropathy in the case of siblings [207,208], HLA identical 
siblings [209,210] (in one case with different outcomes of the disease) [211], 
occurrence in the cases of twins [212,213], a possible syndromic (ie associated 
with deafness) variant of membranous nephropathy in the case of twins [214], 
and instances suggesting a possible mode of inheritance (X-linked) [215,216] 
have all been documented in the medical literature. 
1.10.2  MN Human Leukocyte Antigen (HLA) Associations 
1.10.2.1  The human HLA complex 
History 
The existence of a locus controlling the delineation of self from non-self was first 
confirmed in mice (by P A Gorer and G D Snell in 1948 [217]). The molecular 
complex encoded at this locus was named the major histocompatibility complex   47
(MHC) [218]. The first human element of the MHC was described by Jean 
Dausset in 1958 (investigating sera from recipients of multiple transfusions) and 
was called MAC and later renamed HLA-A2 (Human Leucocyte Antigen) [219]. 
Soon association between HLA determined susceptibility and neoplasias were 
shown in mice (for the mouse HLA analogue H-2 in 1964 [220]) and in 1997 
also in human patients. Noteworthy on the subject of glomerular pathology, the 
first non-neoplasic diseases shown to be associated to particular HLA antigens 
were glomerulonephritis (1969 [221]) and systemic lupus erythematosus (1971 
[222]). 
Structure and function 
HLA molecules present antigenic peptides to T lymphocytes in order to stimulate 
them during the adaptive immune response. All nucleated cells express HLA 
class I molecules, which present intracellular antigens (e.g. viral antigens, after 
viruses entered the cell) to CD8 positive cytotoxic T lymphocytes (CTLs). HLA 
class II molecules stimulate CD4 positive helper T lymphocytes. These are 
activated by specialized antigen-presenting cells (APCs: macrophages, dendritic 
cells, B lymphocytes etc), which are the only cells expressing HLA class II 
molecules. Polymorphisms at the protein level were explored by serological 
typing methods until, with the discovery of PCR it became easier for the 
variability to be assessed by molecular typing at the DNA level. The initial 
naming of HLA ‘entities’ referring to serological types, was adapted to 
accommodate the nomenclature of molecularly defined alleles [223]. 
The human HLA genomic locus 
The human leucocyte antigen (HLA) genes are the most polymorphic genes in 
humans. They are  stretching a genomic super-locus [224] of 4 Mb [225] (or, in 
the extended HLA – MHC locus 6 Mb [226]) on chromosome 6p21. Even though 
it is one of the best defined loci in the human genome, the HLA locus is also 
considered to be one of the most gene dense and complex ones [224]. Therefore 
it is difficult to distinguish causal variants from variants associated with it via 
linkage disequilibrium. Added to that, there are also technical difficulties e.g. the 
inability to amplify HLA sequence segments via PCR [227].   48
Genetics of the R and Q components of the HLA-D region 
The classical D antigen HLA region (which encodes the subunits for the major 
MHC class II antigens: DP, DQ and DR) is located on the chromosome 6p21.3. 
DR and DQ loci are in situated in close vicinity, further away from the DP locus, 
see Figure 6. 
 
 
 
Figure 6 HLA region on human chromosome 6 
Banded ideogram: chromosome 6; red box: extended HLA / MHC region; white boxes: class I 
antigen loci; black boxes: class II antigen loci. 
 
The HLA-D locus is an extended haplotype encoding a ‘superphenotype’. Two 
loci (DR and DQ, which are closely linked) contribute to the expression of this 
superantigen. Both DR and DQ complexes are heterodimeric (the units being 
alpha and beta) cell surface receptors.   49
The HLA-DR locus 
The HLA-DR locus was defined at the seventh Histocompatibility Testing 
Workshop (1977) and refined at the VIII
th Histocompatibility Testing Workshop 
(1980) [228]. The DRA locus encodes the DRα chain of the HLA-DR dimer, the 
DRβ chain is encoded in a more complex way: although there are four possible 
loci, no more than three are present in any individual, no more than two on a 
single chromosome. The HLA-DRB1 locus is ubiquitous and very variable, 
HLA-DRB3, HLA-DRB4 and HLA-DRB5 have variable presence and variable 
variability in humans. 
The HLA-DQ locus 
The DQα chain is encoded at the DQA1 locus and the DQβ subunit is encoded 
by the DQB1 gene. DQB1 is more variable than DQA1. 
HLA-DQA1 
The HLA-DQ locus encompasses two sub-loci (A and B) which encode an 
heterodimeric HLA class II molecule. The two polypeptidic chains (monomers) 
which polymerize to form the dimer are called alpha (DQA, encoded on locus A) 
and beta (DQB, encoded on locus B). The monomers are both membrane 
anchored and form, by their coming together in the class II molecule its so called  
antigen presenting groove, see Figure 7. 
 
 
Figure 7 HLA-DQ dimer structure 
Left: HLA-DQA1 (blue) / HLA-DB1 (magenta) dimer presenting an antigenic polypeptide 
(hypocretin,green) in the antigen presenting groove  (PDB 1UVQ [229]; viewed in Jmol 12.0 
[230]). Right: color coded map of the secondary structure of the same molecular complex. Colour 
key: alpha helix: red; beta sheet: yellow.   50
 
MHC class II molecules have a central role in the immune response. They are 
expressed in antigen presenting cells (APCs): macrophages, dendritic cells, B-
lymphocytes etc. MHC class II molecules present the epitope peptides, which are 
9 – 15 amino acid long and obtained by processing of extracellular antigenic 
proteins within APCs [231]. 
The majority of the polymorphisms within MHC class II molecules are located 
(on both the alpha and the beta chains) within the antigen presenting groove, 
being important in determining its peptide binding specificities. Sequence 
variants in HLA-DQA1 can thus change the shape / conformation of its antigen 
presenting groove and therefore its specificity for the immunogen (epitope) 
presentation. 
 
Membranous nephropathy associations with MHC markers (initially serologic, 
later genetic) have been specifically investigated since the 1970’s.  
1.10.2.2  Serotyping 
The initial studies were performed using serological markers (by 
microlymphocytotoxicity – mlc – serotyping [232] of defined antigens). 
Associations to HLA-DR3 [233-235], HLA-DR3 and MT2 [236], HLA-DR3 and 
B8 [237-239], DR2 and MT1 (in the case of two Japanese [240,241]) and BF 
[242] were found. Later genetic markers were used (by genotyping of STS 
markers situated on the short arm of chromosome 6 which contains the HLA 
region). A mixed (serotyping and genotyping) approach led to contradictory 
results, identifying no association between membranous nephropathy and HLA-
DR3 (DR-DQ) [243]. Different loci encode the molecules which correspond to 
the DR3 serotype. 
1.10.2.3  Genotyping 
Genotyping identified associations between membranous nephropathy and 
DQA1 [244], DRB1 (and DQA1 – DQB1) [245], DR3 and DR5 [246], HLA-
DR2 (in another Japanese study) [247], not C4 (considered to be a possible 
candidate gene, being associated with the DR3 haplotype in Caucasoids and DR2 
haplotype in Japanese) in a Japanese cohort [248], Transporter associated with   51
Antigen Presentation (TAP1; located between HLA-DP and HLA-DQ genes, 
TAP dimers form a dimeric complex in the membrane of the endoplasmic 
reticulum, contributing to the ATP-dependent transport of processed epitope 
peptides from the cytosol to the endoplasmic reticulum lumen [249,250]; 
allegedly not in linkage disequilibrium [251] with HLA-DR3) [252], TAP1 and 
HLA-DM (the products of which participate in the process of loading of the 
epitope peptide on class II molecules [253,254]) [255] and Tumour Necrosis 
Factor (TNF; cytokine polymorphisms are considered good candidates in 
explaining the clinical variability of IMN) [256,257]. 
Observations 
HLA-B8 or DR3 being very rare in Japanese the possibility has been raised of a 
IMG susceptibility gene being in population specific linkage disequilibrium with 
HLA-B8-DR3 in European Caucasoids respectively HLA-DR2 in Japanese 
[247]. 
Limitations of the typing methods made it difficult to assess whether the 
association of IMN with A1, B8, D33 (extended HLA haplotype in European 
Caucasoids) was due to an HLA-DR or -DQ locus, or both, or to another locus in 
linkage disequilibrium to HLA class II [258]. 
1.10.3  Small scale associations 
After the association of membranous nephropathy to the HLA locus (and 
DR3/DR2 haplotype) was established, the search started for the causative gene(s) 
at this locus. Studied candidates were, as mentioned complement factor B (BF; 
human properdin factor, one of the components of the alternate complement 
pathway), complement factor 4 (C4), TAP1 and TNF. 
Based on a similar strategy, non HLA association studies started to be driven by 
the selection of candidate genes, based on the then understanding of the structure 
and function of the glomerulus. 
The results were contradictory, small scale association studies (but not genome 
wide association studies) are known to be plagued by false positive results [259].   52
1.10.3.1  Nephrin 
Nephrin (NPHS1) was considered to be a candidate based on its role in the 
structure of the glomerulus, which was discovered based on the fact that it was 
found to be associated with the congenital nephrotic syndrome of the Finnish 
type in genetic studies [260]. One single nucleotide polymorphism (SNP; 
rs437168) in NPHS1 was found to be associated (the frequency of the G allele 
was found to be significantly higher in the patient group when compared with the 
control group: P = 0.014 < 0.05; OR = 1.82; 95% Confidence Interval = 1.2 – 
12.94) with the susceptibility to membranous nephropathy in a small (132 biopsy 
diagnosed patients) Taiwanese cohort [261]. 
1.10.3.2  NO enzymes 
The NO (nitric oxide metabolism) enzymes were considered meaningful 
candidates based on their physiological role in vasomotility and their role in the 
pathophysiology of progressive renal disorders. The association between 
polymorphisms in NO enzymes and diabetic nephropathy has been queried 
thoroughly [262,263]. A study employing SNP markers in ACE-D (Angiotensin 
Converting Enzyme D) and ecNOS (endothelial cell Nitric Oxide Synthase) 
[264] found no significant associations to the membranous nephropathy trait. 
1.10.3.3   Plasminogen activator inhibitor-1 
Plasminogen activator inhibitor-1 (PAI1) was deemed interesting based on its 
role in renal fibrosis. A polymorphism within this gene was found to be 
associated (P =0.026) with disease progression (renal deterioration) in patients 
with membranous nephropathy [265].  
1.10.3.4  Transient receptor potential cation channel 6 
Transient receptor potential cation channel 6 (TRPC6) was considered a potential 
candidate due to its interaction with nephrin and its proven role in the 
etiopathogenesis of focal segmental glomerulosclerosis (FSGS) [266]. In a 
targeted association study, markers within the TRPC6 gene were not found to be 
associated to membranous nephropathy [267].   53
1.10.3.5  β3 integrin subunit  
Integrins have been implicated in the pathogenesis of glomerulonephritis [268]. 
A study assessing markers within the gene encoding the β3 integrin subunit 
established no association to the membranous nephropathy trait [269]. 
1.10.3.6  Vascular Endothelial Growth Factor 
Expression of the Vascular Permeability Factor (VPF) / Vascular Endothelial 
Growth Factor (VEGF) in the human normal kidney is highest at the level of 
visceral epithelial layer of the glomerulus, suggesting a functional role at that 
level [270]. Its expression has been shown to be altered in glomerular diseases 
(i.e. decreased in sclerotic areas), including in the case of membranous 
nephropathy, suggesting a role in the progression of glomerulopathies [271,272]. 
Its association with chronic kidney disease, of which a subset is documented MN 
has been assessed. An association of a marker with the progression towards 
chronic kidney disease (CKD) has been documented ( P = 0.009) [273]. 
1.10.3.7  Phospholipase A2 Receptor 
Following the immunological investigations of Beck et al., which showed that 
autoantibodies in a majority of membranous nephropathy cases are oriented 
against Phospholipase A2 Receptor 1 (PLA2R1), there have been studies 
investigating the genetic association between polymorphisms of the gene and the 
respective trait.  Two  targeted association studies, one Taiwanese [261] and one 
Korean [274], both confirmed associations of markers in PLA2R1 to the 
membranous nephropathy phenotype. 
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2  Methods of research 
2.1  Genetic dissection 
2.1.1  Genetics 
Genetics (term derived from genetic, adjective from the Greek genesis -  Γενεσιζ 
birth, origin, creation, generation [275]) is the science of heredity. It is generally 
accepted that its use in the present sense of the term was suggested for the first 
time by W. Bateson (in a letter to A. Sedgwick, dated April 18, 1905 [276]). It is 
worth mentioning that J. B. S. Haldane raised the historical point of Titus 
Lucretius Caro referring to genitalia corpora: 
 
“quippe ubi non essent genitalia corpora cuique 
qui possit mater rebus consistere certa?” 
 
("For if there were no factors governing birth, 
how could we tell who anyone's mother was?") 
 
 (De rerum natura, liber primus 1.167-68 [277]) 
 
as being immuable entities which we could consider the equivalent of today’s 
genes [278] (although, arguably, conjuring them into existence in a way that 
resorts to circular argumentation: proof of the assertion [genitalia corpora 
existing] resting on the assertion itself [because they exist they explain maternal 
resemblance] [279]). 
2.1.2  Theories of heredity 
W. Johansson emphasized the distinction between two types of the heredity 
theory, in his terms ‘transmission conception’ vs. the modern ‘genotype 
conception’: 
 
‘The personal qualities of any individual organism do not at all cause the qualities of its 
offspring; but the qualities of both ancestor and descendant are in quite the same manner 
determined by the nature of the “sexual substances” – i.e., the gametes – from which 
they have developed. Personal qualities are then the reactions of the gametes joining to 
form a zygote; but the nature of the gametes is not determined by the personal qualities 
of the parents or ancestors in question.’ 
(Johansson, 1911, p130)   55
2.1.2.1 Transmission conception 
The transmission conception (the generally accepted pre-Mendel paradigm, 
embraced by ‘biometricians’, and consistent with Darwin’s ‘pangenesis’ [280]) 
was based on a ‘blending’ heredity model in which the qualities of the parents 
were blended together in the zygote and which traces its historical roots to 
Hippocrates (the Hippocratic theory of heredity states that different parts of the 
body secrete substances which are gathered in the gonads [281]). The blending / 
transmission theory posed two problems, one of which was pointed out by one of 
the most pertinent critics of Darwin, Fleeming Jenkin [282,283]: continuous 
blending of different characters down the flow of generations would lead to a 
diminishing of the initial differences between them, with the result of vanishing 
variability. But variability is a fundamental prerequisite of the theory of 
evolution, therefore the problem of heredity was from the very beginning situated 
at the core of the most important debate in biology. 
The second problem of the blending heredity theory refers to the fact that it 
supports better the Lamarckian [284] evolutionary theory (transmission of 
acquired traits) than it does the Darwinian (natural selection from a pool of 
existing variants). It is perhaps worth mentioning that the Lamarckian 
evolutionary theory seems to gain new favour in the light of newly discovered 
epigenetic mechanisms [285]. 
2.1.2.2 Genotype conception 
The ‘genotype conception’, initiated by Galton and Weissman, has at its centre 
point the concept of the discrete unit (‘element’ encoding a ‘Merkmal’) of 
heredity that was advocated by Mendel  [286].  
Genotype as a set of discrete units 
The definition of the genotype concept evolved from the blending (Darwin) 
towards the discrete type of inheritance/heredity unit ‘element’ (Mendel). This 
discrete unit was later to be called ‘gene’ by Johanssen [287]. The understanding 
of the discrete nature of inheritance marked the beginning of a debate pertaining 
to the question of how discrete units can explain continuous traits / phenotypes.   56
This split the scientific establishment into 'Mendelians' (Bateson etc.) and 
'Biometricians' (Pearson etc.) [288]. 
What seemed initially to be a strong argument against the theory relying on a 
discrete nature of hereditary elements was its apparent difficulty to explain 
quantitative (continuous) traits. R. A. Fisher’s attempt to solve this difficulty 
(which led to the polygenes / Fisher-Falconer model – in which many discrete 
genes cumulatively explain a continuous phenotype [289]) was the starting point 
of the elaboration of the new evolutionary synthesis. 
Modern synthesis 
The debate was only solved through the elaboration of the modern synthesis of 
the evolutionary theory in the framework of the theoretical foundations of 
population genetics. The foundations of this synthetic evolutionary theory was 
laid in the 1920s and 1930s, when R. A. Fisher [290,291], J. B. S. Haldane and S. 
Wright developed mathematical theoretical accounts on natural selection as a 
genetic process [292]. The real synthesis, a Darwinian fusion of genetics 
(experimental genetics and theoretical population genetics) and natural history 
(with taxonomy at its core), was fashioned in a book written in 1937 by T. 
Dobzhansky (Genetics and the Origin of Species) [292,293]. The fact that E. 
Mayr could have challenged the mathematical school of population genetics 
(Fisher, Wright and Haldane) to having created what he called ‘beanbag 
genetics’ [278] shows how important Dobzhansky’s ‘biological translation’ of 
the theory was.  
 
The “unit factor” (‘in the gamete’) was named gene by W. Johanssen, who also 
introduced the terms genotype and phenotype [294], marking the difference 
between the potential for a trait and the trait itself [295]. 
 
2.1.3  Definition of terms 
Albeit fundamental concepts of biology, the terms gene, genotype, genome, 
phenotypic character, phenotype,  phenome are fluid, ill defined, used in 
different (sometimes contradictory) senses by different authors – appear to be in 
constant evolution / redefinition [296].   57
2.1.3.1 Gene 
The concept of the ‘gene’ itself has a ‘historical burden’ [297]– being defined 
differently in the ‘classical’ period of genetics (that is in relation to the trait it 
encodes for; the ‘instrumental gene’ [295]) as opposed to the recent ‘molecular’ 
period (which is in relation to its underlying physical entity i.e. stretch of DNA; 
the ‘material gene’ [295]). 
2.1.3.2 Genotype 
The initial definition of genotype [298] referred to ‘the totality of genes in a 
gamete’ – closer to what would be today called a genome [299]. The evolution of 
the term led to its actual meaning – which is the ‘genetic composition’ of an 
individual (lato sensu), in practice used as genetic status at a given locus (which 
is stricto sensu a partial genotype). 
2.1.3.3 Phenotype 
In a similar way, the concept of the general phenotype (better termed ‘phenome’ 
as defined by Lewontin in 1992 [296] ‘the actual physical manifestation of the 
organism, including its morphology, physiology and behavior.’) can be viewed 
as the totality of partial phenotypes [298]. 
In practice phenotype is usually used in the sense of what is strictly the partial 
phenotype / phenotypic character (defined by Suzuki et al. as ‘ the form taken by 
some character … in a specific individual’ or ‘the detectable outward 
manifestation of a specific genotype’ [296]). 
The added difficulty in defining the phenotype derives from what has been called 
the ‘blueprint’ concept, in which the phenotype ‘…is the manifestation … of the 
interaction of this information [genotype] with … the environment in the 
broadest sense – that enable the blueprint to be realized.’ (Futuyuma [296]). 
The blueprint concept has also been criticised for its not taking in account of the 
process of development [300], which is another layer of complexity to be added 
to the understanding of the already complicated genotype – phenotype 
relationship.   58
2.1.4  Genotype Phenotype Association 
To dissect the genetic component of a trait means to explore the link / association 
between its phenotype and genotype [300]. We could think of it in the larger 
context of the theoretical task for (population) genetics: to set up a complete 
theory as a set af laws that predictably map genotypes to a phenotype space and 
phenotypes to a genotype space [301]. 
2.1.4.1 Many to many mapping 
The genotype phenotype map [302] represents not one-to-one but rather many-
to-many nonlinear relationships (one genotype many phenotypes: pleiotropy; one 
phenotype many genotypes: genetic heterogeneity) [298]. 
The one-to-one simplified version of mapping is an instance of reductionistic 
approach in science which is opposed (philosophically, epistemiologically) by 
the holistic approach (which, at the limit, argues that mapping is just a theoretical 
construct, all relations being many to many) [303,304]. 
Genotype / phenotype duality? 
In a metaphorical way one might suggest that genotype and phenotype are two 
facets of a fundamental hereditary unit in the same way elementary particules 
have been theorized to have a dual (corpuscular and wave) nature by L. De 
Broglie. 
The ‘pathogenetic tree’ metaphor used by Rimoin et al. is also helpful in 
understanding the genotype – phenotype interrelation in the case of Mendelian 
(but also complex ‘Galtonian’) conditions. In this comparison the mutation is at 
(or veri close to! sic) the level of the genotype and everything more remote 
represents successive layers of phenotype at increasing complexity (in the 
comparison: the root represents the mutation, the trunk represents the aberrant 
gene product, the branches are the pathogenetic pathways – different branches 
for different organ and tissue specific pathology – and the leaves are the 
detectable phenotypic features) [305].   59
2.1.4.2 Two steps (paradigm shifts) enabling genetic mapping 
The one trait – one chromosome paradigm (Mendel – Boveri – Sutton) 
A premise to genetic mapping was the establishing of the fact that the heredity 
‘particles’ (factors, Mendel) are based on chromosomes. This is due to T. Boveri, 
whose experimental program launched in 1889 led to the demonstration that 
nuclear rather than cytoplasmic factors determine the character of the developing 
embryo [306,307], and to W. S. Sutton (who, in 1902, observed the parallelism 
between Mendel’s laws and the segregation and assortment of grasshopper 
chromosomes during meiosis [308]). 
In 1911 E. B. Wilson mapped the first (human, even mammal) gene (the one 
specific for colorblindness) to a specific chromosome (chromosome X):  as 
‘revealed by the cytological evidence; for what I have called the "homogametic" 
and the "digametic" sexes obviously correspond respectively to the homozygous 
and the heterozygous conditions.’ (p. 260) [309]. 
The many traits on one chromosome paradigm (synteny, linkage) 
The fact that there are more traits than chromosomes leads to the possibility of 
linkage (see below). Linkage is an apparent contradiction of Mendel’s law of 
independent segregation, which would only apply strictly if there would be a 
one-to-one correspondence between traits and chromosomes. Serendipitously, 
Mendel studied traits of the green pea (Pisum sativum) that were situated on 
different chromosomes [310]. In 1905, W. Bateson, E. Saunders and R. Punett, 
whilst studying the sweat pea (Lathyrus odoratus), observed the  phenomenon of 
non compliance with Mendel’s second law (due to the fact that the respective 
traits were on the same chromosome – as was to become clear much later), 
phenomenon which at that time they called coupling (or connection, as opposed 
to independent segregation which they termed repulsion) [311]. The occurrence 
of gene loci on the same chromosome has been named ‘synteny’ [312]. 
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The Sutton-Boveri chromosomal theory was further refined by T. H. Morgan 
who was able to show (based on Drosophila melanogaster experiments) that 
‘genetic units’ lie on linear chromosomes like ‘beads on a string’ [313]. 
This led to the practical possibility of mapping. A.H. Sturtevant proved the 
possibility to determine the quasi physical (that is genetic) location of a gene, 
establishing the succession of genes on  the Drosophila  chromosome, and 
introducing the concept of genetic distance as a measure of recombination 
probability between two loci. Genetic sistance is measured in [c]M 
([centi]Morgans), in honor of Sturtevant’s mentor [314]. 
2.2  Mapping (by linkage) 
The practical possibility to map traits to genotypes by measuring recombinations 
between markers in pedigrees was thus established.  
2.2.1  Markers 
The ‘genetic units’ assessed by Sturtevant were genetic markers. They were 
phenotypic proxies for genotypes. It became clear that the effect of a genotype 
associated to a trait can be assessed through the observation of an indirect entity 
associated to the genotype proper. Historically, the initial ‘markers’ were thus 
phenotypic markers (e.g. Sturtevant’s construction of the Drosophila genetic 
map using phenotypic markers such as eye color etc. [314]). 
A (genetic) marker is thus defined as a measurable variable which can provide 
information about allelic variation at a given locus  [315]. 
In the light of the genotype-phenotype duality metaphor, it is understandable that 
early phenotypes had to be discrete in order to be mapped to discrete genotypes. 
The concept of a discrete phenotype has its historical roots with F. Galton [316], 
who believed that large discontinuous variations are at the driving force of 
evolution, as opposed to his cousin C. Darwin, who thought small – yet 
continuous – variations are the ones who enter the ‘ratchet’ of selection to lead to 
evolution [317]. 
W. Bateson, K. Pearson and W.F.R. Weldon were all students of Garrod. 
Bateson became one of the founders of the ‘Mendelian’ (discontinuous variation) 
school of thought in evolutionism whereas Pearson and Weldon founded the 
‘biometric’ (continuous variation) school [318].   61
The collaborations of Bateson with clinicians, notedly E. Nettleship and A. 
Garrod led to phenotypes such as alkaptonuria to be mentioned as an example of 
human Mendelian recessive inheritance by Bateson, and might have been 
important in the crystallization of the chemical variant – genetic unit concept by 
Garrod [319]. Other discrete human (clinical) phenotypes (‘inborn errors of 
metabolism’) studied by Garrod and which paved the way of his cementing of 
the concept of chemical individuality were: albinism, cystinuria and pentosuria 
[320]. 
2.2.1.1 Phenotypic / morphologic markers 
The aforementioned traits / disorders were obvious phenotypic markers due to 
them being visible (albinism: white skin, alkaptonuria: black urine etc). Sex was 
also an obvious, and early studied ‘phenotypical’ marker, used as such to 
elucidate its own heredity [321]. 
One of the early clinical (microscopic, pathologic / morphological) phenotypical 
markers was thalassemia. The study of its transmission and geographical 
distribution led to J.B.S. Haldane’s  evolutionary explanation of the hererozygote 
advantage in the case of malaria susceptibility [322]. 
2.2.1.2 Serological markers 
ABO 
The discovery of the blood groups by Landsteiner coincided with the year which 
is considered to be the moment of rediscovery of Mendelism [323]. At the core 
of this discovery was (again) the crucial question about (quantifiable ergo 
discrete) intraspecific variability: 
 
‘… proteins in various animals … are different…’ [do] ‘… individuals within a species 
show similar … differences.’ [324]? 
 
Landsteiner and Richter probably already realized the possibility that blood 
groups are genetically determined, Landsteiner and Levine suggesting in a later 
publication that they might be used in assessing paternity cases [325]. In 1910, 
von Dungern and Hirzfeld, studying 72 families with 102 children, clearly stated 
the A and B agglutinogens of the red blood cells reflected Mendelian factors 
(they suggested two independent dominant alleles) [326].   62
It was for Bernstein to later demonstrate the correct hypothesis (multiple alleles 
at a single locus) [326]. Thus it has been argued, due not to the least to the 
quantifiable discrete characteristics of its  phenotype, the ABO system locus (of 
which we now know it is situated on chromosome 9q34 [327]) became the first 
bona fide human marker locus [328]: due to the one-to-one correspondence of 
phenotype and genotype in the case of blood groups, it soon became evident that 
serotyping can become a proxy for genotyping of the respective locus. 
Ludwig and Hanka Hirzfeld used the ABO marker in a study associating 
different blood groups to different ethnic groups (establishing that blood type A 
appeared to be more common in northern and central Europe and blood type B 
more common in eastern Europe, Africa and Asia)  [329]. 
It was R. A. Fisher who suggested that the use of serological markers in the quest 
for detecting gene products… 
 
“… is going to lead to a greater advance (…) in the problems of human genetics than 
can be expected from any further work on biometrical or genealogical lines.” [330,331] 
HLA / MHC serology 
The study of Human Leucocyte Antigens started with experiments pertaining to 
tumor biology in mice (showing that the susceptibility of transplantable tumors is  
inheritable ergo genetically determined; Little [332] and Tyzzer, 1916  [333]). 
At the suggestion of J. B. S. Haldane, in the 1930s, P. A. Gorer was studying the 
possible association of resistance factors against growth of allogenic tumors with 
blood groups. Thus he was able to discover the first antigen responsible for 
tumor rejection [334]. P. Medawar was able to show in the 1940s that rejection 
of allogenic skin grafts (host versus graft) has an immune mechanism [335]. In 
1948 Gorer and the geneticist G. D. Snell [217] published a combined study of 
tumor antigenicity and genetics in mice, showing linkage between the gene 
encoding the histocompatibility factor discovered by Gorer (antigen II) and a 
marker called Fu (fused). The locus close to the Fu gene became known as 
histocompatibility locus II (2), in short H-2 [336]. In 1971 it became clear that 
the complexity of H-2 derives not only from the existance of many alleles but 
also of more than one locus [337,338], the H-2 locus became therefore the H-2 
complex, or MHC (Major Histocompatibility Complex) in the mouse.   63
The human equivalent of the MHC, the HLA complex was discovered at the 
antigenic level in sera from multitransfused patients or multiparous women 
which reacted with leucocytes from different tested individuals (Dausset et al. 
[339,340] , Van Rood et al. [341] and Payne et al. [342] in 1958). 
The combinatorial conundrum of the HLA complex: many loci each presenting 
with many alleles, started to be dissected immediately. The discovery, in 1962, of 
the first diallelic system – at the first locus (to be called locus HLA-B with the 
alleles 4a and 4b – which were later renamed Bw4 and Bw6) by analysing the 
reaction patterns of 60 sera from multiparous women with leucocytes from 100 
donors, being another example for the early use of computer analysis in biology 
[343]. The second locus (to be called HLA-A) was suggested by Bodmer and 
Payne in 1966 [344] and confirmed in 1968 [345], and the third one (eventually 
to become HLA-C) was to be firmly established in 1973 [346]. To further deal 
with the increasing amount of complexity, International Histocompatibility 
Workshops (IHW) were established where techniques and results were discussed 
between investigators in the field. The third IHW in 1967 focused mainly on the 
study of families and the genetics of HLA antigens, establishing for the first time 
that most of the specificities were encoded on a single chromosomal region 
[347]. It was also the time and place R. Ceppellini introduced the term 
‘haplotype’ [348]. 
Bach et al. suggested the existance of two classes of antigenic determinants in 
mice: serologically defined (SD) and lymphocyte defined (LD) [349]. This 
classification was later (1977, Klein) to be renamed class I (classical A, B and C 
and non-classical, later discovered G, E and F) versus class II, with LD being 
class II, its locus as HLA-D. The subtypes of the HLA-D antigenic determinants 
were identified as DR (initially DRw = D Related workshop, nomenclatures of 
the antigenic determinants were established by the Nomenclature Committee of 
the IHWS), DQ and DP. 
In the 1970s the HLA complex was localized on the 6
th chromosome (1974) 
[350] on the short arm (6p21-22; 1977) [351]. 
The first reported association of a HLA serologic marker (then called ‘leucocytic 
phenotype’ – as if to further underline the switch from clearly phenotypic 
markers towards serologic / molecular ones!) with a disease (in this case 
Hodgkin’s lymphoma) was reported in 1967 by Amiel at the third IHW [352].   64
This first association was weak: HLA-4C in patients 51% versus  healthy 
individuals 27% [347]. 
Polymorphism 
The concept of polymorphism is another instance in which a universally 
acceptable definition is hard to give. Polymorphisms are thus defined as common 
variants, where common has been set at an empirical threshold of 1% prevalence 
in a population [353]. It is maybe worth noticing that this threshold has been 
chosen mainly relating to the size of samples of human populations which were 
available in 1971, and has not been revised ever since. 
2.2.1.3 Molecular markers 
The first true molecular markers [315] were variants of enzymes (which used to 
be called allozymes, a contraction of the terms allelic [variants of] enzymes) 
distinguishable on gel electrophoresis due to differences (size, charge, 
conformation etc.) caused by amino-acid substitutions. Variability has been 
evaluated for Drosophila [354,355] and man [356] in 1966. The surprising 
results of more than expected within population polymorphism led to the 
hypothesis of (most) mutations being functionally neutral: Kimura’s theory of 
neutral molecular evolution [357]. 
2.2.1.4 (True) genetic markers (DNA molecular) 
In a strict sense, genetic markers are genetic material (DNA) markers. The 
discovery of DNA by Miescher [358] preceded the understanding of the fact that 
it was the vehicle of genetic information (by the momentous experiments of 
Griffith [359], Avery et al. [360], Hershey and Chase [361]). 
The publication of the structure of DNA in 1953 by Watson and Crick, based on 
X-ray diffraction data by Franklin (on ‘sodium thymonucleate’) [362] and 
Wilkins [363], contains the now very famous understatement: 
 
"It has not escaped our notice that the specific pairing we have postulated immediately 
suggests a possible copying mechanism for the genetic material." [364] 
 
which hints toward the importance of the discovery which is considered to mark 
the beginning of the era of molecular biology, and which was later expanded in a 
follow up paper [365]. This conceptual step was followed by a pragmatic step:   65
the ability to manipulate the ‘semantophoretic molecules’ (semantides) [366], 
giving raise to the era of genetic engineering based on recombinant technology. 
In order to achieve this, two breakthroughs were further needed: the first was the 
discovery, understanding of the mechanisms and ability to use the enzymes 
which modify nucleic acids. The isolation of DNA polymerase was published by 
A. Kornberg in 1958 [367,368], that of DNA ligase by Weiss and Richardson in 
1968 [369] and the road towards the use of sequence specific restriction enzymes 
as  ‘workhorses’ of molecular biology was set by a succession of theoretical and 
experimental developments which started with the observation that phage DNA 
is fragmented upon introduction in bacteria and ended with proving the 
usefulness of a combination of restriction enzymes and gel electrophoresis in the 
physical mapping of the SV40 viral genome [370]. The second had to do with 
superseding a technological bottleneck encountered by molecular biology due to 
the fact that cell based DNA amplification (cloning) is very elaborate [371]. This 
second difficulty was surpassed with the invention of the Polymerase Chain 
Reaction (PCR), which led to the possibility of cell free DNA amplification 
[372]. 
Restriction Fragment Length Polymorphisms 
From the point of view of genetic DNA marker development, restriction enzymes 
made it possible to distinguish between single nucleotide polymorphisms that 
were changing the sequence of one of their cutting sites. The difference between 
lengths of cut versus uncut fragments are evidenced through electrophoresis, the 
variants being called Restriction Fragment Length Polymorphisms (in short 
RFLPs) [373]. The first association study which was performed using genetic 
markers in 1989, was based on RFLP technology (markers) at the last step in 
localizing the gene (CFTR) mutated in cystic fibrosis (CF) [374]. 
Minisatellites 
Minisatelites are a class of genetic polymorphisms that has only been of limited 
use as markers (due mainly to their non-random distribution and the technically 
challenging procedure needed to assess them) is the class of minisatellites [375]. 
Minisatellites are tandem repeats of short (6 to 1k bp) motifs which show length 
polymorphism (spanning 0.5 to several kb). There is some similarity between the   66
consensus sequence of minisatellites and a viral (phage) sequence (GCTGTGG). 
They have a distribution in the human genome which shows a high bias toward 
chromosome ends (telomeres) [376]. 
Microsatellites 
Much more often used (more uniformly distributed across the genome, easy to 
assess based on a PCR assay) were microsatellites [377], also called Sequence 
Tagged Site (STS) type markers or Simple Sequence Repeat Polymorphisms 
(SSRPs). Microsatellites are tandem repeats, being composed of very  short 
motifs (1 to 6 bp) which show length polymorphism (therefore are also part of 
the class of Variable Number of Tandem Repeat VNTR elements) [378]. 
 
One can note that DNA polymorphisms / variants / markers can be divided in 
two classess: quantitative variants (structural variants, repeat variation: 
minisatellites, microsatellites) versus  strictly qualitatively variants (sequence 
variants proper: RFLPs, SNPs – transversions translations) [379]. 
SNPs 
At the beginning of the use of the name SNP (Single Nucleotide Polymorphism) 
there has been an ‘unfortunate heterogeneity in the use of the term’. Initially 
SNPs were called only the biallelic sequence variants which were genotyped 
through high-throughput techniques. In time, the evolution of the term has led to 
the tendency to call (almost) all sequence variants SNPs [315]. 
Conceptually RFLPs are SNPs. Jeffrey’s initial estimate ‘one in 100 bp 
polymorphic’ (estimate of human heterozygosity based on RFLPs) [380] was 
with hindsight very accurate. The number of common variants (primarily SNPs) 
identified through the efforts of the Human Genome Project, the SNP 
Consortium and the International HapMap Project was about 10 million [381]. 
The number of validated unique identifiers (#rs) in the NCBI database (dbSNP 
[382]; Build 132) is 19,727,605 [383]. 
 
The use of molecular markers in (linkage) mapping has been advocated in the 
early 1980s in a seminal paper by Botstein et al. [384].   67
2.2.2  Linkage mapping in humans 
Mapping was proved to be easily applicable in model animals with short 
generation times and many offspring (e.g. Drosophila, Mus etc.), where mating 
experiments could be designed according to the question to be addressed. 
 
In humans, the first gene to be assigned to an autosome (chromosome 1) was the 
gene encoding the Duffy blood group. This was based on the observation that the 
Duffy blood group trait co-segregates in the studied family with a cytological 
abnormality (alteration in the coiling structure, visible cytogenetically) on the 
long arm – which was the marker of chromosome 1 [385]. But this was a rather 
rare serendipitous occurrence. 
 
Due to the impossibility to design mating experiments in man (as opposed to 
experimental organisms), special methods of analysis for pedigree data had to be 
developed for human linkage studies [386]. 
2.2.3  Linkage (definition) 
The concept of ‘linkage’ (the term being used in genetics in the sense of Morgan 
and Lynch who wrote an article in 1912 entitled “The linkage of two factors in 
Drosophila that are not sex-linked” [387]) is best defined as the non independent 
segregation of two genetic loci [388]. 
2.2.4  Scoring procedures 
There is a distinction between estimation of recombination frequencies (which 
requires the exact specification of a trait model) and linkage detection (which 
does not require this specification, but is more powerful in the presence of it) 
[389]. Bernstein (1931) applied for the first time scoring procedures to human 
linkage, showing that each family can be assigned a score whose sum provide a 
test of the null hypothesys (given the body of data is sufficiently large for the 
distribution of the score to be nearly normal) [326]. 
A development of Bernstein’s method led to the first study of human linkage, 
published by Bell and Haldane in 1937 (which established the linkage of 
haemophilia and color blindness, on chromosome X) [390].   68
By 1953 there were three apparent methods available for the detection of linkage 
in human pedigrees [391]: The sib-pair method of Penrose (applicable to pairs of 
sisters and brothers when the partents’ genotypes are unknown) [392,393]; the 
method of efficient scores (or weighted u-scores, by Fisher and Finney; 
applicable to nuclear families i.e. families consisting of parents and their children 
as opposed to extended families) and the method of likelihood ratio (introduced 
by Haldane and Smith in 1947; the most suitable for extended families). Smith 
showed that all methods are ultimately different forms of the likelihood / 
probability ratio test (nonsequential) [394]. 
2.2.4.1 Sib pair method 
This is a nonparametric approach (does not depend on the assignment of the 
mode of inheritance). Sib pairs are categorized according to concordance / 
discordance for trait and marker. There is a natural excess of concordance over 
discordance even in the absence of linkage, but linkage between the trait locus 
and the marker locus will lead to additional excess concordants added to natural 
excess. The additional excess can be quantified as δ and can be used as a a test 
for linkage: 
 
δ = (θ - 1/2)
2  >   0         1 .  
 
The sib-pair method of L. Penrose was used by J. Mohr (in 1951) to establish the 
linkage between the Lutheran blood group and the Lewis (AB0 secretor) 
phenotype [395]. 
2.2.4.2 u-scores method 
Linkage is considered to be significant when λ > λ0[ε]    2. 
 
Where: 
 
λ0[ε] is the significance point corresponding to level ε and 
λ - the efficient score is the weighted combination λ = Σaixi 
xi – observations 
Ci ⊂ ai – class of alternatives to the null hypothesis (=1)   69
2.2.4.3 Likelihood ratio 
Haldane and Smith proposed as a test for linkage (λ) the likelihood ratio of the 
probability for recombination fraction (θ) to its value when θ = 0.5  
 
λ = θ/ θ( ½ )          3 .  
2.2.5  LOD score 
C. A. B. Smith (in 1953 [391]) and N. E. Morton (in 1955 [396]) introduced the 
LOD (Logarithm of ODds) score method to genetic analysis. The key 
contribution of Morton was to consider the probabilities of type 1 (false rejection 
of the null hypothesis) and type 2 (failure to reject the null hypothesis) errors of 
the procedure. This was based on the principles of sequential hypothesis testing 
of Wald [397] and made the guidelines that Morton suggested for the analysis of 
linkage data easy to generalize / implement. By suggesting a value for the 
statistical significance of linkage (the now famous LOD > 3) one can add (hence 
the sequencial aspect) individuals / families (of an assumed homogenous 
phenotype) to the analysis until that threshold is met. 
2.2.6  Computer methods 
Allegedly the first use of a computer to solve a biological question was the 
tabulation of a solution for a differential equation in a paper by R. A. Fisher in 
1950 [398]. Already in 1955, a vacuum-tube based predecessor of the IBM 650 
computer was being used to tabulate lod scores for nuclear families (for N. 
Morton’s paper which introduced his implementation of the LOD score). Based 
on Smith’s 1959 formulation of likelihood [399], J. H. Renwick and J. Schulze 
developed software (written in machine language, therefore not transportable and 
implemented in Baltimore on an IBM 7094 computer) which was able to 
calculate LOD scores for large pedigrees [400]. 
The first linkage software to become widely available: LIPED (Likelihood in 
PEDigrees) [401] was developed by Ott to study a large Alaskan kindred with 
familial hypercholesterolemia [402] (1974). It was written in FORTRAN and 
computes two point LOD scores for simple pedigrees. It is based on pedigree 
likelihoods as computed through the Elston-Stewart (peeling) algorithm [403].   70
A series of popular linkage analysis programs followed, of which we mention 
LINKAGE (Lathrop 1984) [404], GENEHUNTER (the first software to perform 
exact multipoint linkage calculations for general families with many markers; 
Kruglyak  et al. 1996) [405],  SIMWALK (Sobel and Lange) [406] and 
ALLEGRO (Gudbjartsson et al. 2000) [407]. 
2.2.7  Positional cloning vs. functional cloning 
Genetic mapping based on linkage of the trait with genetic markers has been 
called positional cloning or reverse genetics. This is in contrast to functional 
cloning (forward genetics) and by similarity with the reverse engineering 
approach [408]. 
Functional cloning is defined as being the identification of genes based on pre-
existing biological information about the defect (disease → function → gene → 
map;  e.g. purification of the normal protein product of the gene, antibodies 
against the protein product etc). The limiting factor of this approach is the fact 
that such functional insight for the vast majority of genetic disorders is non 
existent. By contrast, positional cloning starts with the mapping of the trait to a 
chromosome / region of interest which is then successively narrowed, leading 
eventually to the identification of the responsible gene which can then be studied 
functionally (disease → map → gene → function) [409]. 
Positional cloning has been a very successful approach, but one has to pay 
attention to the caveat of a possible (deliberate) ascertainment bias when using it: 
families are studied that show extreme phenotypes (fully penetrant, early onset 
etc). The understanding of the whole spectrum of alleles is therefore deemed to 
be incomplete [410]. 
2.2.7.1 Genetic mapping 
At the core of positional cloning lies genetic mapping. Genetic mapping is the 
evaluation of relative positions of loci on chromosomes inferred from 
frequencies of recombinations that are taking place between them. The measure 
unit for the genetic  distance is the Morgan (M; usually the measure being in the 
range of centiMorgans - cM). 
Physical mapping refers to establishing the absolute (physical) positions of loci 
on chromosomes and measuring the distance between them. The measurement   71
unit for physical distance is the base (basepair – bp; usually in the range of 
kilobases – kb). 
 
Genetic mapping can be further split conceptually into linkage mapping (linkage) 
and linkage disequilibrium mapping (association) [411]. 
2.2.8  Linkage disequilibrium 
An ‘unfortunate term’ [412] (as linkage equilibrium is suggestive for, yet 
represents no linkage between independent loci) introduced by Lewontin and 
Kojima in 1960 [413], linkage disequilibrium (LD) is defined as the tendency for 
alleles at two different loci to exhibit a statistical association [414]. Two aspects 
can contribute to linkage disequilibrium: (more often) the two loci are linked or 
the two alleles are under (common) evolutionary pressure [413]. Linkage 
disequilibrium can be measured by two variables (D’ and r
2).  
2.2.8.1  D’ 
For one pair of loci (a, b) with two alleles representing the haplotype AB 
 
DAB = pAB - pApB 
 
Where: 
DAB- coefficient of LD between the two alleles at the given loci  
pAB- haplotype frequency 
pApB – product of frequencies of the alleles 
 
D’= D / Dmax  (D’ = 1 at perfect disequilibrium) 
 
2.2.8.2 r
2 
r
2  - is a correlation coefficient: 1 represents perfect correlation and 0 no 
correlation at all. 
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2.2.8.3 Heatmap 
A common form of representing measures of linkage disequilibrium [415] are 
heat map triangles, in which the measure of disequilibrium between two points is 
represented as a shade of colour at the intersection of the perpendiculars on the 
cathetes from the physical coordonates of the respective points plotted on the 
hypotenuse of a right-angled triangle, in a similar way that distances are 
represented on geographical maps, see Figure 8. 
 
 
 
Figure 8 Example of Linkage Disequilibrium (LD) heatmap 
From [415]; white – non significant; clear gray – significant at 5% level, dark gray – significant 
at 1% level, black – significant at 0.5% level. 
2.3  Association mapping 
2.3.1  Background 
Association was introduced as a mathematical / statistical concept by Yule [416] 
– applied to discrete variables, in distinction from correlation (which was defined 
in its biological / anthropometric acception by F. Galton [417] and applies to 
continuous variables). 
The epidemiologic / genetic meaning of the term refers to the variable that 
measures (lato sensu) the co-occurrence of two (genetically encoded)   73
characteristics in a population, more often (stricto sensu) the relation between the 
trait / disease and its causal factor. It is understood that causal factors can be 
external (environmental) or internal (endogeneous). 
 
The first association studies (in a very broad sense of the term) asking the 
question with regard to environmental factors are ancient. A passage in the bible 
(Daniel 1:11-16) can be interpreted as one of the first ‘protocols of diet and 
health’ [418]: 
 
"Prove thy servants, I beseech thee, ten days; and let them give us pulse to eat, and water 
to drink. 
Then let our countenances be looked upon before thee, and the countenance of the 
children that eat of the portion of the king's meat: and as thou seest, deal with thy 
servants. 
So he consented to them in this matter, and proved them ten days. 
And at the end of ten days their countenances appeared fairer and fatter in flesh than all 
the children which did eat the portion of the king's meat." 
 
(King James Version, Dan. 1:12-15) 
 
A better documented instance is the experiment performed by the Scottish ship 
surgeon James Lind in 1746 to prove the link between citrus fruit and scurvy. It 
is generally considered to be the first proto-association study performed for 
medical purposes and was published in 1753 [419]. 
 
Association of traits (including diseases) to internal factors amounts to the 
aforementioned phenotype - genotype correspondence mapping. 
 
The first classic association studies where testing links between blood groups as 
indirect (‘proxy’, phenotypic; vide supra) markers and different pathological 
entities. Weak but consistent associations could thus be established between the 
ABO system and traits involving the digestive tract (the first association thus 
described being the one between ABO blood groups – stated by the authors to be 
an indicator of ‘genetic differences’ - and gastric cancer [420]). 
The evolution of markers from phenotypic to serologic and then molecular has 
been mentioned before. With the advent of molecular genetic (DNA) markers it 
became possible to directly investigate associations between the traits 
(phenotypes) and genotypes.   74
2.3.2  Overview of association studies 
Association studies can be categorized in several types (after Balding [421]). 
2.3.2.1 Based on the phenotype assessed 
Depending on the phenotype one can distinguish between qualitative traits, 
which can be dichotomous (e.g. case-control) and categorical (either ordered e.g. 
mild, moderate, severe; or unordered, e.g. distinct disease subtypes / categories); 
and quantitative, i.e. continuous traits. 
2.3.2.2 Based on the genotype 
Depending on the genotype one can assess association one SNP at a time (allelic 
or genotypic) or combining SNPs (haplotype analysis). 
2.3.2.3 Based on the scope of the study 
Association can be local, including candidate locus (candidate gene or candidate 
polymorphism) studies and fine mapping studies; or comprehensive i.e. genome 
wide. 
2.3.3  The estimation of association significance 
Different tests of association can be applied to assess significance in an 
association study for a dichotomous trait (case-control phenotype) [421]. 
2.3.3.1 Single SNP analysis 
Allelic (allele count) test 
The contingency table for the allelic test is a 2X2 matrix (contingency table)   
[422] containing the counts of the two possible alleles per SNP (A and B) among 
cases and controls. 
 A  B 
cases    
controls    
 
There are many tests of significance [423], of which better known are the general 
tests: Pearson’s χ
2 test [424] and Fisher’s exact test [421,425].   75
Pearson’s χ
2 test 
Is used to obtain a p-value to reject the null hypothesis that the proportions in the 
rows and columns of a m x n unordered contingency table. 
 
The formula used is: 
 
Χ
2 = ∑
=
−
n
i i
i i
E
E O
1
2 ) (
 
 
Where: 
Χ
2 = Pearson’s cumulative test statistic 
Oi = observed frequency 
Ei = theoretical (expected) frequency 
n = number of cells in contingency table 
 
The formula of the expected frequency is: 
 
Ei = 
n
N
 
 
Where: 
N = number of observations 
n = number of cells 
 
Χ
2 transformation to a p-value is based on the fact that Χ
2 approximates a chi-
squared distribution with (m-1)(n-1) degrees of freedom (df). In the case of the  
2 x 2 contingency table (2-1)(2-1) = 1 df. 
 
The p-value is the probability of observing the test statistic at least as extreme (as 
Χ
2) in a chi-squared distribution. 
 
In our case (where X = Χ
2): 
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p(X > x) 
 
The probability distribution of X is completely characterized by the cumulative 
distribution function (CDF) [426]. 
The CDF gives the probability of a real value X to be less than (or equal to) x. 
 
FX(x) = p(X ≤ x) 
 
The two posibilities (X > x respectively X ≤ x) being mutually exclusive: 
 
p(X > x) = 1 - p(X ≤ x) 
 
The p-value will therefore be the substraction of the CDF value from one. 
 
p(X > x) = 1 - FX(x) 
 
Where, for discrete random variables X: 
 
FX(x) = ∑
≤X t
t f ) ( 
 
The empirical threshold of statistical significance has been set at p ≤ 0.05. 
Fisher’s exact test 
Fisher criticized Pearson’s approach to ‘simple laboratory data’ (in a 
characteristically ‘Fisherian’, yet not completely fair way) in that: 
 
‘Not only does it take a cannon to shoot a sparrow, but it misses the sparrow!’ 
 
The problem attacked by Fisher was mainly that of the size of the dataset, his 
hypergeometrical test being amenable to address small samples, which Pearson 
previously had scoffed about [427]: 
 
  ‘Only naughty brewers deal in small samples’ 
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The formula of the Fisher exact test of nonrandom associations between two 
categorical variables (assessed in a 2xr contingency table) is: 
 
p = 
! ! !... !
) ! !... ! )( ! ! (
2 12 11
2 1 2 1
N x x x
c c c r r
r
r  
 
Where: 
c = column 
r = row 
cr x =  cr x the element on column c row r 
cr = column total 
rc = row total 
N= total elements 
Genotypic test 
The contingency table for the allelic test is a 2 x 3 matrix containing the counts 
of the three possible genotypes per SNP (aa, aA and AA) among cases and 
controls. 
 aa  aA  AA 
cases      
controls      
 
Armitage test 
Under the assumption of an additive contribution of individual SNPs to the 
phenotype (aa < aA < AA; with aA being intermediate), the prefered test 
becomes the more conservative proportion trend test (Cochran Armitage). The 
principle of the Armitage test is the testing of the hypothesis zero slope for a line 
fitting the estimates for genotypic risk. For the ordered (by number of minor 
alleles in the genotype: zero, one or two) case / control contingency table: 
 
 aa  aA  AA 
cases      
controls        78
 
The statistic for the Armitage test is: 
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prediction equation for (ordinary) least-squares fit: 
 
p )
1i = p1i + b(si-s )
2 
 
For: 
n10 = count for cases with 0 minor alleles 
n11 = count for cases with 1 minor alleles 
n12 = count for cases with 2 minor alleles 
 
n00 = count for controls with 0 minor alleles 
n01 = count for controls with 1 minor alleles 
n02 = count for controls with 2 minor alleles 
 
N = total count   79
2.3.3.2 Multiple SNPs 
Analysing one SNP at a time ignores the block-structure of linkage 
disequilibrium (LD) in the human genome: regions of relatively low 
recombination frequency (so called haplotype blocks, in short haploblocks) are 
separated by ‘hotspots’ of recombination [428]. 
Linkage disequilibrium blocks 
It has been shown that the human genome is structured in regions protected from 
cross-overs (so called recombination cold spots) separated by regions of intense 
recombinatorial activity (so called recombination hot spots). The regions of low 
recombinatorial activity are defined by loci in the respective stretches 
segregating together (being linked, therefore in linkage disequilibrium). These 
regions are therefore also called linkage disequilibrium blocks. In the European 
population linkage disequilibrium blocks (or haplotype blocks, in short 
haploblocks) have been shown to stretch in average over 30 kb. 
Association studies detect markers that are in linkage disequilibrium with 
causative polymorphisms (or, in extremely lucky cases, the causative 
polymorphism is the marker for which association has been detected). 
 
Information from neighboring markers can be captured by two different 
approaches: one which has been called marker (SNP) based (and is based on 
logistic regression) and a haplotype based one [429]. Importantly, haplotype 
based approaches can capture the combined effects of cis-acting causal variants 
which are tightly linked [430]. The fundamental problem of haplotype based 
methods is the extreme technical difficulty of observing haplotypes as such 
(short of single chromosome typing, spermatide DNA typing and other such 
tedious techniques), which leads to the necessity to infer them (so called phase 
inferrence). This introduces a certain level of uncertainty to the analysis, which is 
indirectly proportional with the level of linkage disequilibrium between markers 
[421].   80
2.3.4  Scope of the study classification of GWA studies 
2.3.4.1 Candidate gene association studies 
Genetic markers started to be used for association studies involving candidate 
genes [431]. Case-control gene association studies though have been shown to be 
biased towards a high false-positive rate; which has been often attributed to 
stratification (though this has not been proven). More likely this bias is due to the 
low prior probability of association for any given gene. It is suggestive then that 
HLA – autoimmune disorder association studies show less false positive bias 
(HLA associations have been repeatedly confirmed), possibly reflecting the 
higher prior probability for this complex of loci when compared to other loci 
tested throughout the genome [432]. 
2.3.4.2 Comprehensive association scans 
Risch & Merikangas suggested the strategical change of the mapping method 
from linkage to association [433]. It became only a matter of technology 
evolving for the first genome wide association studies to be performed. 
Known genes association scan 
An intermediate strategy was the querying of the association of traits with 
functional SNP markers, genotyped by a PCR based high throughput method 
[434], in known genes. The first such study, by Ozaki et al., used 92,788 SNPs to 
establish the association between LTA (Lymphotoxin Alpha) and myocardial 
infarction [435]. The second study assessed the association of rheumatoid 
arthritis with SNPs in known genes, its results being published stepwise, as they 
were revealed [436,437]. 
 
Genome wide proper 
The first successful proper genome wide association study was published by 
Klein et al. in 2005, establishing a polymorphism in complement factor H as a 
cause for age related macular degeneration [438]. By GWAS proper we 
understand a study in which markers are (quasi) evenly distributed across the 
genome, with no regard to the positions of known genes.   81
2.3.5  Problems 
Two problems have to be dealt with when performing an association study: 
population stratification and (for genome wide studies) multiple testing. 
2.3.5.1 Population Stratification / Structure 
Population stratification (initially called population structure by S. Wright [439]) 
is defined as the difference between allele frequencies of cases and controls 
which are not due to the investigated trait but are determined by systematic 
ancestry differences. Population stratification has been shown to influence the 
results of case control association studies [440]. We are aware of the propensity 
of latent population stratification to inflate the type 1 error rate, generating false 
positive signals for association in variants informative for substructure [441,442]. 
The classic example of spurious association due to population stratificationon is 
the study of type II diabetes in Pima Indians. Pima Indians have higher rates of 
diabetes than individuals of Caucasoid ancestry. However the Pima population 
contains individuals with higher degrees of Caucasoid ancestry (with accordingly 
lower diabetes sucseptibility). Loci at higher frequency in Pima versus 
Caucasoids were hence spuriously associated with the disease [443]. The effect 
of population stratification is directly proportional to the number of samples used 
in the study). [444] 
Genomic control 
The careful choice of controls cannot completely alleviate the risk of hidden 
stratification (hidden or ‘cryptic’ stratification being stratification that is difficult 
to detect but which may still be significant in genetic terms) [445]. 
One of the methods suggested to correct for ‘cryptic’ stratification is called 
genomic control [446]. The association statistics are adjusted at each marker by 
dividing it by a uniform factor called genomic inflation factor (lambda), the 
assumption being that stratification artificially ‘inflates’ the probability of 
association. 
Structured association 
The limitations of the genomic control method are due to the differences in 
population frequencies of different markers (some markers have strong   82
differences between different populations, in this case the applied uniform 
genomic control inflation factor might be insufficient; other markers vary less 
markedly between populations, in that case applying the uniform genomic 
inflation factor is going to result in a loss of power for the association statistic). 
Another method to deal with population stratification is structured association. 
Information from unlinked genotypes is used to assign samples to discrete 
subpopulation clusters. The software which implements the structured 
association algorithm is called STRUCTURE [445]. However the method cannot 
be applied to genome-wide association studies because of the computational cost 
of large numbers of markers. To deal with this problem a method called 
EIGENSTRAT [441] has been suggested, in which the discrete clusters of 
subpopulation are obtained (as in STRUCTURE), the difference being that   
principal components are used as synthetic variables. Synthetic variables are 
linear combinations of original variables which are summarized in such a way 
(by multivariate techniques – such as principal component analysis, PCA) as to 
minimize the amount of information lost  [447]. 
2.3.6  Issues of Quality Control 
2.3.6.1 Hardy-Weinberg equilibrium 
The Hardy-[448]-Weinberg equilibrium criterion states that in panmictic 
Mendelian populations gene frequencies are stable [449]. Panmixia pertains to 
the quality of the population to reproduce through random mating (i.e. each male 
of the population has an equal chance of mating with each female); a Mendelian 
population is named as such because the basic Mendelian laws of heredity are 
followed in its interbreeding individuals.  
Deviations from Hardy-Weinberg equilibrium nullify the hypotheses of panmixia 
or evolutionary stasis. This is the case when the studied population is inbred, 
stratified, or when one deals with genotyping errors. It has therefore been 
suggested as a quality control measure in populational studies [421].  
The suggested values (P) at which one considers deviation to be significant (and 
are used as a thresholds for the Hardy-Weinberg quality control step) are either 
10
-3 or 10
-4 [421]. It has to be noted that deviations from Hardy-Weinberg   83
equilibrium can also be a sign of real association (in the case of deletions, 
duplications, mutations under selective pressure etc.). 
2.3.7  Separating false-positive from true-positive associations 
2.3.7.1 Multiple testing correction 
Statements based on statistical evidence are uncertain. This is usually dealt with 
by specifying a maximum probability threshold at which the null hypothesis will 
be rejected even though it is true (type I error) as the level of statistical 
significance. When more than one hypothesis is tested simultaneously (which is 
referred to in multiple testing) each test has its own type I error probability. The 
possibility that type I errors are commited increases therefore with the number of 
hypotheses / tests / comparisons (this increase is called ‘inflation of the alpha 
level’ – where alpha is the set significance level). The rate of Errors Per 
Comparison is usually referred to as PCE [450]. 
 
There are many methods that deal with the multiple testing problem, each 
adapted to different situations. One method that is considered to be suitable to 
address the problem in the case of association studies and therefore has been 
most commonly used herein is the unweighted Bonferroni correction. 
The simple Bonferroni method takes the form: 
 
reject Hi if: pi < 
C
PT
PF
] [
] [
α
α =  
Where: 
α[PT] = alpha per test 
α [PF] = alpha per family of tests 
C = number of tests (Comparisons) 
 
It has been shown that without correction for multiple comparisons (conventional 
level of significance P < 0.05) an association study using 1 million SNPs will 
show 50,000 ‘associations’ to the trait, almost all being false positives (due to 
chance alone) [451].   84
2.3.7.2 Replication 
Many genotype-phenotype associations reported in the era of candidate gene 
association studies have been shown to be spurious. This was done by the means 
of the replication study, which purpose is to evaluate a finding from a previous 
(exploratory) study. The same approach has been suggested in order to provide 
credibility for the validity of the findings in exploratory studies in the case of 
GWA studies [452]. Ideally identified associations have to be replicated in 
independent population studies. 
2.3.7.3 Examination of functional implications experimentally 
Linkage and association studies identify genomic locations in which it is 
assumed polymporphisms causative for the studied trait are harbored. The 
causative link and ultimate proof of association is only provided by functional 
studies elucidating the effects of polymorphisms with functional implication 
(identified by the sequencing of the region of interest) on gene expression or the 
transcribed product. The functional studies usually used include studies of 
morphology, biochemistry, immunology and / or physiology at the cellular level, 
tissue level or organism level in biologic material from humans or from animal 
models (which have been usually genetically manipulated e.g.  knock-out or 
knock-in models [451]). 
2.3.8  Imputation of untyped genotypes 
To increase the power of the studies performed on single platforms, to 
uniformize the datasets and not to lose genotypes that have not been genotyped 
across different platforms the possibility exists to impute missing genotypes 
based on the HapMap dataset. Existing software for imputation are PLINK, 
MACH, BEAGLE, IMPUTE [453].    85
3  Findings 
3.1  MN Linkage mapping 
3.1.1  Family 
We performed linkage analyis studying the largest reported family affected by 
membranous nephropathy to date, described in 2008 by Bockenhauer et al. [215]. 
Of the 34 individuals in the pedigree spanning five generations, 19 were 
investigated and 4 were shown to be affected. 
3.1.2  Phenotype 
In the case of membranous nephropathy, we considered the phenotype to be 
binary: affected versus nonaffected. Given that membranous nephropathy is a 
histopathologically defined entity the clinical diagnosis had to be confirmed 
through renal biopsy. 
 
 
 
Figure 9 Pedigree of the family reported by Bockenhauer et al. 
Squares: males; circles: females; white: unaffected; black: affected. 
 
3.1.3  Genetic component 
Considering the fact that membranous nephropathy is a rare diagnosis in 
childhood (estimated incidence of less than 1 per million in the child population) 
it was assumed that the disease had a common basis in the family (the alternative 
hypothesis – of all individuals being independently affected by chance – having a 
probability of less than 10
-24 = (10
-6)
4). An additional argument in favor of the   86
genetic  versus environmental cause hypothesis was the fact that the affected 
individuals were living in three different households, without any observed 
increased incidence of membranous nephropathy in their vicinities. 
3.1.4  Pathological – Clinical description 
The patients are all males, they presented at different ages (between 1 and 67 
years) with nephrotic-range proteinuria (greater than 3.5 g/1.73 m2/24 hours in 
adults [454]). In all of them kidney biopsies were performed which showed the 
typical pattern of membranous nephropathy (granular deposition of IgG, ‘spike 
and dome’ basement membrane proliferation). There were however some aspects 
consistent more with membranoproliferative glomerulonephritis: mesangial 
proliferation (in one of the individuals) and ‘double contours’ (in two of the 
individuals). Causes of secondary membranous nephropathy were searched but 
not identified: serum complement fractions C3 and C4 were not depressed, 
immunoserology was shown to be negative for anti-nuclear and anti-double-
stranded DNA antibodies (positive in lupus nephropathy), no markers of chronic 
infections were found (hepatitis, HIV). 
3.1.5  Serology 
Serological studies were performed on sera from two of the affected individuals 
and their mothers to assess for antiglomerular antibodies. In the youngest (onset 
of nephrotic syndrome - unresponsive to treatment with corticosteroids - with 
microscopic haematuria at 1 year of age) affected member of the family there 
was positive immunofluorescence suggesting that foeto-maternal 
alloimmunization might have been a triggering factor in this case. The antigen 
remained elusive (it did not recognize specific proteins in the lysates of positive 
specimens on Western blot analysis). 
3.1.6  Inheritance pattern 
The segregation study of the pedigree (the fact that all affected individuals are 
males and connected through the maternal lineage) suggests an X-linked 
inheritance pattern. Other possibilities that cannot be discarded are an autosomal 
dominant inheritance model with incomplete penetrance or a mitochondrial 
inheritance model.   87
3.1.7  Linkage Analysis 
Linkage analysis was performed as follows: 
3.1.7.1 Genotyping 
Blood samples for DNA extraction were collected from 19 individuals - 
including all 4 affected individuals (identified as 90301 to 90319 in the 
pedigree). Genotyping was performed using the highly informative DeCode 
polymorphic STS (Sequence Tagged Site [455]) marker set of 2000 polymorphic 
markers [456],  which covers the human genome at an average marker density of 
approximately 2 cM. The di- tri- or tetra microsatellite genetic markers were 
amplified using multiplex PCR with fluorescently labeled primers. The lengths 
of the markers were resolved by capillary electrophoresis in an automated 
process. In the DeCode set, chromosome X is covered by 86 STS polymorphic 
markers, the coverage for chromosome X being 193 cM  (approximate genetic 
length of chromosome X in the DeCode genetic map) / 86 (number of markers) = 
2.24 cM. Figure 8. 
 
 
 
Figure 10 Chromosome X markers used in linkage analysis 
The figure shows almost uniform coverage of chromosome X with 83 markers. Marker names 
were enquired on the UniSTS.aliases file accessed through the FTP server of the UniSTS [457] 
database at NCBI (accessed at 23/05/2010, last modified 21/05/2010). STS positions, 
corresponding to the human February 2009 (GRCh37/hg19) genome assembly, were obtained 
through the Table Browser data retrieval tool  [458] of the UCSC Genome Browser [459]. For 
three DeCode (DXS*) type identifiers (DXS6786, DXS6799 and DXS9895) there were no aliases 
present in the UniSTS.aliases file that could be used for the UCSC query. Their physical 
positions were retrieved through individual search of the UniSTS database and are plotted on a 
different track in the figure. The plots on chromosome X were obtained using the Browser 
Extensible Data format (BED; tab separated; chromosome, start physical position, end physical 
position, name) custom track annotation tool on the UCSC Genome Browser. Also shown on the 
figure are the sequencing gaps corresponding to the human February 2009 (GRCh37/hg19) 
genome assembly. The largest gap corresponds to the centromere. 
 
3.1.7.2 Quality check: Pedcheck 
The genotypes obtained were checked for Mendelian inconsistencies using Jeff 
O'Connell's software, Pedcheck [460]. Marker DXS1195 (see genotype_error 
custom track in Figure 10) was found to be inconsistent with individual 90309   88
(genotyped 3/3 at this locus) being the child of father 20 (genotyped 0/0 at 
DXS1195) and mother 90305 (genotyped 4/4 at DXS1195). We assumed this has 
been a genotyping error and re-coded the genotypes 0/0 both for individuals 
90309 and 90305. 
3.1.7.3 Quality check: GRR 
The structure of the pedigree (possible errors in the assignment of relative status) 
was checked using Goncalo Abecasis’ software, GRR (Graphical Representation 
of Relationship errors) [461]. 
3.1.7.4 Exact algorithm: Genehunter 
Linkage was assessed first by using a modified version of the exact peeling 
algorithm of Elston and Stewart [462] as implemented by Lander and Kruglyak 
in the second version of the software GENEHUNTER [463]. GENEHUNTER 
performs an exact multipoint analysis. It assesses linkage model free 
(nonparametric) and model based (parametric). The computational time needed 
by GENEHUNTER increases lineary with the number of markers and 
exponentially with the number of individuals to be analyzed in one family. For 
the analysis of the X linked transmission model the X linked version of 
GENEHUNTER (XGG v. 1.3) was used. 
Due to computation time and memory constraints not all individuals of the 
family can be analysed using the GENEHUNTER package.  
3.1.7.5 Merlin / Minx 
To assess the X linked transmission model  of inheritance the MINX (MERLIN 
in X) module (‘unpublished but believed to be correct’ [464])  of  the MERLIN 
software [465] was used. The input for MINX/MERLIN was edited (LINKAGE 
format [404] to MERLIN format) using the data-handling software Mega2 [466]. 
3.1.7.6 Haplotype analysis: Haplopainter 
Haplotypes were reconstructed with GENEHUNTER X and MERLIN/MINX 
and visualized using HaploPainter [467].   89
3.1.7.7 Analysis (GENEHUNTER X) 
We used a transmission model assuming an X linked dominant inheritance 
model,  complete penetrance and a disease allele frequency of 0.001. Encoded in 
the datafile (DAT, which is the file describing the model of inheritance and the 
markers) input of the GENEHUNTER software in the LINKAGE format as 
follows: 
 
0.9990 0.0010 # frequency of the major allele – frequency 
of the minor allele 
1 # number of traits 
0.0000 0.0000 1.0000 # penetrance for females aa, aA, AA 
0.0000 1.0000 # penetrance for males a0, A0 
 
Result 
Due to computation time and memory constraints, individuals 90308, 90314, 
90312, 90301, 90316 and 90315 have been dropped from the analysis. No 
linkage peak was observed using this scenario, see figure 12. 
 
 
 
Figure 11 Trimmed pedigree 
Used for linkage analysis under the constraints of GENEHUNTER. Squares: males; circles: 
females; white: unaffected; black: affected. 
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Figure 12 LOD score curve for the first linkage analysis scenario 
Linkage analysis performed on the GENEHUNTER trimmed pedigree. The y axis quantifies the 
LOD score, the x axis the genetic distance (in cM – centimorgans, for chromosome X), the 
magenta line represents the information content, the blue line the LOD score curve. 
 
3.1.7.8  ‘Affected only’ analysis 
Considering the possibility of incomplete penetrance, the analysis was redone 
using the affected-only scenario (the unaffected individuals were recorded as 
“phenotype unknown”) as suggested by Lander [468], see Figure 13. 
 
 
Figure 13 Pedigree used for the affected-only linkage scenario 
Trimmed pedigree as used for the GENEHUNTER analysis in the phenotype unknown scenario 
(phenotype unknown is represented by question marks – colored gray; affected individuals: 
black, unaffected ones: white). 
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The LOD score curve for the affected-only scenario shows a positive peak (LOD 
~ 1.2) between 110 and 120 cM. Table ; Figure 14. 
 
Table 1 LOD score affected-only linkage scenario 
 
cM  LOD score Information content
118.14 -1.20286 0.965445
118.46 0.996628 0.844138
118.77 1.171701 0.805222
119.09 1.171645 0.811299
119.41 0.99646 0.862723
119.73 -1.20286 0.998735
 
 
 
Figure 14 LOD score curve for the affected-only linkage analysis scenario 
The y axis quantifies the LOD score, the x axis the genetic distance (in cM – centimorgans, for 
chromosome X), the magenta line represents the information content, the blue line the LOD 
curve. 
 
The region of linkage has been defined between the markers where the inflection 
of the curve from negative to positive multipoint LOD scores takes place, see 
Table 2. 
 
Table 2 markers defining the linked region 
Affected-only linkage analysis scenario; physical coordonates (bp) on chromosome X  according 
to the Human Feb. 2009 (GRCh37/hg19) assembly; genetic distances according to the deCODE 
map. 
 
marker names  chrX start   chrX end   cM 
DXS8064 (AFMB319YA5)  117272895 117272895 119.68 
DXS1001 (AFM248WE5)  119836526 119836526 123.76   92
 
3.1.8  Haplotype reconstruction 
Haplotype reconstruction was performed using the MINX software. 
 
 
 
Figure 15 Haplotype reconstruction on chr X 
The affected haplotype is represented in olive-green, the two recombinations establishing the 
upper and the lower limit of the region of interest are observed in individuals III.2 and V.1. 
 
The region of interest has been redefined based on the markers immediately 
outside of the observed meiotic events (which represent the limits of the possible 
physical positions of the respective events): DXS8053 - DXS8064. Table 3; 
Figure 15. 
 
Table 3 markers defining the affected haplotype 
Affected-only scenario haplotype reconstruction; physical coordonates (bp) on chromosome X  
according to the Human Feb. 2009 (GRCh37/hg19) assembly; genetic distances according to the 
deCODE map. 
 
marker names  chrX start   chrX end   cM 
DXS8053 (HSB291XA5)  115564734 115565136 114.85 
cM DXS8064 (AFMB319YA5)  117272895 117273206 119.68 
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Figure 16 genes in region of interest on chromosome X 
Representation of the region of interest on the UCSC Genome browser (human February 2009 
GRCh37/hg19 genome assembly). Shown are the known genes (as defined by UCSC [469]). 
From right to left: SLC6A14, Cxorf61 and KLHL13. 
 
The newly defined region of interest spans 1,678,473 bp and includes 3 known 
genes (as defined by UCSC [469]): SLC6A14 (SoLute Carrier family 6 member 
A14), Cxorf61 (chromosome X open reading frame 61) and KLHL13 (Kelch 
Like family member 13). 
 
Given that membranous nephropathy has a strictly localized visible lesion (in the 
kidney at the level of the glomerulus), one can assume (as a working hypothesis) 
that the molecule(s) important in the pathogenesis of the disorder are going to be 
expressed at that particular location. To address this we performed in silico 
expression analysis on the set of genes which are encoded in the region of 
interest. 
3.1.9  In silico expression analysis 
We compared the expression levels of the known genes in the region of interest 
using the filtering capabilities of the UCSC Gene Sorter [470] program (part of 
the UCSC Genome Browser).  Expression levels of human and mouse transcripts 
accessed through Gene Sorter were provided by Novartis GenAtlas 2. The 
publicly available expression profiles (normal human transcriptome; under the 
BioGPS – Gene Portal Hub [471]) of messenger RNA from a diverse array of 
normal human tissues and cell lines were assessed by hybridization on high-
density custom oligonucleotide array chips targeting predicted genes. 
Biotinylated and fragmented cDNA synthesized based on total RNA from 79 
human tissues was hybridized to the Affymetrix HG-U133A and custom GNF1H 
microarray chips targeting a set of 44,775 nonredundant human transcript probes 
compiled from Refseq, Celera and Ensembl (corresponding to 33,698 unique 
human genes – according to the January 2004 annotation; accounting for 
multiple probe sets interrogating single genes split transcripts). The arrays were 
scanned, the resulting images were analyzed by the M AS5 algorithm [472] and   94
the results were normalized by using global median scaling (to correct for global 
multiplicative effects, assuming that different sets of intensities, i.e. different 
slides, differ by a constant – global – factor [473]). The experimental procedure 
being ‘the equivalent of multiple tissues Northern blots for thousands of genes at 
once’ [474,475]. 
The levels of expression are calculated for each gene as log2 (tissue/reference) 
and the values range from -5.0 to 5.0 (0 being the median expression for the 
group of tissues, i.e. brain tissues, fetal brain included in one expression group). 
 
The only gene expressed in the kidney according to the in silico expression 
dataset is KLHL13, at the relative level of 0.955. 
 
 
 
Figure 17 Expression levels of KLHL13 
Expression levels of KLHL13: x-axis different cells / tissues; y-axis normalized expression levels 
(BioGPS database, accessed 10/01/2011 [471]). 
 
3.1.10  KLHL13 
KLHL13 (Kelch Like protein 13) is a member of the BTB (Bric-a-brac-
Tramtrack-Broad complex)-Kelch protein family. It is a substrate specific 
adaptor for the Cul3-based E3 ligase, interacting with Cul3 (Cullin3). Cul3-BTB 
complexes are ubiquitin ligases [476]. It has been suggested that the 
Cul3/KLHL9/KLHL13 E3 ligase coordinates mitotic progression (completion of 
cytokinesis) [477].   95
3.2  MN Association mapping 
Given the paucity of families where there is a clear Mendelian inheritance pattern 
for the membranous nephropathy trait we considered applying the case-control 
association method to discover genes with an impact on the etiopathology of the 
disorder. 
3.2.1  Exploratory (UK) analysis 
3.2.1.1 Ethical approval 
IRB (Institutional Review Board) approval was  given by the Oxford Multicentre 
Research Ethics Committee (Oxford, UK). 
3.2.1.2 Selection of cases  
The cases that have been selected for the study are 336 patients which have been 
assessed and diagnosed by the UK Membranous Nephropathy Consortium. The 
diagnosis has been confirmed in all of them by kidney biopsy. As expected more 
males than females are affected: 231 males versus 105 females (gender ratio: 
 2.2 / 1). The samples have been provided by the MRC/Kidney Research UK 
National DNA Bank for Glomerulonephritis. 
 
No manoeuvres have been attempted to enrich for specific disease-predisposing 
alleles in the case cohort (e.g. by selecting individuals that are affected to the 
extremes of the clinical spectrum, that  present with an early age of onset or by 
using familial cases [478]). 
3.2.1.3 Genotyping 
DNA was extracted from whole blood samples from patients, collected after 
informed written consent was given by each participant. Genotyping was 
performed on a HumanCNV370-Quadv3 BeadChip (Illumina, Inc.) platform 
(deCODE genetics, Iceland). 
The choice of genotyping chips for the cases was based pragmatically on the 
availability of historical control genotypes assayed with the same platform, and 
the presence of copy number variation data for these chips. 
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Genotyping technology 
The BeadChip genotyping technology is based on the Infinium HD Assay which 
is a Whole Genome Genotyping Single Base Extension (WGG-SBE) assay 
[479], an improvement of the Allele Specific Primer Extension (ASPE) assay 
[480,481]. This technology relies on an initial whole genome amplification step 
[482], performed on 200 – 400 ng genomic DNA followed by fragmentation of 
the DNA and then by the hybridization of the sequences adjacent to the SNP 
query sites on 50 bases long single probe oligonucleotides that have been 
designed appropriately. The hybridization is designed to stop one base before the 
interrogated base (which is the SNP marker proper). In the next step 
fluorescently labeled nucleotides are specifically incorporated according to the 
template through enzymatic single-base extension, see Figure 18. The color and 
intensity of the fluorescent signal are detected on an imaging system (Illumina 
iScan). 
 
 
 
Figure 18 Infinium genotyping assay 
Starting from amplified and fragmented genomic DNA; step 1: hybridization of unlabeled DNA 
fragments to 50mer oligonucleotide on a bead in the array; step 2: enzymatic single base 
extension (with fluorescently labeled nucleotide).   97
 
Genotyping data 
Raw data (intensity data) was normalized using the Bead Studio analysis 
software (Illumina, Inc.). The normalization step used the raw data from the 
array itself plus five essential steps including outlier removal, background 
estimation, rotational estimation, shear estimation and scaling estimation. Eight 
CEPH samples (four pairs of duplicates) were used as controls. The 
reproducibility rate for the CEPH duplicates was greater than 99% per duplicate 
pair (average reproducibility rate 99.55%).  
 
Coverage [483,484]: 373,397 markers were interrogated per BeadChip (344,678 
SNPs, representing 92.31% and 28,286 CNV – Copy Number Variant - markers, 
representing 7.57%). 
 
The definition of a successful sample implies a call rate that was greater than 99 
% for SNPs and greater than 95 % for CNV markers. Lower quality data samples 
have call rates between 0.98 and 0.99. According to these definitions, 313 of the 
336 samples where considered successful (93.15%) and 20/336 (5.95%) samples 
were considered lower quality data. The average call rate was 99.61%. One 
sample was identified as being pooled (i.e. contaminated whith DNA from 
different samples). 
 
The call frequencies were 99.67% for SNPs (343,554 out of the released 344,678 
SNPs on the chip) and 97.67% for CNVs (22,403 out of the released 28,286 
CNV markers on the chip). 
 
Genotypes were encoded according to the ‘Forward’ definition (same as dbSNP, 
see below). 
SNP encoding 
To perform an association analysis one theoretically needs just to distinguish 
between the two possible alleles for each given SNP (called A and B). The 
problem arises when comparing different populations the naming of A and B   98
might have been swapped. Calling them ‘major’ versus ‘minor’ allele (according 
to their respective frequences) is not a solution given that what is a major allele 
(more frequent) in one population might be minor (less frequent) in a different 
one. Ideally one would then want to designate the alleles according to the 
nucleotide present at that locus in the genotype (A, T, C or G). 
The nucleotide type encoding of SNPs with regard to strand designation (sense 
versus antisense) and/or orientation (forward versus reverse) presents theoretical 
challenges due to the ‘work in progress’ nature of successive assemblies of the 
human genome reference sequence, where a clone can be assigned different 
orientations therefore the coding strand being changed (e.g. a sequence can be 
assembled into the forward / coding / sense strand in the previous version of the 
human genome assembly, but being corrected to the reverse strand in the next 
assembly). 
In practice there are three ways of describing a SNP: forward (5’ to 3’) / reverse 
(3’ to 5’) depending on the way the SNP was first (historical) submitted to the 
database (as applied by dbSNP [382]), same (i.e. forward) strand 5’ to 3’ (as 
encoded in HapMap), and top / bottom (which is the proprietary solution to the 
encoding problem suggested by Illumina [471,485]). The most commonly used 
coding scheme is the forward encoding, which assumes that the orientation of the 
strand is known at the given position. Given that the human genome is relatively 
well annotated, the orientation of the strand being usually (but still not always!) 
known, one considers the sense (coding, forward) strand as being the reference 
on which to call the two possible alleles of each SNP. 
Controls 
The control cohort for this study consists of 349 individuals that are assumed to 
be unaffected by membranous nephropathy. The genotypic data has been 
obtained for British controls from the population-based birth cohort (thus being a 
so called ‘historical’ control type cohort). We were aware of a possible 
misclassification bias, which would result from the impossibility to exclude 
latent diagnoses of membranous nephropathy in the control cohort. The 
consequences of misclassification bias are known to be modest unless the trait is 
common, but membranous nephropathy is not common therefore risk for 
selection bias is minimal. The Wellcome Trust Case Control Consortium   99
(WTCC) assuaged concerns about the damaging potential of the misclassification 
bias in a study [486]. 
The control cohort consists of 108 males and 241 females (with a gender ratio of 
~ 1:2.4). DNA was extracted from blood and genotyped on an Infinium 
humanHap300 (Illumina) platform. 
Coverage: 317,503 markers were interrogated per BeadChip (only Single 
Nucleotide Polymorphism SNP type markers, no Copy Number Variation CNV 
markers). 
A successful sample was considered a DNA sample for which the call rate was 
greater than 99 % for SNPs. According to this definition 306 of the genotyped 
349 samples where successful (87.67%). 43/349 (12.33%) samples were 
considered lower quality data (call rates between 0.98 and 0.99). The overall 
average call rate for the cases cohort was 99.51%. 
3.2.1.4 Data management and analysis 
Data management and description 
Files were stored as text files (.txt) and were manipulated using shell commands 
in Cygwin (a Linux like environment emulator [487]) and Python [488] scripting. 
The files encode matrices in which the columns are the genotyped markers and 
the rows represent the genotyped individuals. The data cells contain the 
genotypes of the genotype for the given marker in the given individual (A_B 
where A and B are the two alleles encoded as nucleotides in the forward 
convention). The first two columns of the matrix encode in a binary mode 
(according to the LINKAGE format [489]) the minimal phenotype of the 
individuals (gender: 0 male, 1 female; and affection status: 0 unaffected, 1 
affected), see Table 4. 
 
Table 4 example of a case control matrix 
 
  gender  status  rs12345  rs123456 etc 
B0100603 0 0 C_C  G_G  … 
B0100604 0 1 C_T  A_G  … 
B0100605 1 0 T_T  ?_?  … 
etc  … … … …  … 
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Quality control and analysis were performed using the SNP & Variation Suite 
v7.3.1 (Golden Helix, Bozeman, MT, www.goldenhelix.com). 
Case-control matrix overlap and informative markers 
The intersection of 351,507 markers (cases) with 317,503 markers (controls) 
yielded 305,491 common markers. A common matrix was created by appending 
the two files, that is dropping all columns (markers) that were not overlapping. 
From the 305,491 markers present in the common (case and control) matrix 
305,452 markers are informative, having two alleles (D and d) and 39 markers 
proved to be uninformative, having only one allele (DD or dd) in all genotyped 
individuals. 
3.2.1.5 Pre-QC Analysis 
In order to evaluate the effect of filtering analyses were performed prior and after 
each step of the quality control procedure. The first genotypic association test 
computed was the basic allelic test (BAT), where the amount of minor versus 
major alleles (D versus d) are compared in cases versus controls (the affection 
‘status’: affected vs. unaffected being the dependent variable). The statistic used 
was Pearson’s Chi-squared test. 
Q-Q plot 
The expected chi-squared values were also computed in order to generate a 
quantile-quantile (Q-Q) plot, which visually shows how far the observed values 
deviate from the expected values [490]. 
 
Where there is perfect concordance between the observed values and the 
expected ones, the intersection will be plotted on the X = Y line on the graph 
(where the observed values are projected on the X axis and the expected values 
are projected on the Y axis). 
 
The (slope intercept) equation of the line is: 
 
 y = mx + b 
f(x) = y   101
 
substituting in the slope of m = 1 and Y - intercept b = 0 one would get the line at 
an 45
o angle for the ideal case (of perfect concordance). 
 
 
 
Figure 19 Q-Q-plot for the UK dataset prior to quality control filtering 
Chi-squared test of the basic allelic analysis (D versus d) comparing minor versus major alleles in 
cases versus controls. Blue = Cartesian intersection point between observed and expected chi-
squared values for each marker; black = concordance line corresponding to the null hypothesis (X 
= Y). 
 
The overall adherence (over most of the range; see Figure 19) of observed points 
to the null hypothesis concordance line is an indicator for the absence of 
systematic sources of error (spurious association). The deviation from the null 
hypothesis concordance line observed for real datasets is explained by either 
spurious or real association. 
Stratification 
As previously noted, the effect of population stratification is directly proportional 
to the number of samples used in the study. The number of samples in the present 
study being relatively small (684) the expected influence of stratification on the 
results is also small. To further minimize the possible influence of the   102
stratification effect, cases and controls were selected from the same population 
(British). 
Principal Components Analysis 
The extent of the stratification problem was studied by means of principal 
component analysis analysis (PCA; EIGENSTRAT implemented in SNP & 
Variation Suite v7.3.1). We calcuated the eigenvalues for each individual in the 
datasets studied for the assessment of membranous nephropathy association 
(British, French and Dutch) comparatively with a collection of four populations 
from three continents (Africa, Asia and Europe) which were included in the 
HapMap project [491] dataset. 
 
The four populations (YRI, JPT, CHB and CEU) assessed in the HapMap project 
are considered to be illustrative for the genetic diversity of human populations. 
YRI is the shorthand notation for the Yoruba community from Ibadan, Nigeria 
on the African continent. The individuals genotyped have identified themselves 
as having four Yoruba grandparents. They cannot be considered in any way 
representative for the entire African continent, not even for West Africa, given 
the intricacies of multiple populations sharing that geographical areal. JPT stands 
for Japanese Tokyo, Asia. The people in this particular subset have been 
recruited from the metropolitan area of Tokyo, themselves or their ancestors 
coming from different parts of Japan. They are therefore considered to be 
representative of the majority population in Japan. CHB stands for Han Chinese 
in Beijing, China, Asia. The provenience of the genotyped individuals is the 
residential community at Beijing Normal University. They are self-identified as 
having at least three (out of four) Han Chinese grandparents. This subset can also 
not be considered representative of the entire Han Chinese population. CEU 
represents a a population of Utah Residents of Northern and Western European 
ancestry, which were collected in the 1980s by the Centre d’Etude du 
Polymorphisme Humain (CEPH). Because at that time the importance of the 
correct assessment of the origin of individuals included in the sample was 
underappreciated it is not very clear how accurately this reflects the patterns of 
genetic variation in the respective European area. The term Caucasoid is to be 
avoided due to its potentially racistic overtone and due to the fact that technically   103
Caucasoids are just the inhabitants of the region encompassed between the Black 
Sea and the Caspian Sea. 
 
Up to 100 principal components were computed with EIGENSTRAT, using the 
additive model as the genetic model for principal component analysis (the 
additive model represents dd > Dd > DD). 
The graphical representation of eigenvalues uses a scatter plot type called scree 
plot, which derives its name from the concave upvard image of the homonimous 
accumulation of rock fragments at the basis of a steep cliff. 
 
 
 
Figure 20 Scree plot of the PC eigenvalues for six populations 
X axis: computed 100 principal components, Y axis: eigenvalues. 
 
Comparing the eigenvalues for the known stratified dataset (six populations) with 
our initial case control set (British  population) we get an estimate for the 
differences in stratification: the first 5 principal components computed for the 
stratified dataset being an order of magnitude higher than the first five principal 
components computed for the assessed population (British  case and control set). 
Compare Figure 20 with Figure 21 and see Table 5. 
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Figure 21 Scree plot of PC eigenvalues for British cases versus British  controls 
X axis: computed 100 principal components, Y axis: eigenvalues. 
 
Table 5 Eigenvalues of principal components (PC): UK vs. calibration set 
Comparison of the eigenvalues for the first five principal components (PC) in the case of the 
calibration dataset (including individuals of European, African and Asian origin) with the 
eigenvalues of the principal components for the UK dataset used in the present study.  
 
Eigenvalue of PC  control dataset  UK dataset 
1 26.16 2.20 
2 15.83 1.04 
3 6.92 0.87 
4 1.69 0.76 
5 1.58 0.72 
 
We also compared the scattering of the eigenvalues for the individuals of the 
merged (six populations) dataset in a graphical manner. The distances between 
clouds of aggregation (individuals aggregate based on their geographic origin) 
reflect the amount of stratification observed. The first two principal components 
for each of the six populations were plotted in the following orthogonal 
projection (scatter plot), see Figure 22. 
   105
 
 
Figure 22 ‘Calibrating’ PC scatter plot 
EV = eigenvalue; on the abscisse the first principal component; on the ordinate the second 
principal component; YRI = Yoruban (in black); CHB = Han Chinese (in yellow); Caucasian = 
Caucasoid HapMap population (in pink); UK = British dataset (in red); FR = French dataset (in 
blue); NL = Dutch dataset (in orange). One observes the overall overlap of the three studied 
European populations with the Caucasoid HapMap dataset. 
 
A similar plotting, only including the relevant area, was performed just for the 
British  dataset, overlapping cases and controls to assess the differences between 
the scattering / grouping of cases versus controls (the two first principal 
components which also were plotted on the orthogonal projection), Figure 23. 
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Figure 23 UK case control PC scatterplot 
British dataset: EV = eigenvalue; on the abscisse the first principal component; on the ordinate 
the second principal component; cases (green); controls (blue) XY scatter plots. 
 
To better visualize the overlap of the scattering / grouping of British cases versus 
British  controls the two subsets have also been plotted separately, compare 
Figure 24 with Figure 25. 
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Figure 24 UK cases PC scatterplot 
British cases dataset: EV = eigenvalue; on the abscisse the first principal component; on the 
ordinate the second principal component; cases (green) XY scatter plot. 
 
 
 
Figure 25 UK controls PC scatterplot 
British controls: EV = eigenvalue; on the abscisse the first principal component; on the ordinate 
the second principal component; controls (blue) XY scatter plot.   108
 
Genomic control 
To control for possible stratification we applied the method of genomic control 
(vide supra), where the genomic control inflation factor (λ) for the UK dataset 
was found to be 1.16. 
Results 
Multiple testing 
We applied the Bonferroni correction for multiple tests, dividing the conservative 
linkage significance level P = 0.001 (a more stringent significance level than the 
usual 0.05, the equivalent of LOD = 3, as suggested by Smith in 1953 [391])  by 
N, the number of tests which is  the number of informative markers, in our case 
305,452. 
Associated SNPs 
After Bonferroni correction, 190 markers were shown to be associated with the 
trait (‘status’) above a significance level of Chi-Squared -log10P of 8.48   
(P < 3.27x10
-9). When further correcting for stratification (applying the lambda – 
genomic inflation correction, that is dividing P / lambda = 1.16 thus the corrected 
-log10P becoming 8.54), 188 markers were still associated with the trait. 
Manhattan plot 
The results were graphically presented in form of a Manhattan plot, which is a 
type of scatterplot named after the famous New York skyline. The first time a 
Manhattan plot was used to represent GWAS results was the Klein et al. macular 
degeneration paper of 2005 [438]. 
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Figure 26 BAT Manhattan plot, UK dataset prior to QC filtering  
Chi-squared test of the basic allelic test (BAT) comparing minor versus major alleles (D versus d) 
in cases versus controls. The level of significance (corrected for multiple comparisons and for 
genomic inflation) is represented by the red line at -log10P of 8.54. (Y axis = -log10P, X axis = 
physical positions of the markers corresponding to the human February 2009 GRCh37/hg19 
genome assembly, the chromosomes being plotted successively and shaded alternatively for 
better visualisation). 
 
3.2.1.6 Quality Control 
Genotype quality control (QC) 
Together (on merged case-control matrix) 
The first quality control procedures were initially performed as suggested [492] 
under the assumption that the genotyping was carried out under similar 
conditions (i.e. at the same time, in the same laboratory, ideally in the same batch 
etc) for cases and controls together. For the UK cohort the use of historical 
controls countradicted this strict assumption. We call the matrix that undervent 
the first quality control experiment the common (case and control) matrix. That 
means the two initial matrices (cases and controls) have been merged (the rows 
representing cases have been appended / added to the rows representing 
controls).   110
First step: call rate per marker 
The quality control of the measured call rate per individual is a proxy for the 
quality of DNA genotyped. Some of the markers might present intrinsic 
problems (poor hybridization due to design, local nucleotide composition etc) 
resulting in a low call rate at a given locus. To assess the influence of these ‘bad’ 
markers we look at the minimal call rate per marker was measured, the results 
being as follows (for the complete case-control UK dataset): 109,927 markers 
were completely genotyped (call rate = 100%), 169,470 markers were genotyped 
at a call rate ≥ 99%; as plotted in the following histogram (Figure 27). 
 
 
 
Figure 27 Distribution of call rates per marker for the complete UK dataset 
X axis: call rate, Y axis: marker number. 
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To assess the differences between DNA quality of cases versus controls we 
plotted the same histogram for the two separate matrices and evaluated the 
overlay by using different colours (Figure 28). 
 
 
 
Figure 28 Distribution of call rates per marker, UK dataset 
Cases (red) versus controls (green). Brown represents the overlap of the two instances. The 
genotyping quality of controls is shown to be better than that of cases. 
 
The conclusion is that there is an overal good concordance between the two 
distinct datasets, yet the genotyping quality of controls is shown to be better than 
that of cases. 
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We went on to perform different analyses using the markers that have been 
called at different stringencies: 100% (maximum stringency), 96% (low 
stringency) and 99% (high stringency). 
 
Call rate per marker = 100% (maximum stringency) 
From 305,452 informative markers 109,909 (35.98 %) have a call rate of 100%. 
The basic allelic test (BAT) was computed using the Pearson’s Chi-squared test. 
The expected chi-squared values were computed and the quantile-quantile (Q-Q) 
plot was generated (see Figure 29). 
 
 
 
Figure 29 Q-Q-plot for the UK dataset, maximum stringency scenario 
Q-Q plot for the Chi-squared test of the basic allelic analysis (D versus d) comparing minor 
versus major alleles in cases versus controls for the UK dataset after quality control filtering for 
100% call rate per marker (maximum stringency). 
 
The genomic inflation factor (λ) was found to be 1.14 (down 0.02 from no 
quality control). 
Results 
The Bonferroni correction for multiple tests (P = 0.001 / N = 109,909) yields the 
significance level of Chi-Squared -log10P of 8.04 (P < 9.09x10
-9). At this   113
significance level 60 markers were shown to be associated with the dependent 
variable (‘status’). This is a substantial (138 markers, 69.69%) reduction from the 
198 associated markers in the non quality control scenario. When correcting for 
stratification (P / lambda = 1.14 thus the corrected -log10P becoming 8.09) there 
is no further reduction of the initial 60 associated markers. 
 
 
 
Figure 30 BAT Manhattan plot, UK dataset, maximum stringency scenario 
Manhattan plot for the Chi-squared test of the basic allelic analysis (BAT) comparing minor 
versus major alleles (D versus d) in cases versus controls for the UK dataset after quality control 
filtering for 100% call rate per marker (maximum stringency). The level of significance 
(corrected for multiple comparisons and for genomic inflation) is represented by the red line at  
-log10P of 8.09. (Y axis = -log10P, X axis = physical positions of the markers corresponding to the 
human February 2009 GRCh37/hg19 genome assembly, the chromosomes being plotted 
successively and shaded alternatively for better visualisation). 
 
Call rate per marker = 96% (low stringency) 
From 305,452 informative markers 298,178 (97.61 %) have a call rate of greater 
than 96 %. The basic allelic test (BAT) was computed using the Pearson’s Chi-
squared test statistic. The significance threshold P = 0.001 was corrected for 
multiple comparisons (N = 298,178) and for genomic inflation (lambda = 1.15) at 
-log10P = 8.53. At this threshold 159 markers were found to be associated with 
the trait (as compared to the 60 associated markers for the maximum stringency   114
analysis). This represents a reduction from the non quality control scenario (198 
associated markers) of 39 markers (19.69%). 
Call rate per marker = 99% (high stringency) 
To optimize the threshold a conservative intermediary scenario at 99% call rate 
per genotype was assessed. From the initial 305,452 informative markers 26,094 
did not satisfy the condition, 279,361 (91.45 %) did. The basic allelic test (BAT) 
was computed using the Pearson’s Chi-squared test statistic. The significance 
threshold -log10 became 8.5 for P = 0.001 corrected for multiple comparisons (N 
= 279,361) and for the genomic inflation factor (lambda = 1.14. At this threshold 
145 markers were found to be associated with the trait (a value situated, as 
expected, between the 60 associated markers for the maximum stringency 
analysis and the 159 associated markers of thelow stringency analysis, closer to 
the latter). The reduction from the non quality control scenario (198 associated 
markers) is 53 markers (26.77%). 
Second step: minor allele frequency (MAF) 
The minor allele defined as being the allele with the lowest frequency at a given 
locus. The reasons why it is suggested to drop markers with minor allele 
frequencies less than a given threshold are threefold: rare alleles are likely to be 
genotyping errors, when using the Chi-squared test one might overestimate the 
significance of differences for small counts, and low frequency minor allele 
markers have a low power to detect association. One can add to that the fact that 
multiple testing is going to be reduced by reducing the number of markers. 
 
To evaluate the distribution of minor allele frequencies in cases, controls and the 
common case-control matrix we plotted the number of markers for each minor 
allele frequency in the following histograms, observing similar distribution 
patterns for all three matrices, Figure 31.   115
 
 
Figure 31 Distributions of minor allele frequencies, UK dataset 
Histograms of the minor allele frequencies (MAFs) for the whole UK study set (yellow), for the 
cases (blue) and for the control (green). Note the quasi-similarity of cases versus controls. 
 
In order to assess the influence of dropping markers with different minor allele 
frequencies two scenarios were compared: a minimal one in which all markers 
with a minor allele frequency lesser than 0.01 (1% being the arbitrary threshold 
for the definition of a polymorphic locus – therefore we exclude all rare variants; 
rare variants being defined as any alleles rarer than this) and a maximal scenario 
in which the threshold for minimal allele frequency exclusion was set at 0.1.   116
Minimal drop MAF < 0.01 (exclusion of rare variants) 
According to the 0.01 MAF definition 179 markers were found to be rare 
variants. None of them was amongst the ones (188 markers in the previous – no 
quality control - analysis) found to be associated with the trait at P corrected for 
multiple comparisons (Bonferroni) and for genomic inflation (lambda) -log10P 
being 8.54. The genomic control inflation factor (lambda) was found to be 1.16 
for Chi-Squared. Thus at this threshold MAF filtering is not influencing the 
results (except for minimally reducing the number of comparisons with 179). 
Maximal drop MAF < 0.1 
At the maximal threshold of 0.1 (10% MAF) 41,469 markers were dropped of 
which 8 were associated with the trait in the previous analysis (180 versus 188 at 
-log10P 8.54), 182 when the threshold is lowered according to the new number of 
multiple comparisons (0.001/264,022/1.16 =3.2x10
-9, -log10P being 8.48). 
Medium drop MAF < 0.05 
To optimize the number of markers that can be dropped as non informative due 
to the low minor allele frequency in order to reduce the number of comparisons, 
a MAF threshold between 0.01 (minimal drop) and 0.1 (maximal drop) was 
chosen conservatively at 0.05 (5%). At the medium threshold of 0.05 (5%) 7,534 
markers were dropped, 3 of which being associated with the trait in the previous 
analysis (185 versus 188 at -log10P 8.54). Given that the reduction in the number 
of comparisons (with 7,534 leading to -log10P = 7.54) is obtained at the cost of 
only 3 associated markers being filtered out, the decision was reached to use the 
minimal drop threshold for the analysis. 
Third step: Hardy-Weinberg equilibrium (HWE) filtering 
Associated markers can be in disequilibrium due to e.g. them reflecting a copy 
number variant, CNV. To minimize the risk of bona fide associations to be 
excluded due to HWE filtering one can adopt two strategies: either apply the 
HWE filter only on the controls matrix (thus not excluding CNV markers or their 
SNP proxies that are overrepresented in the cases matrix); alternatively one can 
apply the strictest filtering criterion (cases and controls together), checking the   117
excluded markers for biological relevance a posteriori. We first explored the 
latter approach. 
Distribution of HWE P 
Hardy-Weinberg equilibrium P values were plotted for all the markers in the UK 
dataset (cases and controls together) before any other quality filtering measure, 
Figure 32. 
 
 
Figure 32 Distribution of Hardy-Weinberg Equilibrium P values, UK dataset 
X axis: Hardy-Weinberg Equilibrium P values; Y axis: number of markers.   118
 
Low HWE (P = 10
-4)
 
Hardy-Weinberg equilibrium filtering was based on all samples (as opposed to 
cases only or controls only). At the low threshold of the P value for Hardy-
Weinberg equilibrium 10
-4, 9,060 markers were dropped of which 17 were 
associated with the trait in the non filtered analysis (171 versus 188 at -log10P 
8.54). The genomic inflation factor for this analysis is 1.15 for chi-squared. 
When the threshold is lowered according to the new number of multiple 
comparisons (0.001 / 296,329 / 1.147 = 2.94x10
-9, -log10P being 8.53) one finds 
172 associated markers. 
High HWE (P = 10
-3)
 
Hardy-Weinberg equilibrium filtering was based on all samples (cases and 
controls in the same matrix). At the high threshold of the P value for HWE 10
-3, 
9,816 markers were dropped of which 18 were associated with the trait in the non 
filtered analysis (170 versus 188 at -log10P 8.54). The genomic inflation factor 
for this analysis is 1.15 for chi-squared. When the threshold is lowered according 
to the new number of multiple comparisons (0.001 / 295,636 / 1.15 = 2.95 x10
-9, 
-log10P being 8.53) one finds 171 associated markers. One marker when 
compared to the low P value scenario (171 high P versus 172 low P). 
Extreme HWE (P = 10
-2) 
Hardy-Weinberg equilibrium filtering was performed on all samples (cases and 
controls together). At the high threshold of the P value for HWE 10
-4, 13.614 
markers were dropped of which 20 were associated with the trait in the non 
filtered analysis (168 versus 188 at -log10P 8.54). The genomic inflation factor 
for this analysis is 1.15. When the threshold is lowered according to the new 
number of multiple comparisons (0.001 / 291,838 / 1.146 = 2.99 x10
-9, -log10P 
being 8.52) one finds 169 associated markers (versus 171 for high HWE-P 
respectively 172 low HWE-P).   119
 
Table 6 Markers excluded based on HWE QC filtering 
Columns: low (HWE P threshold at 0.0001): 17 markers excluded; medium (HWE P threshold 
0.001): 18 markers excluded; extreme (HWE P threshold 0.01) 20 markers excluded. The 
excluded markers are represented in red. 
 
#   -log10P  marker   chromosome  position   Low  High  Extreme
1 242.8945505  rs1036819  chr8  135611945          
2 227.0322739  rs1455311  chr4  79964587          
3 139.5238956  rs17400329 chr7  90595695          
4 133.5400546  rs2236479  chr21  46919132          
5 96.9885534  rs6781958 chr3  60724390          
6 93.03622721  rs1975920  chr12  27735986          
7 90.25535638  rs1549343  chr2  171093785          
8 87.24764677  rs2406233  chr4  154034573          
9 75.73985376  rs1447826  chr3  74718758          
10 70.93781263  rs2745566  chr6  1558640          
11 51.25158476  rs3745902  chr19  55378008          
12 36.47536951  rs1959034  chr14  64336479          
13 36.25093906  rs3021387  chr2  8492923          
14 35.28596423  rs2187668  chr6  32605884          
15 33.11544641  rs4393782  chr2  82499876          
16 31.89819588  rs361147  chr4  152890563          
17 28.30104237  rs9291561  chr4  31228884          
18 27.91840586  rs1150752  chr6  32064726          
…                 
38 21.93796759  rs3129963  chr6  32380208          
39 21.70563827  rs7137203  chr12  69548159          
40 21.42088638  rs7750641  chr6  31129310          
41 20.32632332  rs4943552  chr13  38504142          
42 19.25962881  rs7762279  chr6  32755290          
43 18.50487324  rs7057244  chrX  121820344          
44 18.1424215  rs1480380 chr6  32913246          
45 17.97273658  rs2857595  chr6  31568469          
46 17.8204442  rs2221705 chr16  79362411          
…                 
113 10.80170435  rs2844657  chr6  30829522          
114 10.80009518  rs3923330  chr5  53727092          
115 10.78783856  rs2395174  chr6  32404878          
…                 
170 8.878890452  rs2076537  chr6  32317635          
171 8.855174724  rs3911702  chr8  137751040          
172 8.824183304  rs1233579  chr6  28712663          
…                 
188 8.553166436  rs7745603  chr6  27090404          
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Filtered markers check  
Given that deviations from Hardy-Weinberg equilibrium can reflect true 
association, the markers that are filtered out were carefully assessed and 
annotated, with particular attention being paid to the presence of possible 
deletions or duplications. The name of each of the 20 markers, its physical 
position and the name of the gene it coincides with are given in the columns of 
Table 7.  
 
Table 7 Genes close to HWE filtered markers 
The presence of genes in the vicinity (1000 base pairs upstream and 1000 base pairs downstream) 
of the marker has been assessed (Annotation was performed in the UCSC human genome 
browser on the human February 2009 GRCh37/hg19 genome assembly). 
 
marker chromosome position  gene 
rs1549343 chr2  171093785 MYO3B 
rs3021387 chr2  8492923 none 
rs1447826 chr3  74718758 none 
rs6781958 chr3  60724390 FHIT 
rs1455311 chr4  79964587 BC036848 
rs2406233 chr4  154034573 none 
rs361147 chr4  152890563 100bp_BC035179 
rs9291561 chr4  31228884 none 
rs3923330 chr5  53727092 none 
rs2745566 chr6  1558640 none 
rs2857595 chr6  31568469 none 
rs7762279 chr6  32755290 none 
rs17400329 chr7  90595695 PFTK1  
rs1036819 chr8  135611945 ZFAT / ZFATAS 
rs3911702 chr8  137751040 none 
rs1975920 chr12  27735986 PPFIBP1 
rs7137203 chr12  69548159 none 
rs1959034 chr14  64336479 SYNE2  
rs3745902 chr19  55378008 KIR3DL2_duplication  
rs2236479 chr21  46919132 COL18A1 
 
The most interesting occurrence (given that HW disequilibrium can reflect 
associated copy number variants, CNV) is that of marker rs3745902 on 
chromosome 19 (chr19:55378007-55378008) within the KIR3DL2 (killer cell 
immunoglobulin-like receptor, three) gene duplication.   121
KIR3DL2 
KIR3DL2  is a gene which lies within human killer cell immunoglobulin-like 
receptors (KIR) super locus [493], also called leukocyte receptor complex 
(LRC), a stretch of 1Mb sequence on chromosome 19q13.4. The KIR family of 
proteins are transmembrane glycoproteins classified by their number of 
extracellular immunoglobulin domains (2D and 3D) and by the length of their 
cytoplasmic domain (L - Long or S - Short). The long cytoplasmatic domain 
contains an Immune Tyrosine-based Inhibitory Motif (ITIM), therefore the L 
type KIRs transduce inhibitory signals upon ligand binding (whereas S type 
KIRs transduce activatory signals). KIRs are expressed by natural killer (NK) 
cells and subsets of T lymphocytes. There are two sets of NK inhibitory and 
activating receptor genes [494] and they belong either to the Ig superfamily (as 
does the KIR family, implicitly KIR3DL2) or to the C-type lectin superfamily (as 
does PLA2R). 
3.2.1.7 Combining filtering criteria 
Having gotten a feeling for how each filtering step does influence the outcome of 
the analysis for the dataset, different scenarios were tried combining different 
filtering thresholds for two cases: quality control on the combined (cases and 
controls together) matrix and quality control on two separated matrices. 
Cases and controls together QC filtering (together scenario) 
Together low stringency scenario (call rate per marker > 96%) 
In this scenario, the parameters used for the combined quality control filtering of 
genotype (by marker) were: a call rate lower than 0.96; a minor allele frequency 
(MAF) lower than 0.01; a Hardy-Weinberg Equilibrium (HWE) P lower than 
0.001. The filtering threshold thus defined was not passed by 16,827 markers 
(5.5 %; of the informative markers 305,452 = 100%; 39 markers were found to 
be monoallelic, therefore noninformative, from the total number of 305,491 
markers). The markers that were filtered out are distributed as follows: 7,275 
filtered due to the call rate; 179 filtered due to the minor allele frequency; 9,816 
filtered due to the HWE P. cave: some markers did not pass more than one of the   122
filtering criteria, therefore 7275 + 179 + 9816 = 17,270 which is greater than the 
total number of markers (16,827). 
Population Stratification Detection 
As in the previous (non QC analyses), stratification was dealt with by the method 
of genomic control (structured association), the inflation factor (λ) computed for 
the given filtering conditions was found to be 1.14. 
Q-Q plots 
We used the Q-Q plot as a visual estimate of the quality of our dataset. The 
actual association P was plotted against the expected P. For good quality data, 
the plot follows the line y = x. Not only poor quality markers, but also those that 
are associated (true positives) will depart from y = x. The true positive associated 
markers will aggregate at the upper right of the plot [495] (Figure 33). 
 
 
 
Figure 33 Q-Q-plot for the UK dataset, together low stringency scenario 
Q-Q plot for the Chi-squared test of the basic allelic analysis (D versus d) plotting the actual 
association –log10P to the expected -log10P in cases versus controls for the UK dataset after the 
low stringency (call rate > 96%, minor allele frequency > 0.01, Hardy-Weinberg equilibrium  
P > 0.001) quality control filtering (288,664 markers, of which 288,625 informative). 
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Given that large regions of high significance (the Major Histocompatibility / 
Human Leucocyte Antigene HLA region) have a large influence on the Q-Q plot 
it has been suggested to exclude the markers of this region and to compare the 
plot thus obtained to the previous one. The HLA region has been defined 
according to Horton et al. [226] (i.e.  a region of approximately 7.7 Mb on 
chromosome 6:25,652,429-33,421,465 - hg19;  delimited by SCGN – 
secretagogin - on the telomeric end and SYNGAP - Synaptic Ras GTPase 
activating protein - towards the centromere). The 1,376 markers falling within 
the region have been excluded (Figure 34). 
 
 
 
Figure 34 Q-Q-plot: UK dataset, together low stringency scenario, no xMHC 
Q-Q plot for the Chi-squared test of the basic allelic analysis (D versus d) plot of the actual 
association -log10P to the expected -log10P in cases versus controls for the UK dataset after the 
low stringency (call rate > 96%, minor allele frequency > 0.01, Hardy-Weinberg equilibrium  
P > 0.001) quality control filtering; with (1,376) SNP markers in the MHC region excluded 
(287,288 markers).   124
 
To assess the influence of probably true positive associated markers on the Q-Q 
plot, the first 15 associated markers (at a -log10P value of 6.8) have also been 
excluded from the dataset prior to plotting (Figure 35). 
 
 
 
Figure 35 Q-Q-plot: UK dataset, together low stringency, no xMHC, no assoc. 
Q-Q plot for the Chi-squared test of the basic allelic analysis (D versus d) plot of the actual 
association -log10P to the expected -log10P in cases versus controls for the UK dataset after the 
low stringency (call rate > 96, minor allele frequency > 0.01, Hardy-Weinberg equilibrium   
P > 0.001) quality control filtering; with 1,376 SNP markers in the MHC region and 15 
associated SNPs (at  a -log10P value of 6.8) excluded. 
 
Basic Allelic Test (BAT) 
The basic allelic test (D versus d) for genotype association was performed for the 
UK cohort (cases and controls, 684 individuals) for the 288,625 SNP informative 
markers that passed the aforementioned quality control criteria (call rate > 96%, 
minor allele frequency > 0.01, Hardy-Weinberg equilibrium P > 0.001). The 
chosen test statistic (for the 2X2 contingency table) was the Chi-squared test. 
The genomic inflation factor for chi squared was found to be 1.14. The threshold 
for genome-wide significance corrected for multiple comparisons (Bonferroni 
correction) and for the genomic inflation factor (lambda = 1.14) was set at     125
P = 0.001 / 288,625 / 1.142 = 3.03 x10
-9, that is -log10P = 8.518. 151 markers 
were found to be associated with the trait (affected by membranous nephropathy) 
at this genome-wide significance threshold (compared with 188 for the non 
quality control analysis scenario). 
 
 
 
Figure 36 BAT Manhattan plot, UK dataset, together low stringency scenario 
Manhattan plot for the Chi-squared test of the basic allelic test (BAT) comparing minor versus 
major alleles (D versus d) in cases versus controls for the UK dataset after quality control 
filtering for call rate > 96%, minor allele frequency > 0.01, Hardy-Weinberg equilibrium P > 
0.001. The level of significance (corrected for multiple comparisons and for genomic inflation) is 
represented by the red line at -log10 = 8.518. (Y axis = -log10P, X axis = physical positions of the 
markers corresponding to the human February 2009 GRCh37/hg19 genome assembly, the 
chromosomes being plotted successively, shaded and coloured in different colours for better 
visualisation). 
 
Together high stringency scenario (call rate per marker > 99%) 
Of the questioned 305,491 SNP markers, 305,452 markers proved informative 
(with two alleles) and 39 markers uninformative (with one allele). The high 
stringency scenario quality assurance filtering parameters are: call rate > 99%; 
minor allele frequency (MAF) < 0.01; Hardy-Weinberg Equilibrium P value 
(HWE P) < 0.001. 
34,896 (11.42 %; of all 305,491 the markers) markers did not pass the set 
filtering threshold (26,094 due to the call rate; 179 because of the minor allele 
frequency MAF and 9816 due to the Hardy-Weinberg equilibrium P). Some 
markers did not pass more than one of the filtering criteria, therefore the number   126
of filtered SNP markers is smaller than the sum of markers filtered on unique 
conditions (26,094 + 179 + 9816 = 36,089 > 34,896). 
Tests 
A number of genotype association tests were compared for the high stringency 
quality scenario: the basic allelic test (compares D with d); the genotypic test 
(compares DD vs dd vs Dd); the additive model (considers dd > Dd > DD); the 
dominant model (compares DD, Dd vs. dd) and the recessive model (compares 
DD vs. Dd, dd). 
Stratification 
The genomic inflation factor (λ) for the 270,595 used SNP markers that passed 
the quality control threshold was found to be 1.13. 
QQ plot 
As expected, the slope of the QQ plot slightly decreases with the increased 
stringency of the filtering, suggesting a better quality of the data. See Figure 37 
compared with Figure 38. 
 
 
 
Figure 37 Q-Q-plot UK, together low stringency scenario, no xMHC, no assoc. 
Q-Q plot for the UK dataset filtered at a call rate (CR) < 96. Blue: plot; green line: x = y. 
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Figure 38 Q-Q-plot UK, together high stringency scenario, no xMHC, no assoc. 
Q-Q plot of  the UK dataset filtered at a call rate (CR) < 99. Increasing area of the black triangle suggests 
decreasing slope of the plot (blue line). Green line: x = y. 
 
Basic allelic test 
The chosen test statistic (for the 2X2 contingency table) was the chi-squared test. 
The threshold for genome-wide significance corrected for multiple comparisons 
(Bonferroni correction) was set at P = 0.001 / 270,595 / 1.134 = 3.26 x10
-9;  
-log10P = 8.487. 
137 markers were found to be associated with the trait (affected by membranous 
nephropathy) at the genome-wide significance threshold. 
   128
 
 
Figure 39 BAT Manhattan plot, UK dataset, together high stringency scenario 
Manhattan plot for the Chi-squared test of the basic allelic test (BAT) comparing minor versus 
major alleles (D versus d) in cases versus controls for the UK dataset after quality control 
filtering for the high stringency scenario: call rate > 99%, minor allele frequency > 0.01, Hardy-
Weinberg equilibrium P > 0.001. The level of significance (corrected for multiple comparisons 
and for genomic inflation) is represented by the red line at -log10P = 8.487. (Y axis =   
-log10P, X axis = physical positions of the markers corresponding to the human February 2009 
GRCh37/hg19 genome assembly, the chromosomes being plotted successively, shaded and 
coloured in different colours for better visualisation). 
 
Compared with the no quality filtering scenario this represents a drop in the 
number of markers of 27%; 137 of 188), compared to the low stringency quality 
filtering scenario it represents a drop in the number of markers of 9%; 137 of 
151), see Table 8.   129
 
Table 8 Comparison of associated SNPs for three QC scenarios 
Scenarios: no quality control, low stringency (call rate > 96%, minor allele frequency > 0.01, 
Hardy-Weinberg equilibrium P > 0.001) and high stringency quality control (call rate > 99%, 
minor allele frequency > 0.01, Hardy-Weinberg equilibrium P > 0.001); chr – chromosome; 
position – physical position; markers are ordered according to the descending –log10P value; 188 
–associated markers under the no quality control scenario; 151 – associated markers under the 
low stringency control scenario; 137 – associated markers under the high stringency control 
scenario. 
 
chr position  -log10P 188 151 137
8 135681127  242.8945505 rs1036819       
4 80183611  227.0322739 rs1455311       
7 90433631  139.5238956 rs17400329      
21 45743560  133.5400546 rs2236479       
3 60699430  96.9885534 rs6781958       
12 27627253  93.03622721 rs1975920       
2 170802031  90.25535638 rs1549343       
4 154254023  87.24764677 rs2406233       
3 74801448  75.73985376 rs1447826       
6 1503639  70.93781263 rs2745566       
19 60069820  51.25158476 rs3745902       
14 63406232  36.47536951 rs1959034       
2 8410374  36.25093906 rs3021387       
6 32713862  35.28596423 rs2187668       
2 82353387  33.11544641 rs4393782       
4 153110013  31.89819588 rs361147       
4 30837982  28.30104237 rs9291561       
6 32172704  27.91840586 rs1150752       
6 32276749  27.54215129 rs3134942       
6 32369230  26.78993622 rs7775397       
6 32774504  26.66399161 rs1794282       
6 32500855  26.39264916 rs3135353       
6 31420305  26.17015264 rs3134792       
6 32698903  24.86631667 rs3129763       
8 26640531  24.86557187 rs6993922       
6 31978305  24.59074253 rs558702       
6 31709822  24.51763026 rs3115663       
6 31829012  24.41344778 rs3131379       
6 31711749  24.34017935 rs9267522       
6 31740113  24.27564526 rs3130618       
6 32280971  24.17224318 rs3131296       
6 31728499  24.09988556 rs3117582       
6 32471193  23.94354742 rs1980493       
6 32048876  23.89062354 rs389884       
6 32026839  23.79432354 rs1270942       
6 31556955  23.20241306 rs3099844       
6 31166319  22.51337062 rs3130544       
6 32488186  21.93796759 rs3129963       
12 67834426  21.70563827 rs7137203       
6 31237289  21.42088638 rs7750641       
13 37402142  20.32632332 rs4943552       
6 32863268  19.25962881 rs7762279       
X 121648025  18.50487324 rs7057244       
6 33021224  18.1424215 rs1480380         130
6 31676448  17.97273658 rs2857595       
16 77919912  17.8204442 rs2221705       
6 31028103  17.71904934 rs3132580       
17 67919451  17.65103876 rs3744311       
6 31209653  17.5118627 rs3130564       
6 32269344  17.05444751 rs204991       
6 32447625  16.89806951 rs2050189       
1 162803852  16.82989189 rs12039194      
6 32407800  16.75801292 rs1003878       
6 32269408  16.73899681 rs204990       
6 31189184  16.64697203 rs2233956       
6 32444744  16.63777495 rs3129939       
6 31959213  16.49981308 rs652888       
6 31463297  15.87812204 rs2596560       
6 31351863  15.3756805 rs3130696       
6 30889981  15.25937021 rs886424       
6 31230479  14.72784754 rs130065       
6 31580699  14.71700661 rs2855812       
6 31648763  14.46854754 rs1041981       
6 32446673  14.33930723 rs3129943       
6 32242488  14.19429955 rs3096697       
6 32497626  13.99686776 rs3135363       
6 32262976  13.98526138 rs204994       
6 31586965  13.90303718 rs2246618       
6 32254470  13.82089148 rs3134945       
6 32772436  13.75766099 rs2647012       
6 32866372  13.68810007 rs7758736       
6 31710946  13.67704067 rs1046089       
6 31623778  13.61617115 rs2071591       
1 190284246 13.6070483 rs12755225      
16 53836712  13.47712779 rs30960       
2 48065223  13.15638305 rs4953534       
4 27051158  13.04332035 rs2110177       
6 31380240  13.04004135 rs6457374       
6 32381743  13.02140446 rs6457536       
6 32514320  12.99867819 rs3129871       
6 30760760  12.79692907 rs9262143       
6 31001920  12.76307723 rs4678       
6 32217957  12.73912427 rs204999       
X 3143733  12.58474102 rs5983083       
6 31796196  12.4180618 rs805294       
6 30441484  12.25766993 rs3094054       
6 31472686  12.20873767 rs2251396       
6 31248026  12.20838758 rs1265159       
6 32891063  12.13616118 rs7383287       
6 31197610  12.08188775 rs3095314       
6 32263559  12.08163442 rs204993       
6 32853021  12.0723072 rs9276644       
6 31041773  12.04319694 rs3095089       
6 31425326  12.0044511 rs2156875       
6 32030233  11.93785913 rs630379       
6 31525170  11.79222532 rs3128982       
6 32036993  11.77333305 rs437179       
6 32055439  11.77333305 rs389883         131
6 31850569  11.73122654 rs707928       
6 31705732  11.71535927 rs2242660       
6 32352605  11.59886568 rs3130340       
6 32353805  11.59886568 rs3115553       
6 32368328  11.59886568 rs6935269       
6 30652380  11.57972368 rs3132610       
6 32786977  11.38272257 rs9275572       
6 32512837  11.35693255 rs2395173       
6 30387109  11.28067526 rs3130380       
6 32867426  11.22902126 rs3948793       
6 30435818  11.12350718 rs3130350       
6 30339203  11.05297605 rs3094073       
6 31589084  10.87399973 rs2516400       
6 30932511  10.80170435 rs2844659       
6 30937501  10.80170435 rs2844657       
5 53762849  10.80009518 rs3923330       
6 32512856  10.78783856 rs2395174       
6 32873429  10.75282627 rs1383261       
6 31724345  10.73990431 rs805303       
6 32888701  10.69374287 rs11244       
6 31307187  10.5663369 rs3130473       
2 7161487  10.52492845 rs6722663       
9 135267303  10.45449186 rs2285487       
6 31497763  10.44205369 rs2844511       
15 94338085  10.42378661 rs4319717       
6 30140501  10.40575405 rs8321       
6 30315474  10.35851841 rs2844773       
10 19969519  10.25057899 rs1326986       
6 28311279  10.24336538 rs9380069       
6 30146626  10.24336538 rs9261290       
6 32488240  10.1792513 rs6932542       
6 31080844  10.16616096 rs1634718       
6 31126525  10.04722579 rs2523864       
6 29139121  10.04219655 rs3117143       
6 41293408  9.968739987 rs1968871       
6 28106237  9.964254535 rs149990       
6 32509195  9.923210128 rs3135338       
6 32262263  9.778048388 rs204995       
6 32522251  9.751208115 rs3129890       
6 31118179  9.717477279 rs2508015       
6 31902571  9.715886123 rs2763979       
6 28251097  9.712295883 rs9380064       
2 160625743 9.68155809 rs4664308       
6 30053928  9.577058487 rs3132685       
6 32789255  9.559744783 rs2858331       
6 28350773  9.510488147 rs1419183       
6 28317081  9.509599612 rs9295768       
6 28318667  9.509599612 rs967005       
6 31174988  9.473996104 rs2517403       
6 27918605  9.377362194 rs175597       
17 22337222  9.377213207 rs11657089      
6 30805426  9.371116024 rs3094127       
6 31183460  9.351798196 rs2844635       
6 31233756  9.33706266 rs720465         132
6 31429190  9.297097892 rs2596501       
6 31213392  9.240754412 rs1265099       
6 30188253  9.232746147 rs2517598       
6 32759095  9.228489045 rs9275141       
6 27642507  9.196001638 rs10484399      
6 31439808  9.176612019 rs2523554       
6 31443433  9.155420758 rs2844573       
4 6443243  9.14040739 rs2240268       
6 28738670  9.115691387 rs13194504      
2 160778828  9.087908524 rs1870102       
6 27945246  9.068176039 rs200953       
6 27923618  9.064970066 rs13194781      
6 31189968  9.015447581 rs3130977       
6 31168141  8.964154138 rs2517452       
6 30576770  8.948358807 rs3131115       
6 27599278  8.942354142 rs6904596       
6 28365356  8.886294168 rs13211507      
6 32425613  8.878890452 rs2076537       
8 137820222  8.855174724 rs3911702       
6 28820642  8.824183304 rs1233579       
6 31444229  8.795878124 rs2523535       
6 31253899  8.776689747 rs887464       
6 29088686  8.765442152 rs3130893       
6 27339129  8.753000081 rs6938200       
6 32771829  8.739961597 rs6457617       
6 28122576  8.686128447 rs149900       
6 28281198  8.685204466 rs1233708       
6 29450754  8.678537191 rs3749971       
6 31183354  8.65241017 rs1064191       
6 28407666  8.626034003 rs853676       
6 31968316  8.605229099 rs535586       
6 31972283  8.605229099 rs659445       
6 29062272  8.595432246 rs3129791       
6 29645203  8.573750486 rs1235162       
6 27814159  8.55317383 rs9468213       
6 27198383  8.553166436 rs7745603       
 
Genotypic test 
Applying the Chi-square statistic test to the genotypic test (DD versus dd versus 
Dd comparison) for the 270,595 SNP markers which passed the high stringency 
quality control filtering criteria 107 were found to be associated with the trait at  
-log10P 8.463 (corrected for multiple comparisons and for genomic inflation 
factor, λ = 1.07). 
Additive test 
Applying the Cochran Armitage statistic method to the additive model (which 
considers the effects on the trait to be increasing with the presence of none, one   133
or two alleles: dd > Dd > DD) for the 270,595 SNP markers which passed the 
high stringency quality control filtering criteria, 137 were found to be associated 
with the trait at -log10P 8.485 (corrected for multiple comparisons and for 
genomic inflation factor, λ = 1.13). 
Dominant model 
Applying the Chi-square statistic test to the dominant model (which compares 
the effects of DD, Dd versus dd)  for the 270,595 SNP markers which passed the 
high stringency quality control filtering criteria 104 of them were found to be 
associated with the trait at -log10P 8.477 (corrected for multiple comparisons and 
for genomic inflation factor, λ = 1.11). 
Recessive model 
Applying the Chi-square statistic test to the recessive model (which compares 
DD versus Dd and dd)  for the 270,595 SNP markers which passed the high 
stringency quality control filtering criteria only 14 were found to be associated 
with the trait at -log10P 8.474 (corrected for multiple comparisons and for 
genomic inflation factor, λ = 1.10).   134
 
Table 9 Comparison of associated SNPs for five association tests 
Comparison of -log10P values for the strenght of association between the trait and different 
markers under different models: basic allelic test BAT, genotypic test GT, additive model AM, 
dominant model DM and recessive model RM. 
 
Marker  Chr  Position  BAT  GT   AM  DM  RM 
rs2187668  6 32713862 35.286 34.09 33.879 33.827 9.803
rs7775397 6  32369230 26.79 25.865 25.934 26.19  - 
rs1794282 6  32774504 26.664 25.655 25.754 25.967  - 
rs3135353 6  32500855 26.393 25.428 25.507 25.585  - 
rs3129763  6 32698903 24.866 25.858 25.87 24.819 9.232
rs558702 6  31978305 24.591 23.502 23.814 23.745  - 
rs3115663 6  31709822 24.518 22.825 23.924 20.329  11.148
rs3131379 6  31829012 24.413 23.375 23.618 23.716  - 
rs9267522 6  31711749 24.34 22.638 23.737 20.14  11.108
rs3130618 6  31740113 24.276 22.539 23.641 20.007  11.148
rs3131296 6  32280971 24.172 22.801 23.29 22.734  - 
rs3117582 6  31728499 24.1 23.127 23.434 23.416  - 
rs1980493 6  32471193 23.944 22.872 22.872 23.137  - 
rs389884 6  32048876 23.891 22.79 23.204 22.962  - 
rs1270942 6  32026839 23.794 22.645 23.077 22.802  - 
rs3099844 6  31556955 23.202 22.353 22.856 22.432  - 
rs3130544 6  31166319 22.513 22.086 22.829 21.853  - 
rs3129963 6  32488186 21.938 21.091 21.83 20.489  - 
rs7750641 6  31237289 21.421 20.812 21.594 20.501  - 
rs4943552 13  37402142 20.326 17.304 18.338 12.621  13.304
rs7762279 6  32863268 19.26 18.356 18.756 18.919  - 
rs1480380 6  33021224 18.142 16.517 17.219 17.017  - 
rs2857595 6  31676448 17.973 18.096 17.942 18.641  - 
rs2221705 16  77919912 17.82 17.034 17.41 18.085  - 
rs3132580 6  31028103 17.719 16.497 17.467 15.956  - 
rs3130564 6  31209653 17.512 17.424 17.955 17.163  - 
rs204991 6  32269344 17.054 15.795 16.469 15.509  - 
rs2050189 6  32447625 16.898 15.947 16.898 14.765  - 
rs12039194  1 162803852 16.83 15.438 15.494 16.468 - 
rs1003878 6  32407800 16.758 15.949 16.708 15.174  - 
rs204990 6  32269408 16.739 15.422 16.273 14.776  - 
rs3129939 6  32444744 16.638 16.152 16.863 15.977  - 
rs652888  6 31959213 16.5 14.783 15.787 12.339 9.214
rs2596560 6  31463297 15.878 15.184 15.533 15.24  - 
rs886424 6  30889981 15.259 14.355 15.34 13.98  - 
rs2855812 6  31580699 14.717 13.267 13.971 12.896  - 
rs1041981 6  31648763 14.469 14.145 14.768 13.172  - 
rs3129943 6  32446673 14.339 13.315 14.154 12.431  - 
rs3096697 6  32242488 14.194 13.078 14.054 11.103  - 
rs3135363 6  32497626 13.997 14.288 14.674 14.121  - 
rs204994 6  32262976 13.985 12.908 13.851 11.884  - 
rs3134945 6  32254470 13.821 12.885 13.869 11.11  - 
rs2647012  6 32772436 13.758 12.826 13.762 10.334 8.527
rs7758736 6  32866372 13.688 12.967 13.375 13.5  - 
rs1046089 6  31710946 13.677 13.548 13.858 13.07  - 
rs2071591 6  31623778 13.616 13.374 14.086 12.285  - 
rs6457374 6  31380240 13.04 12.596 13.049 12.677  - 
rs3129871 6  32514320 12.999 12.43 13.412 11.46  -   135
rs9262143 6  30760760 12.797 12.179 13.078 12.381  - 
rs4678 6  31001920 12.763 12.055 12.961 11.632  - 
rs204999  6 32217957 12.739 11.83 12.636 8.528 8.988
rs805294 6  31796196 12.418 11.249 12.037 10.162  - 
rs2251396 6  31472686 12.209 13.287 12.584 13.959  - 
rs1265159 6  31248026 12.208 11.1 12.051 9.949  - 
rs7383287 6  32891063 12.136 11.199 11.961 11.086  - 
rs3095314 6  31197610 12.082 11.431 12.355 -  9.064
rs204993 6  32263559 12.082 11.001 11.899 9.982  - 
rs9276644 6  32853021 12.072 10.794 11.613 9.736  - 
rs3095089 6  31041773 12.043 11.438 12.344 11.128  - 
rs2156875 6  31425326 12.004 10.805 11.63 -  8.546
rs630379 6  32030233 11.938 10.753 11.58 10.087  - 
rs3128982 6  31525170 11.792 11.28 12.162 10.108  - 
rs437179 6  32036993 11.773 10.571 11.381 9.96  - 
rs389883 6  32055439 11.773 10.571 11.381 9.96  - 
rs707928 6  31850569 11.731 10.922 11.485 10.471  - 
rs2242660 6  31705732 11.715 11.671 11.841 11.492  - 
rs3130340 6  32352605 11.599 10.811 11.752 9.241  - 
rs3115553 6  32353805 11.599 10.811 11.752 9.241  - 
rs6935269 6  32368328 11.599 10.811 11.752 9.241  - 
rs3132610 6  30652380 11.58 10.969 11.905 11.015  - 
rs9275572 6  32786977 11.383 10.561 11.51 -  - 
rs2395173 6  32512837 11.357 11.117 12.078 10.369  - 
rs3130380 6  30387109 11.281 10.925 11.659 11.581  - 
rs3948793 6  32867426 11.229 10.045 10.844 9.147  - 
rs3130350 6  30435818 11.124 10.909 11.587 11.639  - 
rs3094073 6  30339203 11.053 10.696 11.378 11.256  - 
rs2844659 6  30932511 10.802 10.162 10.991 10.099  - 
rs2844657 6  30937501 10.802 10.162 10.991 10.099  - 
rs2395174 6  32512856 10.788 9.981 10.827 -  - 
rs1383261 6  32873429 10.753 9.293 10.108 8.557  - 
rs805303 6  31724345 10.74 10.61 10.996 10.319  - 
rs11244 6  32888701 10.694 9.417 10.131 9.262  - 
rs2844511 6  31497763 10.442 10.43 10.53 -  10.212
rs8321 6  30140501 10.406 9.977 10.701 10.663  - 
rs2844773 6  30315474 10.359 9.911 10.658 10.403  - 
rs9380069 6  28311279 10.243 9.901 10.752 10.444  - 
rs9261290 6  30146626 10.243 9.807 10.547 10.477  - 
rs6932542 6  32488240 10.179 10.404 10.276 -  10.059
rs1634718 6  31080844 10.166 9.476 10.399 -  - 
rs2523864 6  31126525 10.047 9.019 9.936 -  - 
rs149990 6  28106237 9.964 9.16 10.025 9.544  - 
rs3129890 6  32522251 9.751 9.169 9.829 9.205  - 
rs2508015 6  31118179 9.717 8.634 9.515 -  - 
rs2763979 6  31902571 9.716 8.587 9.351 -  - 
rs9380064 6  28251097 9.712 9.163 10.047 9.574  - 
rs4664308 2  160625743 9.682 -  9.083 -  - 
rs3132685 6  30053928 9.577 8.953 9.807 9.389  - 
rs2858331 6  32789255 9.56 8.658 9.566 -  - 
rs1419183 6  28350773 9.51 8.968 9.832 9.381  - 
rs9295768 6  28317081 9.51 9.077 9.886 9.473  - 
rs967005 6  28318667 9.51 9.077 9.886 9.473  - 
rs2517403 6  31174988 9.474 8.606 9.496 -  -   136
rs175597 6  27918605 9.377 -  9.376 8.686  - 
rs3094127 6  30805426 9.371 8.775 9.685 -  - 
rs2844635 6  31183460 9.352 8.499 9.384 -  - 
rs720465 6  31233756 9.337 -  9.226 -  - 
rs2596501 6  31429190 9.297 -  8.941 -  - 
rs1265099 6  31213392 9.241 8.828 9.267 -  - 
rs2517598 6  30188253 9.233 9.028 9.671 9.628  - 
rs9275141 6  32759095 9.228 -  9.266 -  - 
rs10484399 6  27642507 9.196 8.73 9.574 8.683  - 
rs2523554 6  31439808 9.177 -  9.307 -  - 
rs13194504 6  28738670 9.116 8.745 9.559 9.459  - 
rs1870102  2  160778828 9.088 - - - - 
rs200953 6  27945246 9.068 -  9.114 -  - 
rs13194781 6  27923618 9.065 8.707 9.558 8.75  - 
rs2517452 6  31168141 8.964 -  8.825 -  - 
rs3131115 6  30576770 8.948 -  8.91 -  - 
rs6904596 6  27599278 8.942 -  9.109 -  - 
rs13211507 6  28365356 8.886 -  9.385 9.029  - 
rs2076537 6  32425613 8.879 -  8.884 -  - 
rs1233579 6  28820642 8.824 -  9.294 9.16  - 
rs2523535 6  31444229 8.796 -  9.145 -  - 
rs887464 6  31253899 8.777 -  8.903 -  - 
rs3130893 6  29088686 8.765 -  9.234 9.099  - 
rs6457617 6  32771829 8.74 -  8.76 -  - 
rs1233708 6  28281198 8.685 -  8.57 -  - 
rs3749971 6  29450754 8.679 -  9.12 9.175  - 
rs1064191 6  31183354 8.652 -  8.556 -  - 
rs853676 6  28407666 8.626 -  8.853 -  - 
rs535586 6  31968316 8.605 -  8.496 -  - 
rs659445 6  31972283 8.605 -  8.496 -  - 
rs3129791 6  29062272 8.595 -  9.065 8.909  - 
rs1235162 6  29645203 8.574 -  8.795 8.814  - 
rs7745603  6  27198383 8.553 - - - - 
rs3131093 6  28945416 8.537 -  9.006 8.849  - 
rs2746150 6  29550680 8.508 -  8.927 8.966  - 
rs4324798 6  28884096 -  -  8.87 8.702  - 
rs2523989  6  30186254 - -  8.679 - - 
rs2523987  6  30187972 - - -  8.643  - 
rs2253907  6  31444849 - - - -  8.545  137
 
Nine of the markers (rs4943552 on chromosome 13; rs2187668, rs3129763, 
rs3115663, rs9267522, rs3130618, rs652888, rs2647012 and rs204999 on 
chromosome 6) are associated with the trait in all five scenarios, 88 are 
associated with the trait in 4 of the five scenarios, 20 of the markers are 
associated in 3 of the five, 19 in two and 5 only in one of the five scenarios. 
 
The associated SNPs are distributed on five chromosomes as follows: one SNP 
on chromosome 1 (rs12039194), see Figure 38; two SNPs on chromosome 2 
(rs4664308 and rs1870102), see Figure 39; 132 SNPs on chromosome 6 (all of 
which in the HLA region), see Figure 40; one SNP on chromosome 13 
(rs4943552); see Figure 41; and one SNP on chromosome 16 (rs2221705), see 
Figure 42. 
 
 
 
Figure 40 BAT Manhattan plot, UK, together high stringency, chromosome 1 
Manhattan plot zoomed in on chromosome 1 representing the results of the basic allelic test 
(BAT) of association for the ‘together’ high stringency quality control scenario (together 
meaning appended before cleaning; call rate > 99%, minor allele frequency > 0.01, Hardy-
Weinberg equilibrium P > 0.001). The significance line (red) is drawn at -log10P, Bonferroni and 
genomic inflation factor lambda corrected y = 8.487. The associated (at -log10P = 15.438) SNP 
marker at chr1 164537228 (February 2009 assembly GRCh37 / hg19) is rs12039194. 
   138
 
 
Figure 41 BAT Manhattan plot, UK, together high stringency, chromosome 2 
Manhattan plot zoomed in on chromosome 2 representing the results of the basic allelic test 
(BAT) of association for the ‘together’ high stringency quality control scenario (together 
meaning appended before cleaning; call rate > 99%, minor allele frequency > 0.01, Hardy-
Weinberg equilibrium P > 0.001). The significance line (red) is drawn at -log10P, Bonferroni and 
genomic inflation factor lambda corrected y = 8.487. 
 
 
 
Figure 42 BAT Manhattan plot, UK, together high stringency, chromosome 6 
Manhattan plot zoomed in on chromosome 6 representing the results of the basic allelic test 
(BAT) of association for the ‘together’ high stringency quality control scenario (together 
meaning appended before cleaning; call rate > 99%, minor allele frequency > 0.01, Hardy-
Weinberg equilibrium P > 0.001). The significance line (red) is drawn at -log10P, Bonferroni and 
genomic inflation factor lambda corrected y = 8.487. 
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Figure 43 BAT Manhattan plot, UK, together high stringency, chromosome 13 
Manhattan plot zoomed in on chromosome 13 representing the results of the basic allelic test 
(BAT) of association for the ‘together’ high stringency quality control scenario (together 
meaning appended before cleaning; call rate > 99%, minor allele frequency > 0.01, Hardy-
Weinberg equilibrium P > 0.001). The significance line (red) is drawn at -log10P, Bonferroni and 
genomic inflation factor lambda corrected y = 8.487. 
 
 
 
 
Figure 44 BAT Manhattan plot, UK, together high stringency, chromosome 16 
Manhattan plot zoomed in on chromosome 16 representing the results of the basic allelic test 
(BAT) of association for the ‘together’ high stringency quality control scenario (together 
meaning appended before cleaning; call rate > 99%, minor allele frequency > 0.01, Hardy-
Weinberg equilibrium P > 0.001). The significance line (red) is drawn at -log10P, Bonferroni and 
genomic inflation factor lambda corrected y = 8.487. 
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Description of the regions of interest 
Six regions in the human genome were assessed for elements of interest in the 
light of the association of SNPs in the vicinity. 
Chromosome 1 
The SNP marker defining the region of interest on chromosome 1 is rs12039194 
(physical position 164537228 bp on the February 2009 assembly GRCh37 / 
hg19). It is a coding (+) strand G > A/G type single nucleotide variant, a 
substitution (translation), the ancestral allele being G (present on the positive 
strand in the chimpanzee Pan paniscus genome, on the negative strand in the 
orangutan Pongo pygmaeus genome, and on the positive strand in the macaque 
Macacus rhesus genome).  It has been validated by cluster, by frequency and by 
HapMap. Its average heterozygosity is 0.325 +/- 0.238. The weight quality 
assignment by dbSNP of rs12039194 is 1 (where weight can be 0, 1, 2, 3 or 10 
with 0 and 10 being excluded from the dataset and 1 being the highest quality 
alignment). It lies within an intron of the PBX1 gene. 
PBX1 
Pre-B-cell leukemia homeobox 1 is encoded on the plus (+) / coding strand of 
chromosome 1, spans 292,244 base pairs of genomic sequence, contains nine 
exons (all of them coding). The protein encoded by PBX1 has 430 amino acids 
and is a transcription factor of the TALE (Three Aminoacid Loop Extension) / 
PBX1 homeobox family [496]. It is located in the cell nucleus where it forms 
heterodimers with MEIS1 (Myeloid Ecotropic viral Integration Site 1 
homologue). The PBX1-MEIS complex is known to act as a cofactor to various 
transcription factors (most importantly Hox) [497] by penetrating repressive 
chromatin to mark specific genes for activation or inactivation [498]. The 
complex has selective DNA binding properties, its target DNA binding sequence 
on the genome being a bipartite consensus composed of the 5' PBX (TGAT) and 
3' MEIS (TGACAG) half sites [499]. The DNA binding domain of PBX1 is a 
homeobox 1 DNA binding domain.  PBX1 is expressed in all human tissues, 
with the exception of the cells of the B and T lineage. It has been suggested that 
PBX1 has a role in steroidogenesis (might be therefore important in sexual   141
development and / or differentiation) and even kidney development ([500] and 
iHOP - Information Hyperlinked Over Proteins, [501]). 
Chromosome 2 
The region of interest on chromosome 2 is driven by two SNP markers that 
passed the threshold for association (rs4664308 at -log10P = 9.681 and rs1870102 
at -log10P = 9.088) but the morphology of the peak (aggregation of 16 markers at 
levels below the threshold but with a -log10P score greater than 2 in a quasi 
Gaussian distribution around the marker showing strongest association, i.e. 
rs4664308) also strongly suggests a signal of association. 
 
 
 
Figure 45 Association peaks peri-PLA2R1 
Custom track plotting the  -log10 Chi-square scores of the 86 SNPs in the peri-PLA2R1 region on 
chromosome 2, showing the two association peaks (at rs4664308, in the first intron of PLA2R1 
and at rs1870102, upstream of ITGB6) and the morphology of the quasi Gaussian ‘signal build 
up’ around them. 
 
SNP rs4664308 (physical position 160917497 bp on the February 2009 assembly 
GRCh37 / hg19) is a coding (+) strand A > A/G type single nucleotide variant, a 
substitution (translation), the ancestral allele being A (present on the positive 
strand of the chimpanzee Pan paniscus genome, on the positive strand of the 
orangutan Pongo pygmaeus genome, and on the positive strand of the macaque 
Macacus rhesus genome).  It has been validated by cluster, by frequency, by 
HapMap and by 1000 genomes [502]. Its average heterozygosity is 0.391 +/- 
0.207. The weight quality assignment by dbSNP of rs4664308 is 1. According to 
the functional classification, it is an intronic SNP, lying within an intron of the 
PLA2R1 gene. 
PLA2R1 
Phospholipase A2 receptor 1 isoform 1 precursor is encoded on the minus (-) / 
noncoding strand of chromosome 2, spans 121,110 base pairs of genomic   142
sequence, contains 30 exons (all of them coding). The protein encoded by 
PLA2R1 has 1463 amino acids and is a receptor for secretory phospholipases A2 
(PLA2s). It is a transmembrane protein with one transmembrane pass alpha helix 
domain and has been previously described in detail (vide supra). 
 
Marker rs1870102 (physical position 161070582 bp on the February 2009 
assembly GRCh37 / hg19) is a antisense (-) strand T > C/T type single nucleotide 
variant, a substitution (translation), the ancestral (reference) allele being T 
(present on the negative strand of the chimpanzee Pan paniscus genome, the 
negative strand of the orangutan Pongo pygmaeus genome, and the negative 
strand of the macaque Macacus rhesus genome).  It has been validated by 
cluster, by frequency, by the 2 hit / 2 allele method (i.e. each allele has been 
observed in at least two chromosomes), by HapMap and by 1000 genomes. Its 
average heterozygosity is 0.376 +/- 0.216. The weight quality assignment by 
dbSNP of rs1870102 is 1. It is a SNP of unknown function, which is localized 
upstream of the ITGB6 gene. 
ITGB6 
Integrin beta 6 precursor is encoded on the minus (-) / noncoding strand of 
chromosome 2, spans 98,357 base pairs of genomic sequence, contains 15 exons 
(all of them coding). The protein encoded by ITGB6 has 788 amino acids and is 
a member of the integrin beta chain family - the beta subunits of the integrin 
proteins. It is believed (by similarity) to be a single-pass type I membrane 
protein. It has been shown to activate latent transforming growth factor (TGF)-β1 
in knock-out mice, thus playing a role in the homeostasis of phospholipids and 
collectins, which has apparent implications for the understanding of the innate 
immune response and remodelling of the extracellular matrix / fibrotic 
mechanisms [503]. It has also been shown that ITGB6 is induced in endothelial 
cells by cytomegalovirus (CMV) infection, and leads, through activation of TGF-
β1, to increased collagen production [504]. 
Chromosome 6 
The 132 associated SNPs (at -log10P > 8.487) cluster on chromosome 6 in the 
6p22.2-21.32 region, which corresponds to the extended HLA – MHC locus of    143
6 Mb [226]. For the purposes of this analysis the extended HLA locus is 
considered to be delimited at the telomeric end by the 5’ extremity of SCGN 
(secretagogin precursor; at chr6 25,760,408 - hg18 assembly- respectively chr6 
25,652,429 -GRCh37 / hg19 assembly) and at the centromeric end by the 3’ 
extremity of SYNGAP1 (synaptic Ras GTPase activating protein 1; at chr6 
33,529,444 – hg18 assembly – respectively chr6 33,421,465 – GRCh37 / hg19 
assembly). This region is covered by 1274 SNPs (between rs7747078 and 
rs2247385; at chr6:25,775,918-33,529,555 on the hg18 assembly) and contains 
299 RefSeq genes (curated and non-redundant as defined by NCBI Reference 
Sequence [505]; hg18 assembly), Figure 46.   144 
 
 
 
Figure 46 Extended HLA region on chromosome 6 
Custom track plotting the  -log10 Chi square scores (shown on the y axis, from 1 to 35) of the 1274 SNPs in the respective region. Linkage disequilibrium structure (HapMap Linkage 
Disequilibrium – Phase II – from phased genotypes, LOD LD values, inverted triangle display for the European CEPH CEU population) is shown underneath (hg18 assembly).   145
 
Of the 132 associated SNPs, 63 overlap known RefSeq gene regions 
(respectively 46 genes extended to include 500 bp upstream and 500 bp 
downstream), see Table 10. 
 
Table 10 RefSeq genes in the region of interest on chromosome 6 
46 RefSeq genes corresponding to the 63 SNPs associated to the membranous nephropathy trait 
in the region of interest on chromosome 6 (HLA superlocus). 
 
gene 
associated 
SNP  -log10P  position 
ZNF187   rs1419183  9.510488 intron 
PGBD1   rs13211507 8.886294 intron 
ZNF323   rs853676  8.626034 intron 
OR12D3   rs3749971  8.678537 CDS 
HCG9   rs3132685  9.577058 intron 
ZNRD1   rs8321  10.40575 3'UTR 
RNF39   rs9261290  10.24337 3'UTR 
TRIM31   rs2517598  9.232746 CDS 
HLA-L   rs3094073  11.05298 CDS 
HCG18   rs3130380  11.28068 intron 
ABCF1   rs3132610  11.57972 intron 
KIAA1949   rs9262143  12.79693 CDS 
FLOT1   rs3094127  9.371116 intron 
VARS2   rs4678  12.76308 CDS 
DPCR1   rs3132580  17.71905 CDS 
PSORS1C1   rs3095314  12.08189 intron 
 rs3130564  17.51186 intron 
 rs1265099  9.240754 intron 
PSORS1C2   -//-  -//-  3'UTR 
CCHCR1   rs720465  9.337063 intron 
TCF19   rs7750641  21.42089 CDS 
PSORS1C3   rs887464  8.77669 upstream 
HLA-B   rs2596501  9.297098 downstream
MICB   rs2855812  14.71701 intron 
NFKBIL1   rs2071591  13.61617 intron 
LTA   rs1041981  14.46855 CDS 
BAT2   rs2242660  11.71536 intron 
 rs3115663  24.51763 intron 
 rs1046089  13.67704 CDS 
 rs9267522  24.34018 CDS 
BAT3   rs805303  10.7399 intron 
 rs3117582  24.09989 upstream 
BAT4   rs3130618  24.27565 CDS 
LY6G6C   rs805294  12.41806 intron 
MSH5   rs3131379  24.41345 intron 
C6orf27   rs707928  11.73123 intron 
EHMT2   rs652888  16.49981 intron 
 rs535586  8.605229 CDS 
 rs659445  8.605229 intron 
C2   rs558702  24.59074 intron 
CFB   rs1270942  23.79432 intron   146
RDBP   rs630379  11.93786 intron 
SKIV2L   rs437179  11.77333 CDS 
STK19   rs389884  23.89062 intron 
 rs389883  11.77333 intron 
EGFL8   rs3096697  14.1943 CDS 
RNF5   rs3134945  13.82089 intron 
RNF5P1   -//-  -//-  intron 
PBX2   rs204994  13.98526 intron 
 rs204993  12.08163 intron 
GPSM3   rs204991  17.05445 intron 
 rs204990  16.739 intron 
NOTCH4   rs3131296  24.17224 intron 
C6orf10   rs6935269  11.59887 downstream
 rs7775397  26.78994 CDS 
 rs1003878  16.75801 intron 
 rs2076537  8.87889 intron 
 rs3129939  16.63777 intron 
 rs3129943  14.33931 intron 
 rs2050189  16.89807 upstream 
BTNL2   rs1980493  23.94355 intron 
HLA-DQA1   rs2187668  35.28596 intron 
HLA-DOB   rs11244  10.69374 3'UTR 
 rs7383287  12.13616 CDS 
 
HLA-DQA1 
The SNP with the highest P value (rs2187668, -log10P = 35.28596) is located 
within the first intron of HLA-DQA1, which is a 5 exon (4 of which coding, the 
last one part of the 3’UTR untranslated region) gene spanning 6,246 base pairs of 
genomic DNA at chr6:32,713,161-32,719,407 (hg18 genome assembly). 
Testis Specific Basic Protein (TSBP) 
TSBP (previously called C6orf10) is the gene which overlaps with most 
associated SNPs (rs6935269, rs7775397, rs1003878, rs2076537, rs3129939, 
rs3129943 and rs2050189). It is a 23 exon (all coding) gene which spans 187,160 
base pairs genomic DNA on the minus (-) strand of the GRCh37 / hg19 assembly 
of the human genome at chr6:32260476-32447634. 
TSBP – HLA-DQA1 region 
The two genes are flanking a variable region, containing a published deletion at 
chromosome 6p21.32 (one of the 935 deletions detected by HapMap Phase I data 
genotype analysis; present in an Yoruban individual NA19202 and spanning 
168,339 base pairs on the hg18 genome assembly) [506] and a published copy   147
number variant of unknown direction (not determined whether gain or loss; one 
of 1447 copy number variable regions detected by HapMap Phase II data 
analysis by SNP and BAC microarray) [507], Figure 47. 
 
 
 
Figure 47 TSBP – HLA-DQA1 region 
Representation of the region of interest on the UCSC Genome browser (human March 2008 hg18 
genome assembly). Shown are the the log -10 chi square scores of the SNPs covering the region 
after stringent quality control (call rate > 99% etc.), known genes (as defined by UCSC) and 
structural variation (in red known deletions as described by Conrad et al. [506], in gray the gain 
or loss - unknown direction - variation described by Redon et al. [507]). 
 
Chromosome 13 
The associated SNP marker defining the region of interest on chromosome 13 is 
rs4943552 (physical position 38504142 bp on the February 2009 assembly 
GRCh37 / hg19). It is a coding / sense (+) strand T > C/T type single nucleotide 
variant, a substitution (translation), the ancestral allele being T (present on the 
positive strand of the chimpanzee Pan paniscus genome, on the negative strand 
of the orangutan Pongo pygmaeus genome and on the positive strand of the   
macaque  Macacus rhesus genome). It has been validated by cluster, by 
frequency, by 2 hit / 2 allele, by HapMap and by 1000 genomes. Its average 
heterozygosity is 0.278 +/- 0.248. The weight quality assignment by dbSNP of   148
rs4943552 is 1. Its functional type is unknown, it lies at 60 kb upstream of the 
TRPC4 gene. 
TRPC4 
The Transient Receptor Potential cation channel, subfamily C, member 4 gene 
spans 233,165 base pairs on the negative (antisense) strand of chromosome 
13q13.3. It has 11 exons, 10 of which are coding, the first one transcribed in a 
fragment of the 5’ UTR (untranslated region). Its product is the short transient 
receptor potential 4, a protein predicted to be 804 amino acids long. 
Chromosome 16 
The SNP marker associated to membranous nephropathy on chromosome 16 is 
rs2221705 (physical position 79362411 bp on the February 2009 assembly 
GRCh37 / hg19). It is a coding / sense (+) strand T > C/T type single nucleotide 
variant, a substitution (translation), the ancestral allele being T (present on the 
positive strand of the chimpanzee Pan paniscus genome, the negative strand of 
the orangutan Pongo pygmaeus genome and the positive strand of the macaque 
Macacus rhesus genome). It has been validated by cluster, by frequency, by 2 hit 
2 allele, by HapMap and by 1000 genomes. Its average heterozygosity is 0.157 
+/- 0.232. The weight quality assignment by dbSNP of rs2221705 is 1. Its 
functional type is unknown, it is located downstream from the WWOX gene. 
WWOX 
WW domain-containing oxidoreductase, is a nine exon (all coding) gene that 
spans 1,113,013 base pairs of genomic DNA on the positive (coding) strand (at 
chr16:79,238,846-79,246,564 on the February 2009 GRCh37 / hg19 assembly). 
It encodes a 414 amino acid protein which contains two WW domains and a SRD 
(short chain dehydrogenase / reductase) domain therefore belonging to the SDR 
family. Its expression is highest in hormonally regulated tissues (testis, ovary, 
prostate). The presence of the SRD domain and expression pattern suggests a 
role for this protein in steroid metabolism. Through similarity with its mouse 
homologue it has also been suggested that WWOX is important in tumor necrosis 
factor alpha induced apoptosis.   149
Cases separated from controls QC filtering (separated scenario) 
Separated high stringency scenario (CR > 99) 
The merging of the two initialy separated datasets (cases and controls) ‘dilutes’ 
the proportion of false calls, i.e. a small yet significant proportion of genotyping 
errors for one of the separated datasets might lose its significance when the 
threshold is applied for the merged dataset. To alleviate this pitfall the results of 
quality control performed on the common matrix was compared with quality 
control outcomes on the two datasets filtered separatedly are as follows: 
Cases 
A matrix with 335 rows (UK cases) and 351,515 columns (351,507 assessed 
markers and 8 columns of phenotypic descriptors) was created. The phenotypic 
descriptors are encoded as a binary variable (where 0 = no and 1 = yes) as 
follows: column 1: Ethnicity=YRI? (Yoruban), column 2: Ethnicity=CHB? (Han 
Chinese), column 3: Ethnicity=Caucasoid?, column 4: Ethnicity=UK?, column 5: 
Ethnicity=FR?, column 6: Ethnicity=NL?, column 7: gender (0 = male, 1 = 
female), column 8: status (0 = unaffected, 1 = affected). From the initial 351,507 
assessed markers, 338,680 markers were found to have two alleles, 6,174 
markers presented one allele and 6,653 markers had missing genotypes (no 
alleles). Quality assurance genotype filtering by marker (parameters) was 
performed with the following parameters: call rate < 0.99; minor allele frequency 
(MAF) < 0.01; Hardy-Weinberg Equilibrium P (HWE P) < 0.001. 
 
39,920 (11.36 %; from all markers 351,507 = 100%) markers did not pass the 
filtering threshold (22,413 due to the call rate limitation at 99%; 8,826 due to the 
MAF limitation; 11,422 due to the HWE P condition; cave: some markers did 
not pass more than one of the filtering criteria (therefore: 22,413 + 8,826 + 
11,422 = 42,661 > 39,920). 
Controls 
Similarly a matrix with 349 rows (UK controls) and 317,511 columns (317,503 
assessed markers and 8 columns of phenotypic descriptors) was used. From the   150
assessed makers 317,419 markers were found to have two alleles and 84 markers 
were found to be uninformative (having just one allele). 
Quality assurance genotype filtering by marker (parameters) was performed with 
the following parameters: call rate < 0.99; minor allele frequency (MAF) < 0.01; 
Hardy-Weinberg Equilibrium (HWE P) < 0.001. 
 
44,818 (14.12%; from the total number of markers 317,503 = 100%) markers did 
not pass the filtering threshold (35,878 due to the call rate limit; 235 due to the 
MAF limit; 10528 due to the HWE P limit; cave: some markers did not pass 
more than one of the filtering criteria, therefore 35,878 + 235 + 10528 = 46,641 
> 44,818). 
Case-control matrix overlap 
Pre QC there were 338,680 informative markers (cases) and 317,419 informative 
markers (controls). After QC the informative markers from the controls matrix 
that passed the filtering criteria (272,685) were intersected with the informative 
cases markers which passed the filter (311,587). This operation  yielded 255,264 
informative markers that are common for the two datasets (cases and controls; 
75.46 % out of 338,680 = 100% cases and 80,51% out of 317,419 = 100% 
controls). 
Second HWE cleaning step 
Through the merging of the case and control cohorts, the structure of the 
population was changed, therefore the Hardy-Weinberg Equilibrium filtering was 
reiterated on the common case-control matrix. Acordingly 366 markers were 
filtered out (for a P value of the HWE < 0.001). The number of markers passing 
both cleaning steps remained thus 254,898. 
Population structure 
The estimate for stratification (genomic inflation factor, λ) is for the case control 
combined matrix 1.13 (which is close to 1, therefore not suggestive for 
stratification). The genotype principal component analysis was performed 
computing up to 100 components using the additive genetic model for PCA to 
detect stratification. The values of the Eigenvalues thus computed drop   151
exponentially from 2.22 towards 0.6, suggesting that most of the differences can 
be captured within the first two principal components, Figure 19. These first two 
components (with the eigenvalues – EV – of 2.22 and 1.04) were shown on the 
pre-append (separated) two step quality control filtering UK dataset orthogonal 
projection in Figure 21. 
QQ plot 
 
 
Figure 48 Q-Q plot: UK dataset, separated high stringency 
Q-Q plot for the Chi-squared test of the basic allelic test (D versus d) plotting the actual 
association -log10P to the expected -log10P in cases versus controls for the UK dataset after pre-
append (separated) two step quality control filtering for call rate > 99%, minor allele frequency 
MAF > 0.01, Hardy-Weinberg equilibrium HWE P > 0.001.   152
 
Results 
Basic Allelic Test 
All 254,898 common informative markers filtered through two quality control 
steps (pre append and post append) were used for the analysis. The threshold for 
genome-wide significance corrected for multiple comparisons (Bonferroni 
correction) was set at P1 = 0.001 / 254,898 and then further adjusted for the 
genomic inflation factor P = P1 / 1.13 = 3.462 x10
-9; -log10P = 8.46. 
Basic allelic test (D versus d) the chosen test statistic (for the 2X2 contingency 
table) was the Chi-squared test. 124 markers were found to be associated with the 
trait (MN) at this genome-wide significance threshold, Figure 49. 
 
 
 
Figure 49 BAT Manhattan plot, UK dataset, separated high stringency scenario 
Manhattan plot for the Chi-squared test of the basic allelic test (BAT) comparing minor versus 
major alleles (D versus d) in cases versus controls for the UK dataset after pre-append (separated) 
two step quality control filtering for call rate > 99%, minor allele frequency > 0.01, Hardy-
Weinberg equilibrium P > 0.001. The level of significance (corrected for multiple comparisons 
and for genomic inflation) is represented by the red line at -log10 = 8.46. (Y axis =   
-log10P, X axis = physical positions of the markers corresponding to the human February 2009 
GRCh37/hg19 genome assembly, the chromosomes being plotted successively, shaded and 
coloured in different colours for better visualisation). 
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Genotype Association Test 
When performing the Genotypic association test (DD versus dd versus Dd; the 
chosen test statistic being the Chi-squared test, with a threshold for genome-wide 
significance corrected for multiple comparisons and the genomic inflation factor 
(P1 = 0.001 / 254,898 / 1.07 = 3.666 x10
-9; -log10P = 8.43) 101 markers were 
found to be associated with the trait (MN) at the genome-wide significance 
threshold. 
 
 
 
Figure 50 GAT Manhattan plot, UK dataset, separated high stringency scenario 
Manhattan plot for the Chi-squared test of the genotype association test (GAT) comparing each 
of three possible genotype configurations (dd, dD, DD) in cases versus controls for the UK 
dataset after pre-append (separated) two step quality control filtering for call rate > 99%, minor 
allele frequency > 0.01, Hardy-Weinberg equilibrium P > 0.001. The level of significance 
(corrected for multiple comparisons and for genomic inflation) is represented by the red line at  
-log10 = 8.43. (Y axis = -log10P, X axis = physical positions of the markers corresponding to the 
human February 2009 GRCh37/hg19 genome assembly, the chromosomes being plotted 
successively, shaded and coloured in different colours for better visualisation).   154
 
Additive Model 
The association test on an additive model (dd > Dd > DD; the chosen statistic 
being the Correlation Trend test, with a threshold for genome-wide significance 
corrected for multiple comparisons and for stratification set at P  = 0.001 / 
254,898 / 1.13 = 3.47 x10
-9; -log10P = 8.46) yielded 124 markers associated with 
the trait (MN) at the genome-wide significance threshold. 
 
 
 
Figure 51 AM Manhattan plot, UK dataset, separated high stringency scenario 
Manhattan plot for the Chi-squared test of the additive model (AM) test comparing the three 
possible genotype configurations (under the assumption of an increasing effect of the causative 
allele on the phenotype: dd > dD > DD) in cases versus controls for the UK dataset after pre-
append (separated) two step quality control filtering for call rate > 99%, minor allele frequency > 
0.01, Hardy-Weinberg equilibrium P > 0.001. The level of significance (corrected for multiple 
comparisons and for genomic inflation) is represented by the red line at   
-log10 = 8.46. (Y axis = -log10P, X axis = physical positions of the markers corresponding to the 
human February 2009 GRCh37/hg19 genome assembly, the chromosomes being plotted 
successively, shaded and coloured in different colours for better visualisation). 
   155
Dominant Model 
The association test on an dominant model (DD, Dd versus dd; the chosen test 
statistic being Chi-squared, with a threshold for genome-wide significance 
corrected for multiple comparisons set at P = 0.001 / 254,898 / 1.11 = 3.53 x10
-9; 
-log10P = 8.45) yielded 95 markers associated with the trait (MN) at the genome-
wide significance threshold. 
 
 
 
Figure 52 DM Manhattan plot, UK dataset, separated high stringency scenario 
Manhattan plot for the Chi-squared test of the dominant model (DM) test assumes a binary type 
influence on the phenotype given the presence or absence of causative allele (dd versus dD and 
DD) in cases versus controls for the UK dataset after pre-append (separated) two step quality 
control filtering for call rate > 99%, minor allele frequency > 0.01, Hardy-Weinberg equilibrium 
P > 0.001. The level of significance (corrected for multiple comparisons and for genomic 
inflation) is represented by the red line at -log10 = 8.45. (Y axis = -log10P, X axis = physical 
positions of the markers corresponding to the human February 2009 GRCh37/hg19 genome 
assembly, the chromosomes being plotted successively, shaded and coloured in different colours 
for better visualisation).   156
 
Recessive Model 
The association test on an recessive model (DD vs. Dd, dd; the chosen test 
statistic being Chi-squared, with a threshold for genome-wide significance 
corrected for multiple comparisons set at P = 0.001 / 254,898 / 1.09 = 3.59 x10
-9; 
-log10P = 8.44) yielded only 12 markers associated with the trait (MN) at the 
genome-wide significance threshold. 
 
 
 
Figure 53 RM Manhattan plot, UK dataset, separated high stringency scenario 
Manhattan plot for the Chi-squared test of the recessive model (RM) test assumes a binary type 
influence on the phenotype where only the homozygous presence of the causative allele (both 
alleles genotype) determines the phenotype (dd and dD versus DD) in cases versus controls for 
the UK dataset after pre-append (separated) two step quality control filtering for call rate > 99%, 
minor allele frequency > 0.01, Hardy-Weinberg equilibrium P > 0.001. The level of significance 
(corrected for multiple comparisons and for genomic inflation) is represented by the red line at  
-log10 = 8.44. (Y axis = -log10P, X axis = physical positions of the markers corresponding to the 
human February 2009 GRCh37/hg19 genome assembly, the chromosomes being plotted 
successively, shaded and coloured in different colours for better visualisation).   157
 
Haplotype analysis 
To assess visualy the haplotype block structure of the regions of interest, linkage 
disequilibrium was plottet graphically in triangular heatmap plots, the the colour 
of the point at the intersection of the projection of the lines originating in the 
queried markers reflecting a measure of LD (either r
2 or D’). The complexity of 
the HLA region on chromosome 6 is reflected in its pattern of increased linkage 
disequilibrium, see Figures 54 and 55. 
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Figure 54 LD plot, chromosome 6 (HLA region)  
UK case control association dataset; X axis: physical position; Y axis: association values   
-log10P; inverted triangle: heatmap of linkage disequilibrium (r
2) color coded blue (0) to red (1) 
according to the legend. 
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Figure 55 LD plot, peri-PLA2R1 region  
Chromosome 6 (HLA region) linkage disequilibrium (LD) plot zoom in. Y axis: association 
values -log10P; inverted triangle: heatmap of linkage disequilibrium (r
2) color coded blue (0) to 
red (1) according to the legend. 
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The haplotype association test treats different haploblocks as combined markers. 
Haplotype block definition 
For our analysis, haplotype (LD) blocks were computed in SNP & Variation 
Suite v7.3.1 according to their definition by Gabriel et al. [428] (in order to 
minimize historical recombination). LD blocks were considered to have a D’ at 
an upper confidence bound > 0.98 and a lower confidence bound > 0.7 at 98% 
confidence. Pairs were rejected with an upper bound < 0.9. The minimal allele 
frequency of markers assessed in order to define blocks was set at 0.05. Blocks 
were limited to less than 30 markers per block with a length lower than 160 kb. 
According to these criteria, 18,393 blocks including 42,595 markers were 
defined. 
Haplotype association test 
The Chi-squared test statistics significance threshold (P = 0.001) corrected for 
multiple comparisons (in this case the number of blocks: 18,393) was set at   
-log10P = 7.26. Association was computed per block and per haplotype 
(haplotypes were estimated according to the expectation-maximisation – EM – 
algorithm [508]; the frequency threshold for haplotype estimation was set at 
0.01, EM convergence tolerance was set at 0.0001 and the maximum number of 
EM iterations was set at 50) see Figures 56 and 57. 
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Figure 56 HAT per block Manhattan plot, UK, separated high stringency scenario 
Results of the haplotype association test (HAT) per block analysis performed on the UK dataset. 
The level of significance (corrected for multiple comparisons) is represented by the red line at -
log10 = 7.26. (Y axis = -log10P, X axis = physical positions of the markers corresponding to the 
human February 2009 GRCh37/hg19 genome assembly, the chromosomes have been plotted 
successively, and shaded alternatively for better visualisation. 
 
 
 
Figure 57 HAT per haplotype Manhattan plot, UK, separated high stringency 
Results of the haplotype association test (HAT) per haplotype analysis performed on the UK 
dataset. The level of significance (corrected for multiple comparisons) is represented by the red 
line at -log10 = 7.26. (Y axis = -log10P, X axis = physical positions of the markers corresponding 
to the human February 2009 GRCh37/hg19 genome assembly, the chromosomes have been 
plotted successively, and shaded alternatively for better visualisation.   162
 
Separated permissive scenario (CR > 90) 
As mentioned before, merging of the two initialy separated datasets (cases and 
controls) ‘dilutes’ the proportion of markers which should be filtered out. 
Conversely, using a high call rate threshold for each separated dataset when 
performing a non-merged analysis, might become excessive. Therefore we tried a 
more permissive scenario filtering for call rates of under 90% (CR < 0.9). The 
permissivity for call rate was balanced through the use of a higher stringency 
criterion for the Hardy-Weinberg Equlibrium (HWE P < 0.01). The minor allele 
frequency was filtered as the 1% threshold as per the definition of 
polymorphisms (MAF < 0.01). We performed three separated steps of quality 
control for the separated scenario: first filtering step on the cases matrix followed 
by a second filtering step on the controls matrix and a third filtering step on the 
merged cases and controls matrix. 
Cases 
The initial case matrix with 335 rows (UK cases) and 351,515 columns (351,507 
assessed markers and 8 columns of previously described phenotypic descriptors) 
was used. Of the assessed 338,680 markers are bialellic ergo informative. From 
the total of 351,507 markers 30,532 (8.67%) markers did not pass the filtering 
steps. This is similar to the 39,920 markers (11.36%) filtered in the separated 
high stringency scenario. The informative markers from the cases matrix which 
passed the filter were in the end 320,975. 
Controls 
The control matrix with 349 rows (UK controls) and 317,511 columns (317,503 
assessed markers and 8 columns of phenotypic descriptors) was used. From the 
assessed makers 317,419 markers were found to be informative (biallelic).  
19,959 (6.28% of the informative) markers did not pass the filtering procedure. 
This compares favorably to the 44,818 markers (14.12%) which were filtered in 
the separated high stringency scenario. The informative markers from the 
controls matrix that passed the filtering criteria were finally 297,543.   163
Case-control matrix overlap 
After the quality filtering, the informative filtered markers from the controls 
matrix were intersected with the informative filtered markers from the cases 
matrix. This operation  yielded 282,997 informative (biallelic) markers that are 
common for the two datasets (cases and controls; 83.56% out of the initial 
338,680 = 100% informative markers for cases and 89.15% out of the intitial 
317,419 = 100% informative markers for controls). 
Second HWE cleaning step 
Through the merging of the case and control cohorts, the structure of the 
population was changed, therefore the filtering (call rate < 0.9, MAF < 0.01, 
HWE P < 0.01) was reiterated on the common case-control matrix. Acordingly 
1,988 markers were filtered out (for a P value of the HWE < 0.01). The number 
of markers passing both cleaning steps remained thus 281,009. 
Population structure 
The estimate for stratification (genomic inflation factor, λ) is for the case control 
combined matrix 1.15 (which is close to 1, therefore not suggestive for 
stratification). 
Results 
Significance threshold 
The significance level that we adopted for our analyses (P = 0.001) was corrected 
for multiple testing by dividing it with the number of informative markers (N =  
281,009). Correction for stratification is obtained by dividing the new 
significance value by λ (the genomic inflation factor; λ = 1.15). The corrected  
P = 0.001 / 281,009 / 1.15 = 3.1 x 10
-9; -log10P = 8.51. 
QQ plot 
The QQ plots, comparing the dataset with and omitting the SNPs within the 
extended HLA complex, show that the most extreme dispersion is in the HLA 
region, which is probably due to at least one association in this region and strong 
linkage disequilibrium within the associated region, Figure 58.   164
 
 
Figure 58 QQ plots, UK, separated permissive scenario 
Quantile–quantile plot for observed (y axis) versus expected (x axis) -log10P values comparing 
the impact of the extended MHC region (blue: all SNPs tested; red: SNPs within the extended 
MHC region excluded; dotted black line: null distribution). 
 
Basic allelic test 
At this corrected significance threshold, 146 markers were associated with the 
trait of which two lie within the PLA2R1 / ITGB6 region on chromosome 2 
(rs4664308 – within PLA2R1 and rs1870102 – ITGB6), and 144 lie within the 
extended MHC region on chromosome 6. 
3.2.1.8 Comparison of the different filtering scenarios 
We used the basic allelic test (BAT; the simplest and most robust test) in order to 
compare the positive association hits for the different filtering scenarios that we 
employed (no filtering, stepwise filtering based on the call rate, stepwise filtering 
based on the minor allele frequency, stepwise filtering based on Hardy-Weinberg 
equilibrium; combined filtering performed on the case-control matrix together, 
combined filtering performed on cases and control matrices separatedly at 
different stringencies), Table 11. 
 
Table 11 Comparison of the effects of different filtering scenarios   165
CR: call rate, MAF: minor allele frequency, HWE: Hardy-Weinberg Equilibrium, λ: genomic 
inflation factor 
 
 stringency  CR  MAF  HWE  markers  λ  -log10P   associations 
 NO 
FILTERING  -  -        305,452  1.16  8.54  188
STEPWISE 
CR  low  96  -  -  298,178  1.15  8.53  159
  high  99  -  -  279,361  1.14  8.5  145
  max  100  -  -  109,909  1.14  8.09  60
STEPWISE 
MAF  min   -  0.01   -  305,273  1.16  8.54  188
   med   -  0.05   -  297,918  1.16  7.54  185
   max   -  0.1   -  263,983  1.17  8.48  180
STEPWISE 
HWE  low  -  -  0.0001  296,392  1.15  8.53  172
  high  -  -  0.001  295,636  1.15  8.53  171
  extreme  -  -  0.01  291,838  1.15  8.52  168
COMBINED 
together  low  96  0.01  0.001  288,664  1.14  8.52  151
   high  99  0.01  0.001  270595  1.13  8.49  137
COMBINED 
separated  high  99  0.01  0.001  254,898  1.13  8.46  124
  permissive  90  0.01  0.01  281,009  1.15  8.51  146
 
We chose the permissive scenario for replication, after weighing the number of 
markers lost during the filtering with the overall cleanliness of the data (assessed 
by number of isolated – putative false positive association signals in regions 
other than PLA2R1 on chromosome 2 and extended HLA on chromosome 6). 
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3.2.2  Replication 
3.2.2.1 French 
Selection 
Cases 
75 kidney biopsy confirmed membranous nephropathy cases of French origin 
were selected (courtesy of Professor Pierre Ronco), Paris. Of these 58 were 
males and 17 females, the resulting gender ratio being 1: 3.41. No maneouvers to 
enrich the cohort for specific disease-predisposing alleles were performed. 
Controls 
157 French controls (clinically not affected by membranous nephropathy) were 
assessed, of which 66 were males and 91 females (leading to a gender ratio of  
1: 0.72). 
Genotyping 
Both cases and controls were genotyped on a Illumina Human370k duo v1 
platform at the same time in the same laboratory (Genepole). 339,845 SNPs were 
successfully genotyped.  
SNP encoding and mapping 
SNPs encoded as Forward (corresponding to dbSNP convention). 
 
The Illumina370Map marker map was used. 333,616 markers were successfully 
mapped, 6229 markers from the genotyping chip were not present in the map 
file. 
 
The markers not present in the Illumina map file were checked in dbSNP130 
(accessed through the UCSC genome browser table function, build version 
hg18). 6 markers (rs2662733, rs28625410, rs34131647, rs35588459, rs4215, 
rs4292042) were not found in db SNP 130 (were dropped from dbSNP 128. Of   167
the remaining markers 22 were not uniquely mapped on hg18 (19 duplicates, 2 
triplicates, 1 occured five times). Overall 6,201 markers were added to the map, 
increasing the number of successfully mapped markers to 339,817. 
Quality Control 
Together permissive 
The quality control procedure was performed on the common (case and control) 
matrix [492] (assuming the genotyping has been performed at the same time for 
cases and controls together). For the French replication cohort this was indeed 
the case. From the total of 339,845 genotyped markers, 333,817 markers had two 
alleles, 6,028 markers were monoallellic, therefore uninformative. The criteria 
for quality assurance genotype filtering by marker were the ones established for 
the permissive scenario, that is: call rate CR < 90%; minor allele frequency 
(MAF) < 0.01; Hardy-Weinberg Equilibrium (HWE P) < 0.01. 
24,796 (7.43 %; genotyped markers 333,817 = 100%) markers did not pass the 
filtering threshold. 
QQ plot 
The QQ plots (Figure 59) comparing the dataset with and omitting the SNPs 
within the extended HLA complex, show – similarly to the UK exploratory 
scenario, but with a lesser general dispersion, probably due to the fact that cases 
and controls were genotyped under more similar conditions (Figure 58) -  that the 
most extreme dispersion is within the HLA region. 
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Figure 59 QQ plots, FR replication, separated permissive scenario 
Quantile–quantile plot for observed (y axis) versus expected (x axis) -log10P values comparing 
the impact of the extended MHC region (blue: all SNPs tested; red: SNPs within the extended 
MHC region excluded; dotted black line: null distribution). 
 
Basic Allelic Test 
All 315,049 markers that passed the quality control were used for the analysis 
with following parameters: the first genetic model assessed was the basic allelic 
test (D vs. d); missing values were not used; input data was not corrected for 
stratification (the inflation factor λ found for chi-squared was 1.02, close to 1 
therefore not suggestive for stratification). 
The chosen statistic (of the 2X2 contingency table) for the basic allelic test was 
the Chi-squared test. The threshold for genome-wide significance corrected for 
multiple comparisons (Bonferroni correction) was set at P = 0.001 / 315,049 =  
3.17 x10
-9; further corrected for stratification 1.6 x10
-7  / 1.02 = 3.11 x10
-9;  
-log10 = 8.5. 
3 markers (rs9272192, rs9273327, rs2187668) were found to be associated with 
the trait (MN) at the genome-wide significance threshold, see Figure 60.   169
 
 
Figure 60 BAT Manhattan plot, French replication dataset 
Manhattan plot for the Chi-squared test of the basic allelic test (BAT) comparing minor versus 
major alleles (D versus d) in cases versus controls for the French dataset. The level of 
significance (corrected for multiple comparisons and for genomic inflation) is represented by the 
red line at -log10P  = 8.5. (Y axis = -log10P, X axis = physical positions of the markers 
corresponding to the human February 2009 GRCh37/hg19 genome assembly, the chromosomes 
being plotted successively, shaded alternatively for better visualisation). 
 
The region of interest encompassed by the associated markers encompasses the 
HLA-DQA1 gene as seen in Figure 61. 
 
 
 
Figure 61 Region of association, French replication dataset 
Shown are the three associated markers for the French dataset (rs9272192, rs9273327, 
rs2187668) centered by HLA-DQA1 in the extended MHC region on chromosome 6 (physical 
positions of the markers corresponds to the human February 2009 GRCh37/hg19 genome 
assembly). 
 
Haplotype analysis 
Haploblock definition 
Haplotype blocks (Haploblocks) were computed in SNP & Variation Suite v7.3.1 
according to the definition by Gabriel et al. [428]. As a measure of linkage 
disequilibrium defining each block D’ was chosen at an upper confidence bound 
> 0.98 and a lower confidence bound > 0.7 (98% confidence). Pairs were   170
rejected with an upper bound < 0.9. The markers assessed in order to define 
blocks were chosen with a minor allele frequency of > 0.05. Blocks were limited 
to less than 30 markers per block and a length lower than 160 kb. Adhering to 
these criteria, 25,378 blocks including 59,807 markers were defined. Haplotypes 
were estimated according to the expectation-maximisation – EM – algorithm; the 
frequency threshold for haplotype estimation was set at 0.01, EM convergence 
tolerance was set at 0.0001, the maximum number of EM iterations was set at 50. 
Haplotype Association Test 
The Chi-squared test statistics was calculated per block and per haplotype, the 
significance threshold (P  = 0.001) corrected for multiple comparisons 
(corresponding to the number of blocks: 25,378) was set at -log10P = 7.4, see 
Figures 62 and 63. 
 
 
 
Figure 62 HAT per block Manhattan plot, FR replication dataset 
Results of the haplotype association test (HAT) per block analysis. The level of significance 
(corrected for multiple comparisons) is represented by the red line at -log10 = 7.4. (Y axis =  
-log10P, X axis = physical positions of the markers corresponding to the human February 2009 
GRCh37/hg19 genome assembly, the chromosomes have been plotted successively, and shaded 
alternatively for better visualisation. 
   171
 
 
 
Figure 63 HAT per haplotype Manhattan plot, FR replication dataset 
Results of the haplotype association test (HAT) per haplotype analysis. The level of significance 
(corrected for multiple comparisons) is represented by the red line at -log10 = 7.4. (Y axis =  
-log10P, X axis = physical positions of the markers corresponding to the human February 2009 
GRCh37/hg19 genome assembly, the chromosomes have been plotted successively, and shaded 
alternatively for better visualisation.   172
 
3.2.2.2 Dutch 
Selection 
Cases 
146 kidney biopsy confirmed Dutch cases (courtesy of Professor Jack Wetzels) 
were genotyped, of which 109 males and 37 females which results in a gender 
ratio of male : female ~ 3 / 1. No manoeuvres have been attempted to enrich the 
cohort for disease-predisposing alleles bearing individuals. The cases were 
genotyped on a Illumina Human 370 Quad v3 platform (UCL genotyping core; 
Dr. Mike Hubank). The same chip type was chosen for the genotyping of the 
Dutch cases (second replication study) as the one which was used for the initial, 
exploratory study (UK). 
Controls 
1832 controls from the Netherlands (906 males, 926 females; sex ratio ~ 1 / 1) 
genotyped for 370,404 SNPs were provided by the Dutch group. Dutch controls 
were genotyped by deCODE genetics, Iceland, using the HumanCNV370-Duo 
SNP chip. They are part of the Nijmegen Biomedical Study, a population-based 
survey conducted by the Department of Epidemiology and Biostatistics and the 
Department of Clinical Chemistry of the Radboud University Nijmegen Medical 
Centre [509]. This historical control dataset was rendered in PLINK [510] 
format. Reading the file in PLINK identified 30,038 heterozygous haploid 
genotypes, the minor allele frequency (MAF) was 0 for 23,981 SNPs, the total 
genotyping rate for the remaining SNPs was 0.93. No frequency or genotyping 
pruning was performed in PLINK. Reformatting of the binary file was performed 
in PLINK, separated textfiles were obtained formatted as in the PEDFILE 
linkage format: 
FAM ID FATHER_ID MOTHER_ID SEX AFFECTION_STATUS MARKERS 
and associated map file: 
CHROMOSOME, SNP_ID, ?, PHYSICAL_POSITION 
which were combined in a case matrix (similar to the case-control matrix shown 
in Table 4) to be analysed in the Helix SNP & Variation Suite v7.3.1. 
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Quality control 
The same stringency quality control scenario as for the exploratory analysis and 
French replication has been applied for the Dutch dataset. 
Combined Separated Permissive Scenario 
Given that this is a setting of a historical control type dataset (genotyping 
performed at different timepoints for cases and for controls) we performed the 
first quality control steps before merging the two matrices and then added a 
second filtering step (as has been previously described for the UK dataset). 
Cases matrix 
373,397 SNPs (including CNV markers) were genotyped and successfully 
mapped with the Illumina 370k quad v3 map: 338,258 markers with two alleles, 
6,824 markers with one allele (ergo noninformative), 28,288 markers with no 
alleles (all missing; of which 21,890 CNV markers). Quality assurance 
parameters for the genotype filtering by marker: call rate   
CR < 0.90; minor allele frequency (MAF) < 0.01; Hardy-Weinberg Equilibrium 
(HWE P) < 0.01. 
44,837 (13,25 % of the informative markers 338,258 = 100%) markers did not 
pass the filtering threshold. 
Controls matrix 
370,404 SNPs including CNV markers were genotyped. Of which 340,836 
markers are informative (biallelic), 5,587 markers are monoallelic, 23,981 
markers are missing (of which 21,890 dedicated CNV type markers). The same 
quality assurance parameters as the ones for the cases were used (call rate < 90%; 
minor allele frequency (MAF) < 0.01; Hardy-Weinberg Equilibrium (HWE P) < 
0.01). 
20,465 (6 %; informative markers 340,836 = 100%) markers did not pass the 
filtering threshold. 
Together HWE < 0.01 
293,421 case matrix markers intersected with 320,371 control matrix markers 
yielded 283,512 common case control matrix markers). Applying the Hardy-  174
Weinberg Equilibrium filtering condition to the combined case / control matrix 
(HWE P) < 0.01 on the merged (case and controls) matrix led to 1,072 markers 
being inactivated. 
QQ plot 
The QQ plots comparing the Dutch dataset in two scenarios: with and omitting 
the SNPs within the extended HLA complex, showing the most extreme 
dispersion within the HLA region, Figure 64 
 
 
 
Figure 64 QQ plots, NL replication, separated permissive scenario 
Quantile–quantile plot for observed (y axis) versus expected (x axis) -log10P values comparing 
the impact of the extended MHC region (blue: all SNPs tested; red: SNPs within the extended 
MHC region excluded; dotted black line: null distribution). 
 
Basic Allelic Test 
All 282,440 of the informative markers that passed the quality control were used 
for the analysis with following parameters: the first genetic model assessed was 
the basic allelic test (D versus d); missing values were not used; input data was 
not corrected for stratification (the genomic inflation factor λ = 1.12 was close to 
1 hence not suggestive for stratification); the statistic method used was the robust   175
basic allelic test (D versus d), the test statistic used being Chi-Squared with 
Bonferroni (multiple testing for 282,440 markers) correction and genomic 
inflation factor (λ = 1.12) adjustment (P = 0.001 / 282,440 / 1.12 = 3.16 x10
-9;  
-log10P =  8.5). 
 
197 markers were found to be associated with the trait (IMN), see Figure 65. 
 
 
 
Figure 65 BAT Manhattan plot, Dutch replication dataset 
Manhattan plot for the Chi-squared test of the basic allelic test (BAT) comparing minor versus 
major alleles (D versus d) in cases versus controls for the Dutch dataset. The level of significance 
(corrected for multiple comparisons and for genomic inflation) is represented by the red line at  
-log10P = 8.5. (Y axis = -log10P, X axis = physical positions of the markers corresponding to the 
human February 2009 GRCh37/hg19 genome assembly, the chromosomes being plotted 
successively, shaded alternatively for better visualisation). 
 
Haplotype analysis 
Haploblock definition 
Haplotype blocks (Haploblocks) were computed according to the definition by 
Gabriel et al. [426]. D’ was set at an upper confidence bound > 0.98 and a lower 
confidence bound > 0.7 (98% confidence); pairs were rejected at an upper bound 
< 0.9. The minor allele frequency of assessed markers (less than 30 per block) 
was set at > 0.05. The maximum length of a block was set at 160 kb.   176
21,409 blocks including 56,807 markers were defined. Haplotypes were 
estimated according to the expectation-maximisation – EM – algorithm; the 
frequency threshold for haplotype estimation was set at 0.01, EM convergence 
tolerance was set at 0.0001, the maximum number of EM iterations was set at 50. 
Haplotype Association Test 
The Chi-squared test statistics was calculated per block and per haplotype, the 
significance threshold (P = 0.001) was corrected for multiple comparisons 
(corresponding to the number of blocks: 21,409) was set at -log10P = 7.33, see 
Figures 66 and 67.   177
 
 
 
Figure 66 HAT per block Manhattan plot, Dutch replication dataset 
Results of the haplotype association test (HAT) per block analysis. The level of significance 
(corrected for multiple comparisons) is represented by the red line at -log10 = 7.33. (Y axis =  
-log10P, X axis = physical positions of the markers corresponding to the human February 2009 
GRCh37/hg19 genome assembly, the chromosomes have been plotted successively, and shaded 
alternatively for better visualisation. 
 
 
 
Figure 67 HAT per haplotype Manhattan plot, Dutch  replication dataset 
Results of the haplotype association test (HAT) per haplotype analysis. The level of significance 
(corrected for multiple comparisons) is represented by the red line at -log10 = 7.33. (Y axis =  
-log10P, X axis = physical positions of the markers corresponding to the human February 2009 
GRCh37/hg19 genome assembly, the chromosomes have been plotted successively, and shaded 
alternatively for better visualisation.   178
 
3.2.3  Joint GWAS 
3.2.3.1 Common matrix and QC 
The common Caucasoid descent of all the cases and controls in the 
aforementioned studies (i.e.  UK, French, Dutch) suggested the possibility of 
performing a joint analysis of all 556 cases and 2,338 controls. The marker 
matrices of UK cases, UK controls, Dutch cases and Dutch controls have been 
filtered separatedly, using the criteria (CR < 0.9, MAF < 0.01, HWE P < 0.01) of 
the separated permissive filtering scenario; the marker matrix of the French cases 
and controls has been filtered using the same criteria applied within the together 
permissive filtering scenario (having been genotyped together).  The common 
matrix, obtained through the interesecting of all the filtered matrices, contains 
244,860 common markers before the secondary (HWE P < 0.01) filtering step, 
which leads to further pruning of 2,036 markers, leading to a final (common, 
quality filtered) marker set of 242,824. 
3.2.3.2 Stratification 
The genomic inflation factor (λ) was found to be 1.29. 
3.2.3.3 QQ Plots 
QQ plots comparing the joint (UK, FR and NL) datasets, with and omitting the 
SNPs within the extended HLA complex, show the most extreme dispersion 
within the HLA region, Figure 68. 
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Figure 68 QQ plots, joint analysis, separated permissive scenario 
Quantile–quantile plot for observed (y axis) versus expected (x axis) -log10P values comparing 
the impact of the extended MHC region (blue: all SNPs tested; red: SNPs within the extended 
MHC region excluded; dotted black line: null distribution). 
 
3.2.3.4 Analysis 
We performed the Basic Allelic Test, with the test statistic being Chi-squared, at 
a significance level corrected for multiple comparisons (242,824 markers) and 
genomic inflation factor (λ = 1.29): P = 0.001 / 242,824 / 1.29 = 3.19 x 10
-9;  
-log10P = 8.5. 
3.2.3.5 Results 
312 markers were found to be associated with the trait, the signal for association 
reaching significance level only at the two regions of interest previously 
described (i.e. the PLA2R1  locus on chromosome 2 – 30 markers; and the 
extended HLA locus on chromosome 6 locus – 282 markers) see Figure 69. 
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Figure 69 BAT Manhattan plot, joint analysis 
Manhattan plot for the joint genome-wide association study (GWAS) of idiopathic membranous 
nephropathy (IMN). Joint analysis of genome-wide association study for 556 Caucasoid cases of 
IMN and 2338 Caucasoid controls using 242,824 SNPs. The horizontal red line indicates the 
genome-wide significance level for the basic allele test (upper plot) utilizing chi-square test after 
Bonferroni correction and adjustment for the genomic inflation factor (-log10P < 8.5). The x axis 
shows the physical position / chromosomes, the y axis shows the –log10P significance levels.  
Note the highly significant associations with an allele on chromosome 6 (containing HLA-
DQA1) and an allele on chromosome 2 (containing PLA2R1). 
 
3.2.4  Comparison of the results 
3.2.4.1 Chromosome 6 
From the 282 significant associations between trait and marker for the joint 
analysis which are located within the extended HLA region on chromosome 6, 
112 are positive association signals in the UK cohort, 68 in the Dutch cohort and 
only 1 in the French cohort, see Table 12.   181
 
Table 12 Comparison of association signals on chromosome 6 
Association signals in the extended HLA region on chromosome 6, shown in red the (-log10P 
values above the significance threshold (-log10P > 8.5); rs9267522 (at position 31711749) 
nonexistent in dbSNP 130 (being previously called rs11229) appeared only in dbSNP 131, hence 
no allele information for this marker in the table. 
 
Hg18 
 
dbSNP130 Locus Region  F  NL  UK   3P 
Marker  Position  alleles  Gene  -log10P  -log10P  -log10P  -log10P 
rs7776065  25853721 C/T    0.3706 3.9939 4.9934 10.283
rs9885831 25858772  A/C    0.4676  3.68  4.9653 9.7686
rs1324087  25949387 C/T    0.9333 2.0233 5.8477 11.04
rs13198474 25982402 A/G  SLC17A3  2.0635 3.7801 6.7085 12.114
rs9467632  25997685 A/G    1.8861 2.1353 6.2465 10.266
rs7748167  26012631 A/C    2.2469 2.3868 6.3758 11.113
rs3734523  26033966 C/T  SLC17A2  1.9161 2.4504 6.2955 10.515
rs6940007  26039936 A/C    1.9161 2.3604 6.2955 10.523
rs3857546  26265741 C/T    1.1344 3.4411 4.9231 12.222
rs6923139 26421327  C/T    1.7473  4.7525 6.099 16.554
rs9379858 26475668  C/T  BTN3A2  1.1275  2.7331  7.22 11.456
rs9379859 26477528  C/T  BTN3A2  1.1711 2.788  7.22 11.656
rs12176317 26480765 A/G  BTN3A2  1.1711 2.5377 7.0639 11.346
rs3799380  26575161 C/T  BTN2A1  0.4825 3.9338 7.3691 11.078
rs2093169  26603078 C/T    0.6153 3.3224 7.4443 9.7421
rs9379897 26709505  C/T    1.2094  3.8355 7.382 12.487
rs7745603 27198383  C/T    1.6885  3.4862  8.5532 10.306
rs6913660  27199404 A/C    1.6572 4.7186 7.0969 10.293
rs13219354 27293643 C/T    2.0207 5.5738 6.4362 12.54
rs6938200 27339129  A/G    1.3992  2.7063 8.753 9.2423
rs7746199 27369303  C/T    0.4855 3.447 4.006 10.826
rs2076305  27483590 G/T    0.6385 5.2314 7.8076 11.647
rs6926142  27503743 C/T    0.2664 4.0238 7.1763 8.6462
rs1569566 27508010  G/T    0.5688 4.694  7.0489 9.9575
rs1883216  27533164 A/C  ZNF184  0.5204 4.6696 6.8013 9.2255
rs6904596 27599278  A/G    1.5164  9.4505  8.9424 21.441
rs10484399 27642507 A/G    1.2639 9.9443  9.196 20.104
rs10946940 27668566 A/G    0.2839 4.3513 5.5708 8.9692
rs9380010  27791551 A/G    0.6188 3.2199 5.7046 10.209
rs9295740 27797481  A/G    1.4989 7.077  4.9644 15.729
rs9468213 27814159  A/G    0.3858 5.029  8.5532 10.193
rs9283880  27823222 A/C    0.6743 4.1942 7.3583 11.537
rs7776351  27834710 C/T    0.6177 4.2088 6.5877 11.565
rs742047  27847359 A/G    0.4446 5.1169 7.3739 11.182
rs175597 27918605  A/G    1.6826  8.0349  9.3774 20.98
rs200997  27919794 C/T    0.422 3.6758 6.3572 9.6978
rs200991 27923473  G/T    1.3031  4.218  7.8529 16.111
rs13194781 27923618 A/G    1.821 9.8488  9.065 20.757
rs200951  27943909 A/G    0.2098 2.9651 6.9215 9.7883
rs200953 27945246  C/T    1.9161  8.0349  9.0682 21.287
rs200969  27967432 A/G    0.3524 4.0121 6.8267 11.317
rs203890  28130227 C/T    0.4208 5.0106 7.2635 12.016
rs9468276  28135667 A/C    0.4208 5.8547 6.8496 12.243
rs1233708 28281198  A/G    0.1754  3.7221  8.6852 8.9672
rs9380069 28311279  A/G    0.7612  6.9437  10.243 17.073  182
rs9295768 28317081  A/G    0.6221  5.6408  9.5096 14.494
rs967005 28318667  A/G    0.6221  5.8677  9.5096 14.564
rs1419183 28350773  G/T  ZNF187  0.8292  7.1478  9.5105 16.603
rs13211507 28365356 C/T  PGBD1  1.822 9.2152  8.8863 19.259
rs853676 28407666  A/G  ZNF323  0.4677  8.2542  8.626 16.612
rs213228 28439231  G/T  ZKSCAN3  0.2768  3.569  3.3782 8.9879
rs13194504 28738670 A/G    2.004 9.4365  9.1157 21.484
rs6456834  28808331 G/T    1.3115 6.2656 4.4396 16.555
rs1233579 28820642  A/G    2.296  10.088  8.8242 22.371
rs1233585  28824324 A/G    0.95 3.0704 4.7398 8.9699
rs4324798 28884096  A/G    2.004 7.247  8.4233 18.947
rs209181  28900456 C/T    0.8524 3.7326 3.4978 8.623
rs3131093 28945416  C/T    2.004  9.4873  8.5373 20.396
rs3129791 29062272  A/G    2.004  9.9477  8.5954 21.074
rs3130893 29088686  A/G    2.004  9.7775  8.7654 21.049
rs3117143 29139121  A/C    1.9772  10.367  10.042 21.784
rs3130817  29287216 G/T    1.0294 5.6655 7.0367 12.032
rs3130827 29338662  C/T  LOC651503  0.7832 2.541  6.1895 10.387
rs1884123  29364399 C/T    0.9088 2.5901 6.4598 10.793
rs3117426  29379991 C/T    1.2527 5.7202 7.8585 11.693
rs6934993  29445479 A/G    1.4695 3.4696 5.9243 11.337
rs3749971 29450754  C/T  OR12D3  2.3641  7.9768  8.6785 19.581
rs2746150 29550680  C/T    2.2818  8.8813  8.5081 20.363
rs1235162 29645203  C/T    2.6527  10.641  8.5738 23.434
rs3129073 29723801  C/T    2.5969  9.1772 4.626 14.267
rs2535238 29753017  G/T  ZFP57  2.0873  8.6813 2.8818 12.684
rs2747430  29756485 A/G  ZFP57  1.7247 5.3952 1.8882 9.6963
rs2747457  29764396 G/T    1.5592 7.6506 2.8945 11.751
rs3131888 29771868  A/G    0.7598  6.3377 0.334 8.9165
rs3129055  29778240 C/T    1.2893 7.1085 2.7555 10.681
rs1610601  29808162 G/T  AX747705  1.7486 7.2935 4.4511 12.631
rs1633021 29854848  A/G    1.5592 4.715  4.6694 11.683
rs1736971 29884301  A/C    1.3053 4.415  1.7644 9.6238
rs1611133  29917361 C/T    1.7141 5.9956 1.6283 12.938
rs2734986  29926547 A/G    2.2009 7.6196 4.8836 17.449
rs2734985  29926641 A/G    1.6006 4.9737 3.7588 14.965
rs2517861  29929961 A/G    1.3109 4.8343 3.1529 14.703
rs1611710  29936895 C/T    1.0459 3.1167 2.4418 8.6783
rs2524005  30007656 C/T  AK097625  1.4196 6.6557 2.8877 14.254
rs3132685 30053928  C/T  HCG9  2.7478  9.8333  9.5771 23.906
rs259940 30119913  C/T    0.8462  5.9664  4.719 9.709
rs259919  30133482 C/T  C6orf12  0.3783 6.0351 5.9001 10.775
rs8321 30140501  G/T  ZNRD1  2.1589  10.664  10.406 26.152
rs1245371  30146331 C/T  RNF39  0.9708 6.4095 4.7543 9.9776
rs9261290 30146626  C/T  RNF39  2.4238  11.587  10.243 27.076
rs1264702  30173554 A/G    1.6289 7.3517 1.7322 13.478
rs916570  30174010 C/T    1.6023 6.4868 1.4364 13.418
rs1264695 30175871  C/T    1.2708  6.4081 1.492 12.152
rs1116221 30179309  A/G  TRIM31  1.2797  7.0751 3.015 11.512
rs2523989  30186254 A/G  TRIM31  0.4056 7.3749 8.4011 19.083
rs2523987 30187972  G/T  TRIM31  0.6944 8.583 8.1736 20.823
rs2517598 30188253  C/T  TRIM31  0.4011  6.2418  9.2327 18.695
rs2517592  30201116 A/G    0.4266 7.6361 4.1248 15.369
rs3129690  30304834 C/T    1.3322 2.0916 7.5359 10.476  183
rs2844773 30315474  G/T    3.0002  11.872  10.359 25.261
rs1362089  30317781 A/C    1.4428 2.5293 6.5166 9.3141
rs3094073 30339203  C/T  FLJ45422  2.9746  14.567  11.053 27.909
rs3130380 30387109  A/G  AK055657,CR624833  1.4913  12.742  11.281 29.155
rs3094626 30431602  A/G    0.5439  4.8971 6.196 13.406
rs3130350 30435818  G/T    1.0115  12.615  11.124 28.071
rs1012411  30440534 A/C    0.0981 4.4121 4.4912 12.03
rs3094054 30441484  A/C    0.6587  10.981  12.258 27.024
rs2844745  30451682 A/G    0.0204 2.5736 3.6733 8.9233
rs3132622  30456653 A/G    0.452 3.8623 5.6184 12.36
rs3094694  30559883 A/G    0.383 6.5398 6.5614 16.42
rs3131115 30576770  C/T    0.9388  5.6115  8.9484 15.235
rs3132610 30652380  C/T  ABCF1  0.7689  13.338  11.58 29.383
rs1140809 30719655  A/C  C6orf134  0.8696  5.3036 1.707 14.216
rs1076828  30736231 C/T  DHX16  0.0529 7.1707 2.4949 11.95
rs9262143 30760760  C/T  KIAA1949  1.0532  14.552  12.797 33.027
rs1075496 30766218  G/T  NRM  0.3974 6.049  2.2449 13.233
rs3094127 30805426  C/T  FLOT1  1.3505  8.9215  9.3711 27.42
rs2535319  30822458 A/G    0.407 2.7068 7.2064 10.706
rs3129975  30840033 C/T    0.3796 6.8938 8.2598 18.833
rs886424 30889981  A/G  hCG_2038200  0.5642  13.026  15.259 35.995
rs1264344  30908556 A/G    0.9791 2.7504 2.5619 9.4865
rs2844659 30932511  A/G    1.0842  17.606  10.802 32.588
rs2844657 30937501  C/T    1.259  16.564  10.802 32.212
rs1264323 30963886  C/T    1.7171  8.6893 4.6079 16.185
rs1049623 30972808  A/G  DDR1  1.7171  8.6627 4.5206 16.095
rs753725  30998850 A/G  VARS2  0.2406 5.7645 2.8766 11.402
rs4678 31001920  C/T  VARS2  2.3385  15.22  12.763 33.948
rs2532934  31002738 C/T    0.2081 5.7715 2.7942 11.335
rs3132571 31013292  C/T    1.0132 9.599 5.6112 23.094
rs3132580 31028103  C/T  DPCR1  1.7086  11.662  17.719 39.534
rs2240804  31028869 C/T  DPCR1  0.8594 4.7147 0.9508 9.759
rs3095089 31041773  A/C    0.9891  12.571  12.043 30.878
rs886403  31065597 C/T  MUC21  0.3317 8.0382 7.9733 21.166
rs1634718 31080844  A/G    0.6832  9.0402  10.166 24.595
rs2523898  31101512 C/T    0.1139 5.6968 6.2234 10.324
rs2844665  31114834 A/G    0.6522 3.2197 4.6524 14.846
rs2517552  31115569 A/G    0.528 3.1448 4.9821 15.496
rs2523864 31126525  A/G    0.374  5.1812  10.047 24.994
rs3130955  31162490 A/C    1.0115 4.4701 5.0403 13.248
rs3130544 31166319  A/C    3.504  16.318  22.513 57.063
rs2517448  31170646 A/G    0.4536 3.3357 5.4021 15.913
rs6457327  31182009 A/C    0.5491 3.1726 5.2726 15.599
rs1064191 31183354  A/G    0.515  4.4337  8.6524 19.11
rs2844635 31183460  C/T    1.0668  8.3229  9.3518 24.907
rs2233956 31189184  A/G    3.4641  13.456  16.647 46.232
rs3130981  31191792 C/T  CDSN,PSORS1C1  0.3401 2.0781 4.1963 10.605
rs3094212  31193749 C/T  CDSN,PSORS1C1  0.4131 3.0885 5.3738 8.6289
rs3095314 31197610  A/G  PSORS1C1  0.5802 4.357  12.082 23.965
rs3130564 31209653  C/T  PSORS1C1  1.5942  10.403  17.512 41.953
rs1265099 31213392  C/T  PSORS1C2,PSORS1C1 1.4859 5.9567 9.2408 14.664
rs3094663 31215066  A/G  PSORS1C2,PSORS1C1 0.8917 0.9322 4.9394 10.559
rs1265086  31217861 A/C    0.9046 4.0696 5.2211 18.145
rs746647  31222161 C/T  CCHCR1  1.4275 8.1528 7.0604 23.187  184
rs2240064  31222552 C/T  CCHCR1  1.0578 2.4834 5.4072 11.226
rs1265112  31225998 A/G  CCHCR1  1.4275 8.0999 7.0604 23.059
rs3130453 31232828  C/T  CCHCR1  0.9351 2.742  5.6616 13.651
rs2239524  31233548 G/T    0.8358 2.6043 3.9323 10.59
rs720465 31233756  G/T    0.9529  5.3099  9.3371 25.384
rs7750641 31237289  C/T  TCF19  3.5133  17.534  21.421 57.586
rs1419881  31238572 C/T  TCF19  1.098 2.2446 7.4291 14.641
rs3130931 31242867  A/G  POU5F1  0.5196 1.031 6.097 11.701
rs1265159 31248026  C/T    2.2573  9.9806  12.208 36.416
rs3094188  31250224 G/T    0.5955 3.3801 4.8408 14.13
rs3868542  31253818 A/G    0.5434 2.9514 3.6226 11.048
rs887464 31253899  A/G    1.4875  3.7839  8.7767 13.201
rs3869109  31292175 C/T    0.787 3.2466 5.1618 12.105
rs3130685  31314185 C/T    0.7707 3.4918 4.5248 13.468
rs3095250  31316319 A/G    0.6138 2.7772 5.1403 9.4846
rs3130712  31317489 C/T    0.5685 2.9138 5.6381 9.9645
rs3130696 31351863  A/G    1.1949 5.486  15.376 31.095
rs2243868  31369255 A/G    1.6376 4.6862 4.9776 14.198
rs2524089  31374501 A/C    1.7959 6.8793 4.8714 16.075
rs9366778  31377152 A/G    0.4704 3.3277 2.9961 10.15
rs3873386  31381724 A/G    1.0797 2.6775 2.0578 10.343
rs3134792 31420305  A/C    4.4733  27.465  26.17 71.195
rs2156875 31425326  A/G    0.5327  5.4475  12.004 14.098
rs2596501 31429190  A/G    1.4368  3.1407  9.2971 10.541
rs2523608  31430538 C/T    0.1993 3.7633 4.8535 13.025
rs2523589 31435313  A/C    2.4315  5.2704 6.059 15.301
rs2523554 31439808  A/G    2.6823  4.6519  9.1766 17.232
rs2844575  31442924 A/G    1.0904 4.8986 5.7741 12.05
rs2844511 31497763  C/T    1.7987  3.4477  10.442 13.731
rs2596464  31520940 A/G    1.4882 6.5352 7.9235 19.004
rs3128982 31525170  A/G    1.4131  7.1607  11.792 27.706
rs2284178  31540104 C/T  HCP5  2.6928 3.1855 4.5907 10.354
rs2523674 31544768  C/T    1.0365 6.101  6.1973 17.723
rs2516424  31556294 C/T    1.3953 4.8866 7.4155 15.825
rs2516400 31589084  C/T    1.5617  5.4749  10.874 18.912
rs2516398  31589505 A/C    1.38 2.8311 4.6629 8.5409
rs2844494  31591394 G/T    1.4769 3.6301 4.4251 9.4993
rs3132454  31597623 C/T    1.4632 2.2161 3.7258 9.7831
rs2071591 31623778  C/T  NFKBIL1  2.2342  7.0109  13.616 25.656
rs1041981 31648763  A/C  LTA  2.2342  6.4028  14.469 25.52
rs2857595 31676448  C/T    2.3329  10.326  17.973 34.41
rs2260000  31701455 C/T  BAT2  1.1625 3.1182 4.3287 8.9515
rs2242660 31705732  C/T  BAT2  2.6802  8.9307  11.715 24.484
rs3115663 31709822  A/G  BAT2  5.0536  17.968  24.518 56.169
rs1046089 31710946  A/G  BAT2  2.7508  9.2599  13.677 27.589
rs2261033  31711570 C/T  BAT2  1.0578 6.4914 7.5908 18.409
rs9267522 31711749  -/-  BAT2  5.0536  17.992  24.34 55.959
rs1077393  31718508 C/T  BAT3  1.5347 4.5059 7.9876 13.883
rs805262  31736712 A/G    0.3943 2.8445 5.4315 9.2152
rs3130618 31740113  A/C  BAT4  5.0536  17.992  24.276 55.808
rs707928 31850569  C/T  C6orf27  1.8107  10.879  11.731 26.601
rs2763979 31902571  C/T    2.5165  8.5065  9.7159 24.101
rs660550  31945256 A/C  SLC44A4  0.7255 4.6255 6.8635 11.063
rs644827  31946420 C/T  SLC44A4  0.7255 4.5352 6.8635 11.135  185
rs494620  31946692 A/G  SLC44A4  0.6362 4.4143 6.4153 10.276
rs2242665  31947288 A/G  SLC44A4  0.7255 4.9364 6.8635 11.38
rs652888 31959213  C/T  EHMT2  3.8863  12.284  16.5 45.483
rs535586 31968316  A/G  EHMT2  0.8114  4.8041  8.6052 16.631
rs659445 31972283  C/T  EHMT2  0.747  5.6782  8.6052 17.224
rs2734335 32001923  C/T    1.1059  3.36  6.9536 10.085
rs2072633  32027557 C/T  CFB  0.2038 4.4137 5.9927 10.866
rs630379 32030233  G/T  RDBP  1.5147  5.6013  11.938 20.72
rs437179 32036993  G/T  SKIV2L  1.63  5.194  11.773 20.094
rs389884 32048876  C/T    5.5692  21.982  23.891 65.09
rs389883 32055439  A/C    1.7802  5.0261  11.773 20.626
rs185819  32158045 C/T    1.0249 3.4547 7.9711 12.097
rs204999 32217957  A/G    1.7823  12.172  12.739 39.045
rs3096697 32242488  C/T  EGFL8  3.0569  14.3  14.194 40.948
rs2269423  32253685 G/T  AGPAT1  1.4127 3.4381 4.9105 14.677
rs3134945 32254470  G/T  RNF5  2.6429  13.548  13.821 39.72
rs204994 32262976  A/G PBX2  1.2401  12.064  13.985 35.807
rs204993 32263559  C/T PBX2  0.8566  10.332  12.082 32.81
rs2071277  32279661 A/G  NOTCH4  2.7735 4.3283 5.2274 11.634
rs394657  32295001 A/G  NOTCH4  2.4139 5.9284 6.3815 16.084
rs422951 32296361  A/G  NOTCH4  1.5146  4.2236  4.519 10.539
rs443198  32298384 C/T  NOTCH4  1.1377 8.0363 5.6897 24.657
rs9267873 32307330  C/T    0.9679 7.664  2.5875 14.652
rs411326  32319295  A/G    1.3592 1.367 6.281 8.633
rs3130320  32331236 C/T    0.565 2.9526 6.4581 11.931
rs3115553 32353805  A/G    1.8352  9.7634  11.599 29.601
rs926070  32365544 C/T    2.7058 4.0703 6.7694 14.162
rs6935269 32368328  C/T    1.8352  9.7806  11.599 29.644
rs7775397 32369230  G/T  C6orf10  6.025  22.393  26.79 70.277
rs6457536 32381743  A/G  C6orf10  1.8549  9.9079  13.021 29.957
rs2076537 32425613  C/T  C6orf10  1.5671 4.959  8.8789 14.953
rs2395150  32434023 A/G  C6orf10  1.6601 3.6357 7.1133 13.522
rs3129939 32444744  A/G  C6orf10  2.2009  11.833  16.638 39.657
rs3129943 32446673  A/G  C6orf10  2.3347  7.3385  14.339 30.457
rs2050190 32447054  C/T  C6orf10  1.5976  8.5241 5.5981 18.903
rs2050189 32447625  A/G  C6orf10  1.4989  9.6428  16.898 34.181
rs4424066  32462406 A/G    1.6455 3.8071 4.6858 9.4172
rs3817973  32469089 A/G    1.6601 4.0874 4.7622 9.7493
rs1980493 32471193  A/G  BTNL2  3.3075  14.707  23.944 47.85
rs2076530  32471794 A/G  BTNL2  1.5732 4.5123 5.7953 10.985
rs6932542 32488240  A/G    2.0615  3.7305  10.179 13.7
rs3135338 32509195  A/G    2.3627  2.6091  9.9232 13.303
rs2395174 32512856  G/T    1.8288  5.2422  10.788 17.29
rs2395182  32521295 G/T    0.8205 3.5825 5.6435 9.6605
rs3129890 32522251  C/T    2.4025 9.842  9.7512 24.636
rs9268832  32535767 C/T    0.4327 3.3204 5.5041 8.768
rs2187668 32713862  A/G  HLA-DQA1  8.7471  26.252  35.286 92.097
rs9275141 32759095  G/T    0.9307  3.4623  9.2285 9.7872
rs6457617 32771829  C/T    0.2934  4.2025  8.74 12.25
rs2647012 32772436  A/G    1.411 5.353  13.758 18.764
rs9275390  32777134 C/T    0.5038 4.5102 3.8592 10.771
rs9275572 32786977  A/G    1.4146  5.7745  11.383 16.035
rs2858331 32789255  C/T    1.1781  1.5938  9.5597 9.5227
rs12177980 32794062 A/G    0.1538 2.6311 5.6477 8.7223  186
rs9461799  32797507 C/T    0.1538 2.7697 5.6477 8.9401
rs2301271  32833171 C/T  HLA-DQB2  0.7209 1.6788 7.0465 8.8639
rs7453920  32837990 A/G  HLA-DQB2  0.7209 1.7135 7.0465 8.8536
rs2051549  32838064 C/T  HLA-DQB2  0.7604 2.0292 7.0717 9.2192
rs2071550  32838918 G/T  HLA-DQB2  0.1507 2.3812 5.0638 10.065
rs9368741  32845485 A/G    0.1507 2.3013 5.0638 10.023
rs9276644 32853021  C/T    2.2133  6.2554  12.072 22.966
rs719654 32860117  C/T    1.6019  1.289  6.6841 8.8607
rs7758736 32866372  A/G    2.6799  8.7077  13.688 27.832
rs3948793 32867426  C/T    1.9549  5.9739  11.229 21.162
rs1383261 32873429  A/G    2.5831  3.8469  10.753 14.868
rs11244 32888702  C/T  HLA-DOB  3.4825  4.8119  10.694 17.877
rs2856997  32889754 G/T  HLA-DOB  1.218 3.7591 7.8105 20.259
rs2071474  32890560 A/G  HLA-DOB  1.6536 1.4819 7.5475 12.053
rs7383287 32891064  A/G  HLA-DOB  1.9926  6.5058  12.136 27.816
rs241424 32912912  C/T  TAP2  2.8887  1.6293  6.727 10.024
rs6924102  32919361 A/G  PSMB8  0.6949 3.6305 6.1974 12.673
rs6929078  32946642 C/T    1.4111 2.3594 5.7007 9.8467
rs7757767  32953851 A/G    1.4111 2.3217 5.5148 9.7788
rs241404 32973975  A/G  AK057104  2.0394  1.773  6.5301 8.9604
rs1480380 33021224  C/T    4.3916  7.0487  18.142 38.393
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3.2.4.2 Chromosome 2 
Within the extended PLA2R1 region on chromosome 2 there are 30 significant 
associations between trait and marker for the joint analysis, 2 of them are 
positive association signals in the UK cohort, 6 in the Dutch cohort and none in 
the French cohort (Table 13). 
 
Table 13 Comparison of association signals on chromosome 2 
Association signals in the extended PLA2R1 region on chromosome 2, shown in red the (-log10P 
values above the significance threshold (-log10P > 8.5). 
 
Hg18 
 
dbSNP130 LocusRegion F  NL  UK   3P 
Marker  Position  alleles  Gene  -log10P  -log10P  -log10P  -log10P 
rs2042772 160370304  T/C  LY75  1.03 1.34  2.14 9.10
rs6711770 160401007  T/C  LY75  0.72 1.40  4.21 9.29
rs10929956 160422861 T/C  LY75  0.67 4.85  3.62 13.70
rs2666986 160451017  C/T  LY75  0.96 6.84  1.88 13.58
rs7601374 160462296  T/C  LY75  1.67 5.10  5.15 19.76
rs12692575 160478277 G/A    0.79 4.46  2.34 9.30
rs1995950 160508874  G/A  PLA2R1  0.87 2.94  3.58 9.00
rs6432570 160516560  T/C  PLA2R1  1.57 3.41  4.18 15.79
rs3792161 160517469  T/C  PLA2R1  1.00 2.95  3.69 9.10
rs2715921 160550074  G/A  PLA2R1  0.93 5.16  3.10 10.18
rs1567537 160565814  T/C  PLA2R1  0.52 5.22  3.62 10.05
rs2667014 160576628  A/G  PLA2R1  1.43 6.47  2.32 13.12
rs883423 160587897  C/T  PLA2R1  1.13 2.53  2.49 8.92
rs3749117 160593688  C/T  PLA2R1  2.48 10.10 7.11 27.37
rs3792189 160594118  C/A  PLA2R1  1.65 10.39 5.05 23.62
rs3792192 160595121  A/G  PLA2R1  2.31 9.87 7.25 26.96
rs6722275 160601506  T/C  PLA2R1  2.39 9.43 6.98 26.98
rs877635 160611093  A/C  PLA2R1  0.97 4.21  4.80 13.68
rs4664308 160625743  G/A  PLA2R1  2.29 8.98  9.68 28.06
rs7598162 160643828  T/C    0.28 5.47  6.63 12.68
rs7573270 160657779  C/T    0.28 5.35  6.40 12.41
rs10497213 160671849 T/C  ITGB6  2.23 7.65  6.83 22.79
rs10497212 160672946 C/A  ITGB6  0.12 3.56  3.73 8.70
rs4580348 160694788  G/A  ITGB6  1.71 2.60  1.89 8.70
rs983916 160723312  C/A  ITGB6  0.58 5.25  3.75 14.34
rs4665164 160778324  T/G  ITGB6  0.96 3.45  4.98 12.72
rs1870102 160778828  C/T  ITGB6  1.51 8.92  9.09 25.31
rs3772069 160840008  A/G  RBMS1  0.88 1.61  3.26 9.95
rs12620861 160937905 C/A  RBMS1  0.83 1.61  3.04 9.13
rs7423892 161037890  T/C  RBMS1  2.06 2.98  4.88 12.50  188
3.2.5  Linkage disequilibrium 
3.2.5.1 Chromosome 2 
The marker on chromosome 2 with the second strongest association P value to 
IMN, rs1870102 (see Figure 70) is situated upstream of a gene (ITGB6 – integrin 
beta 6 precursor) which is a neighbour of PLA2R1, a strong candidate for 
idiopathic membranous nephropathy. The situation of rs1870102 within a linkage 
disequilibrium block encompassing that gene has been checked for the HapMap 
Phase II release data on European (CEPH) samples (computed using the 
Haploview program [511], visualised in the UCSC genome browser as a track 
which has been created by D. Thomas; Figures 70 and 71) and on our own data 
(Figures 72, 73 and 74; computed in Haploview 4.2; according to the method of 
confidence intervals; the selected attributes being: confidence interval minima 
for strong linkage disequilibrium 0.9 - 0.6, upper confidence interval maximum 
for strong recombination 0.7, fraction of strong linkage disequilibrium in 
informative comparisons 0.7, markers with a minor allele frequency < 0.05 were  
excluded).  
 
 
 
Figure 70 LD blocks, HapMap CEU, in the region of interest on chromosome 2 
Inverted triangle display for the linkage disequilibrium (LD) structure of CEPH CEU population 
(HapMap Linkage Disequilibrium – Phase II – from phased genotypes, LOD LD values; hg18 
assembly). Four haplotype blocks are perceivable. 
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Figure 71 LD block peri-PLA2R1, HapMap 
The third of the four linkage disequilibrium blocks in the region of interest previously shown on 
chromosome 2. It encompasses the two association peaks (in PLA2R1 and upstream of ITGB6). 
Inverted triangle display for the linkage disequilibrium (LD) structure of CEPH CEU population 
(HapMap Linkage Disequilibrium – Phase II – from phased genotypes, LOD LD values; hg18 
assembly). 
 
 
 
Figure 72 LD plot, peri-PLA2R1, joint analysis cases  
Region coordonates chr2: 160032130 - 161140312 (rs964176 - rs13010247). 
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Figure 73 LD plot, peri-PLA2R1, joint analysis controls 
Region coordonates chr2: 160032130 - 161140312 (rs964176 - rs13010247). 
 
 
 
Figure 74 LD plot, peri-PLA2R1, joint analysis cases and controls 
Region coordonates chr2: 160032130 - 161140312 (rs964176 - rs13010247). 
 
It appears that rs1870102 is situated within an LD block including PLA2R1 in 
both the HapMap and our own dataset. The question arises whether the 
association signal detected at rs1870102 is due to a causative polymorphism 
affecting the closest gene (ie ITGB6) or reflects the strong linkage disequilibrium 
to a region where the causative polymorphism resides in PLA2R1.   191
The r
2 values for the most significantly associated markers around the locus of 
interest on chromosome 2 are shown (colour coded) in Figure 75, which was 
generated with LocusZoom version 1.1 [512]. 
 
 
 
Figure 75 LocusZoom plot of the region on chromosome 2 
Plot on Human Genome build hg18, range chr2:160006257-161127367; number of markers 
plotted: 93, reference SNP: rs4664308 (P = 8.63 x 10
-29). Y axis: significance level for 
association, left X axis: physical position, right X axis: recombination hotspot level (continuous 
blue curve along the lower margin of the graph); color coded: r
2 level. HapMap population used 
for LD computation: HapMap Phase II CEU. Upper margin of the graph: coverage of the region 
with Affy500 and HapMap markers vs. plotted markers. 
 
3.2.5.2 Chromosome 6 
Linkage disequilibrium has also been assessed for the extended MHC region on 
chromosome 6. We compared the LD block structure in cases (Figure 76) with 
controls (Figure 77) and case-control together (Figure 78). LD blocks were 
computed using Haploview 4.2).   192
 
 
Figure 76 LD plot, joint analysis, extended HLA region, cases 
Coordinates of the region assessed: chr6:25853721 - 33021224 (rs7776065 - rs1480380). 
 
 
 
Figure 77 LD plot, joint analysis, extended HLA region, controls 
Coordinates of the region assessed: chr6:25853721 - 33021224 (rs7776065 - rs1480380). 
 
 
 
Figure 78 LD plot, joint analysis, extended HLA region, cases and controls 
Coordinates of the region assessed: chr6:25853721 - 33021224 (rs7776065 - rs1480380).   193
 
The LD values (r
2) for the most significantly associated markers around the locus 
of interest on chromosome 6 (colour coded; generated with LocusZoom version 
1.1), are shown in Figure 79. 
 
 
 
Figure 79 LocusZoom plot of the region on chromosome 6 
Plot on Human Genome build hg18, range chr6:32213160-33219407, number of markers plotted: 
209, reference marker: rs2187668 (P value 8 x 10
-93); genes omitted: RNF5, RNF5P1, AGER, 
PBX2, GPSM3, NOTCH4, PSMB8, PSMB9, PPP1R2P1. Y axis: significance level for 
association, left X axis: physical position, right X axis: recombination hotspot level (continuous 
blue curve along the lower margin of the graph); color coded: r
2 level. HapMap population used 
for LD computation: HapMap Phase II CEU. Upper margin of the graph: coverage of the region 
with Affy500 and HapMap markers vs. plotted markers. 
 
3.2.6  Epistasis 
Statistical epistasis (non-additivity, deviation from additivity) is considered to be 
suggestive for biological epistasis (interaction among biomolecules). In the case 
of allele by allele epistasis for two loci there are 4 possible alleles: a, A, b, B. If 
two alleles (one at each locus: A, B) are causative, the effect of alleles on the 
phenotypes can be quantified, Table 14. 
 
Table 14 Epistasis 
 
Alleles 0  A  B  AB 
Quantified phenotype  0  x  y  x + y + e 
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In the case of e = 0 the model is additive. If e > 0 one deals with synergistic 
epistasis, in the case of e < 0 with antagonistic epistasis. 
Allele by allele epistasis was estimated using the logistic regression module 
implemented in PLINK for a binary trait (affected vs. unaffected by IMN). The 
allele dosage model to be fitted is: 
 
Y ~ b0 + b1.A + b2.B + b3.AB + e 
 
Not all combinations of SNPs were tested due to computationally constraints. We 
selected a subset of 13 significantly associated SNPs in the PLA2R1 region of 
interest and 281 SNPs significantly associated SNPs in the region of interest on 
chromosome 6 (extended HLA) for the combined analysis of the three assessed 
populations. Multiple pairwise correction for 3,653 comparisons yielded a 
significance threshold (for P < 0.05) of -log10P = 4.86. None of the values of the 
pairwise epistasis signals reached this significance level (Table 15). 
 
Table 15 Pairwise epistasis signals 
Pairwise epistasis signals for the allele by allele test combining 13 SNPs on chromosome 2 and 
281 SNPs on chromosome 6. Shown are the results for -log10P > 3. 
 
SNP/chr2  SNP/chr6  -log10P 
rs1870102 rs6924102 4.48096
rs4665164 rs6924102 3.639217
rs4664308 rs1736971 3.570086
rs12620861 rs1633021 3.496482
rs12620861 rs1736971 3.408824
rs6722275 rs443198 3.300683
rs4664308 rs7383287 3.270916
rs4664308 rs1633021 3.258297
rs4664308 rs6924102 3.212469
rs1870102 rs7383287 3.211337
rs4664308 rs2844635 3.207678
rs3792192 rs443198  3.19942
rs3749117 rs6924102 3.172825
rs7423892 rs1736971 3.136083
rs3749117 rs443198 3.134659
rs3772069 rs1633021 3.128485
rs4665164 rs2395150 3.100727
rs983916 rs2516424 3.09114
rs877635 rs7383287 3.019542
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3.2.7  Relative Risk / Odds Ratio 
In statistical epidemiology, the relative risk (RR) refers to either the risk ratio or 
the odds ratio. The risk ratio refers to the proportion of the risk of an event (i.e. in 
cohort studies or clinical trials developing a disorder) occuring, between one two 
groups in which the risk is estimated. One of the two groups being exposed (to a 
potentially causal factor) the other being non-exposed (to the same factor). In 
case control studies the risk ratio cannot be obtained directly. A substitute can be 
calculated which is the odds ratio (OR), also named relative odds and 
approximate relative risk. OR and RR are considered interchangeable for 
practical purposes (especially when dealing with large samples and rare diseases,  
[513]). 
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Where: 
RR = Relative Risk 
OR = Odds Ratio 
P0 = incidence of the outcome of interest in the nonexposed group 
P1 = incidence of the outcome of interest in the exposed group 
 
In the case of our study we assessed the risk of developing membranous 
nephropathy in the group bearing the predisposing genotype(s) vs. the same risk 
in the group bearing the protective genotype(s). The Odds Ratios for the most 
significantly associated alleles are given in Table 16.   196
 
Table 16 Odds Ratios for most significantly associated alleles 
CI Confidence Intervals, MAF Minor allele frequency. 
 
 
chr6: rs2187668 
(HLA-DQA1) 
chr2: rs4664308 
(PLA2R1) 
French GWAS       
OR (95% CI)  4.48 (2.68 – 7.50)  1.87 (1.20 – 2.92) 
MAF cases / MAF 
controls  31.3% / 9.2%  23.3% / 36.3% 
p-value 1.8x10-9  5.1x10-3 
Dutch GWAS       
OR (95% CI)  3.76 (2.92 – 4.86)  2.27 (1.73 – 2.97) 
MAF cases / MAF 
controls  37.0% / 13.5%  26.0% / 44.4% 
p-value 5.6x10-27 1.0x10-9 
British  GWAS       
OR (95% CI)  5.33 (4.04 – 7.02)  2.10 (1.67 – 2.64) 
MAF cases / MAF 
controls  41.9% / 11.9%  25.3% / 41.6% 
p-value 5.2x10-36 2.1x10-10 
Joint GWAS       
OR (95% CI)  4.32 (3.73 – 5.01)  2.28 (1.96 – 2.64) 
MAF cases / MAF 
controls  39.2% / 13.0%  25.2% / 43.4% 
p-value 8.0x10-93 8.6x10-29 
 
The combined risk of individuals homozygous for both risk alleles (SNP 
rs4664308 - PLA2R1 and SNP rs2187668 - HLA-DQA1) reaches an odds ratio 
(OR) of ~ 80 (additive based upon the combination of genotypes), which reaches 
a level which might even be considered diagnostic, as shown in Table 17. 
 
Table 17 Odds Ratios for the combined risk genotypes 
Odds Ratios for idiopathic membranous nephropathy computed depending on combined risk 
genotypes at at SNP rs4664308 (PLA2R1) and SNP rs2187668 (HLA-DQA1). Individuals 
homozygous for the low risk allele are considered to be the reference category. For each 
category, the OR of IMN is listed, followed by the 95% confidence interval, followed by the 
number of individuals / number of cases in that genotype category for the joint analysis. 
 
                                            SNP rs4664308 
 GG  GA  AA 
GG 
OR=1 
(ref) 
n=354/14 cases 
OR=2.22 
(1.24-3.97) 
n=944/79 cases 
OR=4.19 
(2.36-7.46) 
n=659/97 cases 
GA 
OR=6.07 
(3.01-12.27) 
n=115/23 cases 
OR=8.49 
(4.73-15.22) 
n=363/94cases 
OR=25.43 
(14.32-45.16) 
n=348/178 cases 
SNP 
rs2187668 
 
 
 
 
  AA 
OR=20.24 
(5.51-74.38) 
n=11/5 cases 
OR=31.03 
(13.72-70.19) 
n=41/23cases 
OR=78.46 
(34.55-178.17) 
n=55/42 cases   197
4  Discussion 
4.1  Phenotype  
Membranous nephropathy is a disorder in which patients lose large amounts of 
protein through the urine, and the progression of a substantial proportion of those 
affected by it towards renal failure cannot be efficiently stopped. In order to treat 
this affliction, and most importantly to prevent the progression in the cases where 
it happens, we would ideally want to base our treatment on an etiological / 
pathogenetical basis. That, of course, would imply the understanding of the 
cause(s) and of the mechanism(s) of the disorder. Strong evidence has been 
gathered as to the autoimmune nature of the disease, which in turn is based on an 
important genetic component. The most important proportion of the genetic 
predisposition in the case of autoimmune disorders has been shown to be 
conferred by molecules encoded in the HLA region. HLA associated disorders 
are caused by a complex interplay of genes and environmental factors. It is 
generally considered that HLA variants are necessary but not sufficient for these 
diseases to develop [514]. An important and difficult question is which of the 
many polymorphic loci in the HLA region is causally involved (ie  primarily 
associated) and which one is secondarily associated due to the strong linkage 
disequilibrium existing between genes at this super-locus [515]? This raises a 
catch-22-like problem: since in order to establish the primary associations, the 
knowledge of the mechanisms is needed and the reason to unveil associations is 
for them to suggest possible mechanisms. 
4.2  Methods: Genetic mapping 
4.2.1  Linkage 
Given the rarity of IMN, a classical Mendelian monogenic transmission 
mechanism was plausible. This was further supported by the existence of known 
families where the phenotype was segregating. At least one of these families 
suggested X-linked transmission. The X chromosome effect was further 
supported by the knowledge of the different prevalence of IMN in males versus 
females. The classical linkage analysis of the respective family yielded   198
inconclusive results. One possible explanation for this is that IMN is not ‘simple’ 
(monogenic Mendelian), but could theoretically follow a digenic (oligogenic) or 
even polygenic model of transmission. The real question is: ‘how complex is 
IMN?’. The concepts of complexity and, implicitly, complex disorder are best 
treated in the context of the ‘effect size / allele frequency determinants 
paradigm’, which has been suggested by McCarthy et al. in 2008 [478], see 
Figure 80.  
 
 
 
Figure 80 Effect size – allele frequency paradigm graph 
Mendelian diseases: usually determined by rare (frequency: 0.001 – 0.005) alleles with high (> 3) 
effect size; are best mapped by linkage. Common diseases: considered to be determined by either 
common (frequency > 0.05) or rare (frequency: 0.001 – 0.005) alleles of (usually) low (< 1.1) 
effect size; are usually mapped by association. 
 
This paradigm also suggests different strategies to be used in different gene 
mapping projects depending on the situation of the target in one of the 
classification sets. Rare disorders assessed are usually Mendelian monogenic and 
mapped via linkage (positional cloning), while complex disorders are generally 
considered to be caused by common alleles which contribute a small effect size 
to the phenotype and are best addressed via GWA studies. In order to adapt our 
mapping strategy, we should rephrase the question pertaining to the complexity 
of IMN as ‘where is it situated within the effect size / allele frequency 
paradigm?’ (Figure 80).   199
 
4.2.2  Association 
After the initial success of mapping the causative gene (rare variant) in an 
apparently simple rare monogenic disorder (age related macular degeneration) 
was considered to be a proof of principle [438], the most visible GWAS studies 
started focusing on common diseases, therefore falling in the low effect size 
common variant category. There is a debate which opposes the ‘common allele 
common disorder’ (CACD) and the  ‘rare alleles common disorder’ (RACD) 
hypotheses. Our understanding of the age-related macular degeneration (AMD) 
lesson is that a common complex disorder (AMD latu sensu implies at least 7 
known loci) can be addressed by ‘splitting’ the complex phenotype in simpler 
well defined sub-phenotypes (the successful association study found the gene 
associated with AMD4, CFH – complement factor H,  based on a genome-wide 
screen of only 96 cases and 50 controls!), or alternatively by brute force 
(associations in diabetes started to become significant only after increasing the 
numbers of the cases and controls by extensive international collaboration, a 
‘lumping’ approach). In defining a genetic entity, the approach can be either a 
‘splitting’ or a ‘lumping’ one [516]. One could envision glomerulonephritis to be 
a ‘lumped’ entity, of which IMN would be a better defined (pathologically 
defined through renal biopsy) ‘splinter’. Therefore one might expect relatively 
small numbers of cases versus controls to be sufficient to identify a hypothetical 
major influence locus. Our exploratory (UK) study proved this to be true, by 
employing 336 cases and 349 controls, with the resulting 2 loci of association: on 
chromosome 6, in the extended HLA region, and on chromosome 2, in the 
vicinity of PLA2R1. The main conclusion of our studies is that sequence 
variations within HLA and PLA2R1 may be partially responsible in determining 
the susceptibility for MN (in Caucasoids). The findings regarding the PLA2R1 
locus support, in an unbiased manner (genome wide association studies being 
hypothesis free - therefore unbiased by a priori assumptions) and using a 
different approach, the finding by Beck et al. (whose results are based on 
serological – immunological technology) that PLA2R1 is an important 
autoantigen in patients with MN.   200
Our studies revealed a stronger association of the HLA locus with IMN than the 
one of PLA2R1, which suggests that the risk conferred by HLA-DQA1 alleles is 
higher than the risk conferred by PLA2R1 alleles. For the joint analysis the Odds 
Ratio for the HLA-DQA SNP on chr6 (rs2187668) is 4.32 (confidence interval: 
3.73 – 5.01) compared with the Odds Ratio for the PLA2R1 SNP on 
chromosome 2 (rs4664308) which is 2.28 (confidence interval: 1.96 – 2.64). 
4.2.2.1 Problems of association studies 
There are two classes of known important problems in interpreting association 
results, both deriving from the same question: is the result relevant? A positive 
association result can be a false positive due to chance or to a systematic bias 
introduced through the study design or the way the data were analysed. It can 
also be a real association in linkage disequilibrium with the true (causative) site 
or the causative site itself (which is the real target). This problem can be 
addressed in a statistical / epidemiological approach (to eliminate false positives) 
– by replicating the initial exploratory study, thus adding statistical relevance. 
The best way of addressing the causality problem is to look for biological proof / 
meaning of the results. 
4.2.2.2 Replication 
Replication studies were performed according to the criteria (study 
independency, population and phenotype similarity, demonstration of similar 
effects and their magnitudes) suggested by the NCI-NHGRI Working Group on 
Replication in Association Studies [452] for establishing positive replication. The 
results of the initial exploratory study (UK) were replicated in two independent 
yet similar (historically, geographically and culturally) Caucasoid populations: 
French (analysing 75 cases and 157 controls) and Dutch (analysing 146 cases and 
1832 controls). The French study replicated the locus on chromosome 6, the 
Dutch study both loci (on chromosomes 2 and 6). 
 
The causality problem implies different aspects: linkage disequilibrium, 
combined independent signals and epistasis.   201
 
4.2.2.3 Linkage Disequilibrium 
Linkage disequilibrium was expected to be a problem at the level of the extended 
HLA locus on chromosome 6 due to the complex structure of this locus (genes in 
this complex are linked tightly due to the fact that recombination rarely occurs, 
possibly to protect some evolutionary advantageous grouping of gene variants on 
the same haplotypes). Establishing the primary HLA association is therefore 
notoriously difficult, which is further complicated by the possibility of a primary 
association with a particular combination of genes in the region (ie an extended 
haplotype); or by phenotype heterogeneity (in which different forms of the 
disorder could be associated with different HLA haplotypes). Empirical evidence 
can suggest primary association candidates: they are usually considered to have 
the strongest association signal and functionally they usually are variants of 
peptide presenting HLA molecules [517]; both conditions apply to our 
(strongest) association signal in HLA-DQA1. 
Even at the locus on chromosome 2, there is at least a pair of markers which are 
in strong linkage disequilibrium, which could be either incidental or suggest a 
common regulatory element being important in the expression of functionally 
related genes in the genomic region (vide infra). 
4.2.2.4 Independent association signals 
A general problem for association studies is the question regarding association 
signals in a region of interest: how many are due to linkage disequilibrium and 
how many may represent independent association signals? This is an even more 
acute problem when dealing with association studies for immune related traits. 
Many show associations within the HLA region [518], the association signal 
within this super-locus often showing a ‘cloud’ morphology. Much of the 
dispersion of the cloud can be explained by the tight linkage disequilibrium of 
the region, but there is also accumulating evidence for the contribution of 
combined independent signals.   202
In our studies, the presence of significant associations within the extended HLA 
locus, with SNPs in little linkage disequilibrium with the top signal, suggest the 
presence of independent risk variants.  
4.2.2.5 Epistasis 
The problem of epistasis appears once we realize we are dealing with one 
phenotype (at least, if we do not take into account heterogeneity) and (at least) 
two loci. Epistasis and pleiotropy are recognized as explanations for the 
deviations from simple Mendelian ratios. If a simple disorder is (ideally) defined 
by a one-to-one relation between phenotype and genotype, complex disorders 
can be defined (in theory) by a many-to-many relationship. Many phenotypes 
would reflect phenotypic heterogeneity or pleiotropy, whilst many genotypes 
reflect genotypic heterogeneity or epistasis. 
Epistasis (which etymologically means ‘standing upon’) has been defined 
statistically and biologically. In 1901, Bateson used the term for the first time to 
describe the masking effect of one gene upon another gene. Fisher in 1918 
referred to ‘epistacy’, which would reflect deviations from additivity between the 
effect two loci have upon a phenotype. There are instances in which statistical 
epistasis does not correspond to biological epistasis (which is nowadays 
understood to reflect interactions of products of genes) and, conversely, 
biological interactions between products of genes can sometimes be not observed 
as statistical epistasis [519]. In the case of our study, the signal for statistical 
epistasis between chromosome 6 and chromosome 2 does not reach statistical 
significance (Table 15). This can be explained by the fact that the two loci are 
probably not encoding molecules which are part of a biological module of 
coevolved molecules.  It seems to be more plausible that we are dealing with 
‘accidental epistasis’ (immunology ‘weapon / target’), in which there is no 
evolutionary gain from this interaction, therefore no statistical deviation from the 
additivity of the influences on the trait would be expected. Referring back to 
Figure 80, one can understand the spectrum of disease being flanked by the two 
extreme cases: on one hand unique detrimental mutations (the most detrimental 
being non viable) and, on the other hand, the genes whose function has been 
efficiently ‘canalized’ (canalization being defined as the mechanism by which 
gene functions are multiplied in complex organisms, making them redundant   203
ergo robust to single mutations [520], epistasis thus contributing to robustness 
[521]), to allow for flexibility and higher adaptability of the organism even when 
confronted with mutations at the respective loci. A subset, perhaps even the 
majority, of genes are situated in between these two extremes [522]. 
4.2.2.6 Causation 
The jump from statistically relevant association to inferring causation is an 
important and difficult one. Given that biological relationships can only be 
inferred from empirical observations, the problem can be stated as ‘what 
constitutes sufficient evidence for causation?’ [523]. There have been proposals 
to quantify clear criteria of causality, modelled on the Henle-Koch postulates 
which were considered the sine qua non for establishing a causal relation 
between an organism (pathogenic agent) and the disease it was supposed to cause 
[524,525], but the danger has been recognized early of inflexible rules becoming 
a hindrance rather than an aid in elucidating etiopathogeny (Rivers, 1937, 
commenting on the inadequacy of Koch’s postulate applied to viral infections 
[526]). Therefore the consensus shifted towards using guidelines as opposed to 
formal rules. An important set of principles pertaining to the relation between 
association and causation (strength, consistency, specificity, temporality, 
biological gradient, plausibility, coherence, experiment, analogy) were stated by 
Hill in 1965 [527]. Our data adhere to the conditions of strength, due to our 
choosing of a conservative P value. Consistency has been ensured by successive 
replications following our exploratory study. Our replication studies can be 
considered then to be, within the theoretical framework of Lykken, conceptual 
replications, as opposed to operational replications [528]. The latter would strive 
to repeat the original study exactly whereas the former had the purpose to 
confirm the initially observed associations by using different methods i.e. 
genotyping method, phenotyping method, statistical procedure, data-analytic 
software i.e. PLINK). Specificity must not be overemphasized, given that we 
cannot assume a simple one-to-one relationship between cause and effect. 
Plausibility, coherence and analogy are addressed within the framework of 
immunogenetics, two exemplary cases, which illustrate a similar approach to the 
deciphering of molecular mechanisms being type I diabetes [529], with a 
prevalence of ~ 1-2/1000, and celiac disease, with a prevalence of ~ 1/100)   204
[530]. Diabetes and celiac disease turned out to imply a strong, major locus, 
HLA effect and added polygenic and environmental components. The 
environmental aspect is best understood in the case of celiac disease, where the 
disease inducing agent is known to be gluten. The very small incidence of IMN 
when compared to celiac disease suggests probable differences along with the 
similarities in the pathogenetic architecture of the two disorders. 
The most important of the conditional principles suggested by Hill i.e. 
experimental evidence, will have to be addressed through further investigation. 
4.3  Molecular dissection 
The highly significant associations between alleles of HLA-DQA1 and PLA2R1 
and the IMN trait do not establish causality. They could, however, suggest a 
possible mechanism in which risk variants of immune system proteins and 
glomerular components can interact to establish a basis for the development of 
membranous nephropathy. We have reviewed the knowledge pertaining to 
PLA2R1 and HLA in order to delineate what is known, what is to be still found 
out about their biology – and whether we can suggest biologically relevant 
scenarios in which genetic variants at the two loci might be thought to influence 
the pathogenesis of IMN, in the hope to add to the conditions of biological 
plausibility and coherence, on the quest for causality. 
4.3.1  Peri PLA2R1 locus 
There are three genes comprised in the two linkage disequilibrium blocks which 
show association signals on chromosome 2: LY75, PLA2R1 and ITGB. 
4.3.1.1 PLA2 / PLA2R unit 
PLA2R1 seems to be an obvious candidate as the causal molecule in the 
association region of interest on chromosome 2 since Beck and colleagues 
suggested, based on immunological methodology, that it is the target antigen in 
IMN [1]. PLA2R1 is likely to encode two isoforms: the proteins corresponding 
to the two alternative splicing products are predicted to be transmembrane and 
soluble. The membrane bound form is expressed at the level of the podocytes, 
whilst the soluble form, produced by the cleaving of the membrane bound form 
by metalloproteinases, is hypothesized to be secreted by the liver and by the   205
kidney. Their physiological function is not well defined. PLA2R1 is a member of 
the subgroup VI (mannose receptor family) of the C-type animal lectin 
superfamily. The members of this family (which also include CD-205 / LY75 
and CD-206 / MMR) are antigen-uptake receptors which bind, internalize and 
deliver ligands to the endosomal compartment of antigen presenting cells, where 
the HLA class II type loading occurs, Figure 81. One can consider the antigen-
uptake receptors ‘interface molecules’ linking the simple, innate, pattern 
recognition based immune response with the complex, specific adaptive immune 
response mediated by HLA molecules. 
 
 
 
Figure 81 Presentation of Exogenous Antigens 
Antigens are taken up through endocytosis mediated by antigen-uptake receptors (APR). The 
antigens are cleaved at the level of phagosomes (P). Phagosomes merge with endosomes (E) into 
endophagosomes (PE). The antigen peptides occupy the presentation groove of the HLA class II 
dimer which had been previously protected by the CLIP (Class II Inhibiting Protein) fragment. 
Ncl – nucleus, RE – endoplasmic reticulum, GA – Golgi apparatus, TGN – trans Golgi network. 
 
Apart from its possible role as an antigen-uptake molecule, PLA2R can function 
through ligand binding, as classical receptors. The known ligands of PLA2R are 
synthesized as inactive pro-enzymes which are activated through proteolytic 
cleavage by proprotein convertases: secreted PLA2s. The discovery of PLA2 
receptors expanded the concept of simple, enzymatic, PLA2 function into that of 
the more complex biological activity of the PLA2 / PLA2R functional unit. The   206
simple function of PLA2 is presumed to be primarily digestive and pertains to 
the enzymatic hydrolysis of fatty acid ester bond of phospholipids. The complex 
biological activity of PLA2 / PLA2R manifests itself through the binding of 
PLA2 to the cell surface PLA2R. The binding of the enzyme to its receptor has 
been hypothesized to be regulatory for the enzymatic function (in both ways: 
stimulatory and inhibitory). The inhibitory mechanisms are supposed to be based 
on ligand internalization by endocytosis (for the membrane bound isoform) and 
inhibitory binding – leading to the clearance of the active enzyme (for the 
circulating, soluble form). The stimulatory mechanisms are based on the 
activation of signal transduction signals through the occupying of the receptor by 
its ligand. The signal transduction can lead to a plethora of biological effects, 
mostly mediated by the products of lipid mediators (thromboxane, arachidonic 
acid, prostaglandins): growth promotion and proliferation, chemokinetic 
migration, secretagogue effects, contractile response etc. 
sPLA2 are considered to be a class of proinflammatory mediators, stored within 
inflammatory cells and released in the extracellular space (plasma) upon 
activation (during local or systemic inflammation) [531]. It therefore follows that 
depending on the prevailing effect, the regulatory function of the binding by the 
receptor (PLA2R1) will lead to it having a proinflammatory (in the case of 
stronger activation) or anti-inflammatory effect (if, on the contrary, inhibition is 
stronger), Figure 82. 
 
 
 
Figure 82 Influence of the sPLA2/PLA2R functional unit on inflammation 
Upon dockage of the ligand (sPLA2) on its receptor (PLA2R) two antagonistic effects impacting 
on the inflammatory role of sPLA2 can occur: inhibitory, due to the clearance of the enzyme by 
its receptor-dependent endocytic internalization followed by digestion ergo inactivation; 
stimulatory, due to the activation of a stimulatory (eicosanoid) signal transduction pathway.   207
 
 
Antigen PLA2R1 
The findings of our association studies also suggest another aspect of the 
pathogenesis of IMN: the formation of autoantibodies. PLA2R1 has been shown 
to be present not only on normal podocytes but also in the immune deposits of 
patients with idiopathic membranous nephropathy. Sequence variants causal for 
(or increasing susceptibility to) IMN could lead to conformational changes of the 
peptide or to changes to the pattern of antigen processing, PLA2R1 could be the 
antigenic protein, and the epitopes could be fragments of it. A similar mechanism 
has been shown in the case of the Goodpasture autoantigen [532]. 
A candidate to the title of causal polymorphism in this sense (possible 
conformation change resulting in pathogenic autoantigenicity) could be the 
methionine to valine (M292V) amino acid substitution (SNP rs3749117) which is 
associated with IMN in our study.  
This appears to be even likelier in the light of the suggestion that sulfhydril (-SH) 
groups of the PLA2R1 extra cytoplasmic domains could be modified under the 
influence of environmental factors i.e.  therapeutic or accidental exposure to 
heavy metals (gold, mercury etc. [533-535]), which is an important cause of 
secondary MN. 
4.3.1.2 LY75 
It is worth noting that LY75 (Lymphocyte antigen 75), the gene situated 
telomeric from PLA2R1, is the human equivalent of DEC-205 (CD 205) [536] 
which is also a member of subgroup of the VI C-type animal lectin family. The 
tandem situation of the two genes (similarity) suggests the possibility of a past 
gene duplication event followed by divergent evolution. Theoretically, being an 
antigen-uptake molecule at the interface between innate and adaptive immune 
responses (like PLA2R1) LY75 could also be involved in the pathogenesis of 
IMN.   208
4.3.1.3 ITGB6 
The gene situated centromeric from PLA2R1 is ITGB6 (Integrin Beta 6 
precursor). It could be functionally relevant to IMN through its role in the 
homeostasis of phospholipids and collectins, and in the remodelling of the 
extracellular matrix (it has been shown to lead to increased collagen production 
via activation of TGF-β1 when induced by viral infection in endothelial cells; 
[504]). It is worth mentioning that the association signal upstream of ITGB6 
could be associated to a regulatory element (enhancer, silencer) which might 
participate in the co-regulation (expression) of genes downstream (ITGB6, 
PLA2R1, LY75).  
4.3.2  HLA 
The association of IMN with the HLA super-locus [224], demonstrated both 
serologically and through molecular typing has been reviewed by Powis [537]. 
One of the most polymorphic regions within HLA is DQ – DR, with DR being 
considered the most polymorphic class II HLA human locus. The IMGT / HLA 
database (part of the ImMunoGeneTics project [538]) documents to date 
(December 2010) 966 different DRB alleles, the HLA-DQB1 locus harboring 
144 alleles and HLA-DQA1 35 alleles. Associations of HLA-DQA1 alleles with 
various immune related disorders have been published. In MN the culprit 
between the two loci seemed to be DQ, given the number of publications 
showing association of DQA1 with the phenotype [244,245,539]. Another 
argument why the HLA-DQ region appears to be important in defining the 
genetic basis for susceptibility for IMN is a study of the H2 region in mice, in 
which the Aβ / Aa region was found to be linked to susceptibility to anti-GBM 
disease (Goodpasture syndrome). The murine Aβ / Aα region corresponds to the 
human HLA-DQ region. This suggests a possible role for HLA-DQA1 alleles in 
immune related glomerular disorders [183]. 
 
Our study has managed to define the HLA-DQ – MN trait association with a 
better resolution of detail (we have been able to identify 282 SNP type markers 
within the HLA region which are associated with the MN trait. The strongest 
association was shown to be with HLA-DQA1 alleles).   209
Advances in genotyping technology allow for a higher resolution in resolving 
HLA alleles (the Illumina genotyping platform being designed with a high 
density of coverage over the complex HLA super-locus [226]). A possible reason 
which led to misleading results in the past is also the fact that HLA-DQA1 is not 
(as of December 2010) part of the routine HLA typing routine for renal 
transplantation (at least in the UK). 
 
The presence of significant associations within the extended HLA locus, with 
SNPs in little linkage disequilibrium with the top signal, suggests the presence of 
independent risk variants. The distribution of the association signal (Figure 46) 
may suggest a possible functional link between the type II HLA molecules 
(HLA-DQA1) and type I HLA molecules. This has been suggested e.g. in the 
case of vitiligo [540]. 
 
Alternatively, this might be just the result of strong linkage disequilibrium 
between class I and class II molecules encoding genes due to co-evolution under 
similar evolutionary constraints of a functional / physiological / immunological 
unit (‘immune response module’). 
Even though our findings are highly suggestive towards implying the importance 
of genetic variants within HLA-DQA1 in the pathogenesis of IMN, we cannot 
exclude the possibility of causal variants (in linkage disequilibrium with 
associated markers) being located in one of the genes close by. 
4.4  Suggested pathogenic models 
4.4.1  Main pathogenic model 
In trying to depict this vulnerability, we could use a ‘shooting barrack’ metaphor, 
in which the ‘target’ is the autoantigen at the level of the glomerular basement 
membrane (PLA2R1 etc), the ‘bullets’ are the autoantibodies which are fired by 
the ‘gun’ (which is the immune system) of which the ‘trigger’ is the HLA type II 
component (with its molecular representative in this particular case being HLA-
DQA1). The question remains as to what the ‘finger of the trigger’ (the causative 
event) might be.   210
In a ‘key-lock’ type of compatibility, IMN specific sequence variants of PLA2R1 
might lead to autoantigenic conformations, leading to their recognition by IMN 
specific HLA-DQA1 products, with their subsequent presentation by APCs to 
immune competent cells (CD4
+ T cells, B-lymphocytes) and the resulting 
triggering of autoantibodies, see Figure 83. 
 
 
 
Figure 83 Suggested schematic pathogenic mechanism  
TCR – T cell receptor; HLA-II - Human Leucocyte Antigen class II molecule (DQA-DQB 
dimer); APC – Antigen Presenting Cell; green – schematic structure of PLA2R1; red – hypothetic 
epitope; white arrow – endocytosis, processing of the antigen and presenting of the epitope on the 
surface of the antigen presenting cell.  
 
The co-occurrence of risk alleles in PLA2R1 and HLA-DQA1 in an individual 
may lead to the possibility of a shortcut in the tightly regulated adaptive immune 
system and allow for a breach in self-tolerance, the immune attack leading to 
lesions at the level of the glomerular basement membrane (with the characteristic 
pathology of membranous nephropathy). 
 
It is known that a proportion of IMN patients have a negative serology for anti 
PLA2R1 antibodies, which might be explained by the fact that HLA-DQA1 risk 
alleles can trigger autoantibodies against PLA2R1 or other targets. Two possible 
such autoantigenic targets have been published  [157]. We did not identify 
significant associations (neither in the three separate population based studies nor 
in the pooled analysis) of the MN trait to markers within these genes (AKR1B1 
on chromosome 7q33 and SOD on chromosome 6q25.3 respectively). 
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Other instances in which similar models of ‘trigger and target’ autoimmune 
mechanisms may apply have been published: in vitiligo, genetic markers have 
been shown to be associated with trigger variants in the HLA region and with 
target variants of TYR (tyrosinase - a previously well characterized autoantigen 
in vitiligo [541]). 
Another lesson from previous HLA related genome wide association studies has 
been the hint that predisposition to autoimmune disorders might imply a 
complicated interplay of innate and adaptive immunity, which is based on 
variants encoded at the HLA super-locus (e.g. alopecia areata [542]). 
4.4.2  Extended pathogenic model  
The pathogenic mechanism of IMN can be modelled as a combination of two 
elements: an autoimmune aspect (the common element, including MN in the 
genus proximum of autoimmune disorders) and the reaction to the autoimmune 
attack, which includes the inflammatory response and the pathognomonic aspect 
of the basal membrane thickening (which is the defining differentia specifica of 
MN), see Figure 84. 
4.4.2.1 Autoimmune attack 
PLA2R1 is an endocytosis receptor / pattern recognition like molecule. The role 
of pattern recognition molecules is to bind potential extracellular antigens. The 
pattern recognition process leads to endocytosis. The receptor bound antigens are 
processed in the early endocytic vesicles of the Antigen Presenting Cells: 
polypeptidic fragments are cleaved by peptidases. Some of these fragments (~ 10 
amino acids) are extrinsic epitopes which will be taken up on the antigen 
presenting groove HLA type II molecules, in order to be then presented to the 
executor cells (T cells etc.) of the adaptive immune response system. 
In the pathogenic context of IMN it seems that a part of PLA2R1 has its 
conformation altered as to be recognized as non self. The antigenic fragment of 
PLA2R1 (the intrinsic epitope) is processed (cleaved by peptidases) in the 
endocytic vesicle and be transferred on HLA type II triggering the production of   212
autoantibodies oriented against the autoantigenic portion of the extracellular 
chain of PLA2R1. 
4.4.2.2 Response to the autoimmune attack 
Anti PLA2R1 autoantibodies can alter its function by blocking the binding of its 
ligands. In the case of sPLA2 this will have an effect on inflammation; in the 
case of collagen fragments [543] extracellular matrix turnover will be affected. 
Inflammation 
The most probable effect of the binding of sPLA2 by PLA2R1 is anti-
inflammatory, due to the clearance of proinflammatory (Figure 82). Inhibition of 
this effect might lead to increased local inflammation with the subsequent lesions 
of podocytes (the long term vulnerability thereof being possibly the key to the 
evolution of the disorder towards resolution or towards progression) which will 
be manifest clinically as nephrotic syndrome. 
Extracellular matrix (ECM) / collagen turnover 
Both elements of the sPLA2/PLA2R1 functional unit have been shown to be 
important in extracellular membrane homeostasis: sPLA2 has been shown to 
activate the self aggregation of fibronectin (via the activation of integrin dimers 
through lysophosphatidic acid LPA); PLA2R1 has been shown to be able to bind 
collagen fragments. The reduced collagen binding capability of PLA2R1 due to 
autoantibody blocking of the binding site 
Importance of collagen uptake in MN 
Functional sequence variants having an effect on the collagen uptake function of 
PLA2R1 can, in theory, confer a ‘membranous type’ pathology to autoimmune 
lesions determined by autoantigens different from PLA2R1 itself (in a ‘two hit’ 
like hypothesis). This might be the case in type V lupus nephritis. The 
autoimmune attack (first step) could be determined by a lupus like autoantigen, 
whereas the membranous anatomopathological aspect of this particular subtype 
could be determined by a genetic variant of PLA2R1 which would impede 
collagen clearance.   213 
 
 
Figure 84 Extended suggested pathogenic mechanism  
A. Physiological immune response at the level of the glomerulus; B. Pathogenic autoimmune response in the case of Membranous Nephropathy. 
Blue and red circles – extrinsic antigen, red circles – extrinsic epitope, grey ‘Y’ shape – endocytosis receptor / pattern recognition molecule, green ‘Y’ shape – HLA type II 
receptor, purple ‘Y’ shape – Antibody, blue ‘Y’ shape - autoAntibody; pm – (podocytic) plasma membrane, ev – endocytic vesicle, PR – Pattern Recognition, E – 
Endocytosis, C – Cleavage (by peptidases), U – Uptake (by HLA type II), IR – Immune Response, AIR – Autoimmune Response, BM – basal membrane.   214
4.4.3  Alternative pathogenic models 
A loss of function mutation of PLA2R1 could reduce its capacity to inhibit the 
antiinflamatory action of sPLA at the level of the glomerulus. Mutations of 
regulatory elements reducing the level of expression of PLA2R1 would lead to 
similar results.  
Loss of function mutation of PLA2R1 could lead to its reduced capacity to clean 
up cellular detritus (immune complexes) in the case of local inflammation, 
resulting in the accumulation of extracellular material at the level of the 
glomerular basal membrane. 
Gain of function mutations of PLA2R1 (or regulatory mutations resulting in its 
overexpression) could result directly in activation (or exacerbation) of a signal 
transduction pathway (autacoid factors, probably eicosanoids: arachidonic acid / 
prostaglandins) leading to pathologic results, possibly through the induction of 
ER stress responses which would result in glomerular epithelial cell lesions. 
Mutations leading to the functional transformation of PLA2R1 from a molecule 
specialized mainly in interacting with sPLA2 into an antigen-uptake molecule 
(similar to DEC205, MR) could lead to the endocytosis of a polypeptidic 
fragment acting as an autoantibody. 
Another possible pathogenetic mechanism was suggested by El Kossi et al. [544] 
who described a recipient of a kidney transplant in which the onset of  de novo 
membranous nephropathy was associated with a donor specific alloantibody 
directed against HLA DQ7. In this scenario HLA type II molecular complexes 
are themselves the targets of antibodies as opposed to being triggers of the 
autoantibody synthesis. This model could be consistent with the modulation of 
the predisposition to autoimmune disorders by self HLA derived peptides [545]. 
4.5  Remaining questions 
It is not clear what the trigger of the autoimmune process is that ultimately leads 
to the deposition of immune complexes at the level of the basement membrane in 
the course of membranous nephropathy. A related question is why the onset of 
the process occurs usually late in life (with the exception of perinatal 
membranous nephropathy) and why the time of onset is so variable. As in the 
instances of many autoimmune disorders, infections have been suggested as   215
potential triggering factors since the first clinical descriptions of membranous 
nephropathy (mentioning of a history of upper respiratory tract disease one to 
three weeks before the onset of symptoms of the nephrotic syndrome [546]).  
The delineation of the epitope (which part of the sequence of PLA2R is the 10-15 
aminoacid long peptide that will be recognized as non-self by the immune 
system? Is the epitope native or is it ‘exposed’ in the course of time by triggering 
conditions? (the latter hypothesis being more consistent with a solution to the 
problem of the late / variable age of onset of the disease). The nature of this 
condition can be speculated upon (given also what is known from the etiology of 
secondary membranous nephropathy). 
Metal exposure (environmental, accidental or therapeutic) has been involved in the 
pathogenesis of the nephrotic syndrome. In the literature there are descriptions of 
instances where glomerulonephridites seem to have been induced by exposure to: 
cadmium and nickel [547], bismuth [548] (used in arthritis therapy), gold [549] 
(also used in arthritis therapy), mercury [533-535] (used in lues therapy, skin 
lightening compounds etc.). More specifically, mercury has been suspected to be 
a trigger in the generation of anti-laminin antibodies [550]. 
Furthermore, smoking has been suggested as a cause of rheumatoid arthritis 
[551], hypothesis which has led to a model of the etiology of RA in which 
citrullination of peptides at the level of the lung of the smoker leads to the loss of 
tolerance and triggers an HLA restricted immune response against what has 
become an autoantigen [552]. This hypothesis found recent confirmation by gene 
environment interaction enquiries in the context of genome wide association 
studies [553]. 
Food antigens have been implied as a possible cause for ‘some cases of human 
glomerulonephritis’ based on anecdotal evidence [554]. 
 
What is the mechanism of the lesion: IgG4 does not lead to complement 
activation; could direct toxicity of the antibody (neutralizing enzymatic or non-
enzymatic activity, stimulating receptor-related pathways) [156] be an 
explanation? Alternative lectin pathway activation [555,556]? What would then 
the role of MBL (Mannose binding lectin) be? Could the similarity between 
PLA2R MBL play a role? Can the immune complexes be completely uncoupled 
from the damage [557]?   216
 
The question remains as to what the mechanism of the gender influence in 
membranous nephropathy is. A related unanswered question is why the 
prevalence of membranous nephropathy is higher in males, which is the opposite 
from the usual higher prevalence of autoimmune disorders in females. 
 
Other questions relate to the putative functional link between PLA2R, AKR1B1 
and SOD2, if one exists. It has been shown that PLA2R can regulate senescence 
in a reactive oxygen species – DNA damage – p53 dependent manner [558]. 
Given that AKR1B1 and SOD2 are important elements of the reactive oxygen 
species protection mechanisms, ‘pathogenic senescence’ could be hypothesised 
to be this ‘missing link’.   217
5  Conclusions 
The most effective treatment for a disorder is the one that addresses its cause 
(etiologic treatment) or its mechanism (pathogenetic treatment) directly. This 
implies that effective treatment relies on the understanding of the usually 
complex interplay between genes and environment which makes up the specific 
phenotype (disease) dealt with. In a simplified model, health state is the result of 
an equilibrium between the challenges of the environment and the homeostatic 
mechanisms of the organism. These mechanisms can be conceptually dissected 
into ‘unit steps of homeostasis’ [559]. The variability of the unit steps (proteins), 
which allows for an optimal adaptation to the environment (in the case of 
homeostasis) is encoded at the genetic level. The genetic variants (alleles) which 
lead to disease susceptibility (the effect size of it being a gradient between all and 
nothing) can be identified by applying genetic mapping techniques. 
The classical gene mapping approach to a rare disorder is linkage analysis. The 
power of this approach is limited by the small number of informative families 
available. Therefore there are usually no twin studies for the estimation of   
heritability, but the usefulness of heritability estimates is considered to be limited 
[560]. We proved in our study that a rare, well defined phenotype can be 
successfully mapped by applying the genome wide association method on 
relatively small cohorts of patients. We were able to show that in 556 (398 male) 
cases of IMN of Caucasoid descent, the disorder is strongly associated with risk 
alleles within the HLA locus in general and with HLA-DQA1 in particular, as 
well as with PLA2R1 alleles on chromosome 2. No other autosomal allele was 
significantly associated with IMN, within the technical limitations of our study 
(power and coverage). 
The conceptual limitations of association studies pertain mostly to the issues of 
causality and confounders. Association is not proof for causality, but strength of 
association (quantified in high –log10P values) and consistency thereof 
(replication in two Caucasoid populations – FR, NL –  similar to the exploratory 
one – UK) are suggestive for it. Confidence in the strength of association is 
enhanced by the biological plausability of these findings. In our case, there are 
independent studies suggesting the importance of the PLA2R1 molecule and the   218
HLA region in the etiopathogeny of IMN. We suggest a pathogenic mechanism 
in which the antibody response in IMN is related to presentation of a “risk” 
PLA2R1 epitope by an “IMN” HLA-DQA1 allele.  
Further confounders of the relation between association and causality that we 
encountered in our study are: the issue of independent associations, epistasis, 
environmental influences (including the internal environment differences which 
lead to different susceptibilities in males versus females), linkage disequilibrium 
and copy number variants. 
Ultimately solving the etiopathogenical problem in the case of IMN will rely on 
further studies to assess sequence variations in the HLA-DQA1 and the PLA2R1 
regions and ulterior functional experiments performed to assess the biological 
relevance of the identified variations.   219
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